

厚生労働科学研究費補助金

循環器疾患・糖尿病等生活習慣病対策総合研究事業

脳卒中の医療体制の整備のための研究

平成 28 年度～平成 30 年度 総合研究報告書

研究代表者 飯原 弘二

(九州大学大学院医学研究院脳神経外科)

平成 31 (2019) 年 3 月

目 次

I. 総合研究報告	
脳卒中の医療体制の整備のための研究	1
九州大学 飯原 弘二	
〔資料〕	
J-ASPECT Study 平成 28 年度～30 年度 発表論文	16
II. 研究成果の刊行に関する一覧	63

厚生労働科学研究費補助金(循環器疾患・糖尿病等生活習慣病対策総合研究事業)
総合研究報告書

脳卒中の医療体制の整備のための関する研究

研究代表者 飯原 弘二 九州大学大学院医学研究院脳神経外科 教授

研究要旨

急性期脳梗塞に対する rt-PA 静注療法の治療効果が発表された 20 年後、2015 年に機械的血栓回収療法の有意な治療効果が相次いで発表されたことにより、脳梗塞超急性期における標準治療は一変し、その医療体制の整備は喫緊の課題となった。しかしこれまで本邦で脳梗塞超急性期の医療体制の整備に特化した研究は行われていない。本研究では、急性期脳梗塞の rt-PA 静注療法の均てん化、血管内治療の集約化を図るため、脳梗塞超急性期医療の臨床指標を策定し、本邦の大規模データベースから策定した臨床指標を算出することで、地域の実状を考慮した脳梗塞急性期医療の提供体制の整備に資する資料を提供する。

研究分担者氏名・所属研究機関名及

神戸市立医療センター中央市民病院・

び所属研究機関における職名

部長

(分担研究報告書の場合は、省略)

星野 晴彦

研究分担者氏名・所属研究機関名

東京都済生会中央病院・部長

及び所属研究機関における職名

長谷川 泰弘

聖マリアンナ医科大学・教授

西村 邦宏

橋本 洋一郎

国立循環器病研究センター・部長

熊本市民病院・首席診療部長

吉村 紳一

小川 彰

兵庫医科大学・主任教授

岩手医科大学・理事長

塩川 芳昭

鈴木 倫保

杏林大学・教授

山口大学・教授

嘉田 晃子

辻野 彰

名古屋医療センター・室長

長崎大学病院・教授

小笠原邦昭

北園 孝成

岩手医科大学・教授

九州大学・教授

豊田 一則

国立循環器病研究センター・副院長

A. 研究目的

東 尚弘

2015 年に機械的血栓回収療法の治療効果が相次いで発表されるに伴い、急性期脳梗塞に対する標準治療は一変し、急性期医療体制

国立がん研究センター・センター長

坂井 信幸

の整備は喫緊の課題となった。本研究の目的は、急性期脳梗塞のt-PA 静注療法の均てん化、血管内治療の集約化を図るため、脳梗塞超急性期医療の実態を把握した上で、臨床指標を策定し、大規模データベース(J-ASPECT Study など)から、策定した臨床指標を算出し、地域の実状を考慮した脳梗塞超急性期医療の提供体制の整備に資する資料を提供することにある。

B. 研究方法

(1) 脳梗塞超急性期治療の地域別実態把握と評価:

①日本脳卒中学会、脳神経外科学会、神経学会、脳神経血管内治療学会の協力のもと、脳梗塞超急性期治療の退院調査を行う。具体的には学会の教育訓練施設を対象に、前年度に治療した脳梗塞急性期症例のDPCデータを、ICD-10コードを用いて抽出し、rt-PA静注療法、血管内治療を施行した患者情報を収集する。患者情報(性、年齢、併存疾患、入院時、退院時 modified Rankin Scale、入院中死亡など)、病院情報(都市圏分類、包括的脳卒中センタースコアなど)を含む統合データベースを作製、患者要因、病院要因を考慮した hierarchical multiple regression analysis を行い、予後に与える影響を解析する(西村、嘉田)。また、全国悉皆救急搬送情報との突合を確率的データマッチングの手法を用いて、専用の高機能コンピューターを用いて解析する。

②血管内治療のエビデンスが出版された2015年前後の脳梗塞超急性期におけるrt-PA静注療法、血管内治療の治療数、受療率を、既に構築された統合データベース(J-ASPECT Study など)を活用して、地理的要因を考慮し

て比較、検討することによって、エビデンス・プラクティスギャップの可視化を図る。これまでに、J-ASPECT Study では過去5年間約400施設から脳卒中データベースを構築し、現在まで約33万件の脳梗塞症例を登録しており、本研究期間の3年間で、さらに約20万件の登録が見込まれる。

③分担研究者の鈴木、長谷川、塩川、星野、辻野は、山口県、神奈川県、東京都、長崎県(僻地・離島)に代表される人口密度の異なる地域における遠隔医療の活用を含めた実態調査を担当する。

坂井は、JR-NET3、吉村は、RESCUE Japan から見た血管内治療の実態把握と評価を、北園は Fukuoka Stroke Registry、橋本は熊本脳卒中地域連携ネットワーク研究会、小川、小笠原らは、地方自治体(岩手県)で構築された脳卒中データベース、豊田はSAMURAI Registry を活用し、血管内治療のエビデンスが出版された前後におけるrt-PA静注療法、血管内治療の地域、研究参加施設別の実態を把握する。

(2) 地域特性を考慮した、rt-PA療法の均てん化、血管内治療の集約化を目指した医療体制構築のための指標:

脳梗塞を発症してからの搬送、診断、治療の3つの段階で、rt-PA静注療法、血管内治療の施行に関わる臨床指標(ストラクチャー指標、プロセス指標、アウトカム指標)を策定(長谷川、東、西村、嘉田、小川、小笠原)し、継続的なモニターの可能性につき検討する。

具体的には、都道府県単位で取得可能な必須指標に加えて、以下の5つの大項目につい

て詳細な指標を検討する。

- 1) 人的要因(例:脳卒中医療に関係する学会専門医(ストラクチャー指標))
- 2) 診断機器(例:MRI 拡散強調画像や脳灌流画像などの高度の画像診断が常時施行可能(ストラクチャー指標)、適応患者が来院してから画像診断までの時間(プロセス指標)、病院前脳卒中スケールの活用や覚知から病院到着までの時間(プロセス指標))
- 3) 介入治療(例:発症後2時間以内に来院した患者における3時間以内のrt-PA 静注療法実施率(プロセス指標)、入院死亡率、退院時日常生活自立度(アウトカム指標))
- 4) インフラ(例:ストロークケアユニット、集中治療室(ストラクチャー指標))
- 5) 教育(例:多職種や住民に対する教育(プロセス指標))

(3) rt-PA 療法の均てん化を目指した、rt-PA 静注療法適正治療指針の改訂に資するデータの蓄積:

rt-PA 療法の均てん化に向けて、上記の脳卒中データベースを活用して、脳梗塞超急性期治療に関する臨床指標の継続的な収集を行い、rt-PA 静注療法適正治療指針の改訂に資するデータの蓄積を図る。

(倫理面への配慮)

- 1) 本研究において予測される危険性
本研究は患者の治療過程で得られる情報を整理、統合して構築する二次資料を用いるものであり、既存資料の利用にとどまり、研究対象者に身体的リスクを与えるものではない。
- 2) 被験者の利益および不利益
被験者にとっての直接的な利益は無い。集積される情報には個人識別情報を含まず、複

数の情報から個人を推定できないように配慮している。さらに、情報の収集、蓄積に用いるシステムの厳格な管理、運用、目的を限定した情報の取り扱いにより、被験者に与える情報リスクを極小化しており、実質的な不利益は無い。

3) 費用負担

本研究に要する経費は平成28年度厚生労働科学研究費で負担する。本研究に参加する被験者に、本研究参加のために新たな費用の負担を求めるとはしない。

4) 倫理的事項

人を対象とする医学系研究に関する倫理指針に従い、公開すべき事項を含むポスターを各施設の外来および病棟の目につくところに掲示し、情報の公開と拒否の機会を設ける。

5) インフォームドコンセント

本研究は、公衆衛生上の重要性が高い研究であり、通常診療において生成される診療情報を収集、匿名化して解析するものであり、研究目的の達成には悉皆性の担保が重要であることから、登録の際に患者個人から個別の同意は取得しない方針とし、各参加施設では研究の目的を含む研究の実施についての情報を院内掲示と入院時のお知らせ等により公開・広報し、登録の実施を周知する。併せて、何ら診療上の不利益を受けることなく、研究目的での協力を拒否できることを明示し、協力拒否の申し出があった患者については研究目的の情報登録の対象から除外する。

6) 個人情報の保護

レセプトデータ、DPC データはすでに各施設で連結可能な匿名化となっている。データセットには個人を識別できる情報を含めない。

7) 知的所有権に関する事項

この研究の結果として特許権当科生じた場

合、その権利は国、研究機関、民間企業を含む共同研究機関および研究遂行者などに属し、研究に参加した被験者には属さない。また特許権等に関して経済的利益が生じる可能性があるが、被験者はこれらについても権利はない。

C. 研究結果

(1) 脳梗塞超急性期治療の地域別実態把握と評価:

① 平成 27 年度から 29 年度の脳梗塞超急性期治療を対象とした DPC 情報をもとにした退院調査を施行、データ収集を行った。また脳卒中診療施設を対象に、脳卒中患者の救急医療体制の現状を把握することを目的として、平成 22 年度、平成 26 年度に続いて、平成 30 年度の第 3 回診療施設調査を行った。

また平成 29 年度は平成 29 年 8 月 31 日に、第 1 回班会議、平成 30 年 2 月 22 日に第 2 回班会議を、平成 30 年度は平成 30 年 7 月 20 日に、第 1 回班会議、平成 31 年 2 月 22 日に第 2 回班会議を行った。

② J-ASPECT study における 2010 年から 2014 年までの脳梗塞急性期治療に関するデータを検討した。雇用圏別に比較すると、大都市雇用圏では t-PA 静注療法の実施率は経年的に上昇していたが、小都市雇用圏ではほぼ横ばいの状況であった。急性期血栓回収療法に関しても、大都市では急速に上昇していたが、小都市ではその増加率は低かった。これを反映するように、アウトカム(mRS0-2、死亡率)に関しても、小都市と比較して大都市のほうが良好であった。また入院経路に関して、t-PA 静注療法を行った患者は、小都市においてより他院からの転送が多く、t-PA が初回搬送施設で

施行できず、治療可能な施設に転送されていることがわかった。このように脳梗塞超急性期医療に関しては、依然大きな地域格差が存在することが明らかとなった。

③ 各年度 2 回ずつ行った班会議において、各分担研究者の調査・研究結果の報告をもとに、rt-PA 静注療法、血管内治療に関する遠隔医療など地域医療の実態について検討を行った。

RESCUE-Japan Project における 2016 年から 2017 年にかけての急性期血栓回収療法に関して、脳血管内治療専門医所属施設(約 600 施設)のデータの集計を行った。2016 年、2017 年における人口 10 万人あたりの急性期血栓回収療法の治療件数と血管内治療専門医の人数を都道府県別に評価し、いずれも概ね増加傾向にあるが(治療件数:34.5%増加、専門医数:12.8%増加)、地域の格差は大きいことが示された。

急性期脳卒中における遠隔医療の実体について山口県における取組み(Telestroke)の報告では、脳卒中診療医のいない施設において Telestroke を用いることで約 25%の転送が行われ、治療適応など適切な判断がなされていた。t-PA 静注療法、急性期血栓回収療法の対象となりうる心原性脳塞栓症では、約 1/3 が転送されているが、1/3 の症例は重症のため治療適応がなく転送されていない実体が明らかとなった。Telestroke を用いることで、脳卒中診療医がいない地域においても超急性期治療が可能となることが示された。

(2) 地域特性を考慮した、rt-PA 療法の均てん化、血管内治療の集約化を目指した医療体制構築のための指標:

脳梗塞急性期治療に関する臨床指標として、「脳卒中・診療の質指標」および「包括的脳卒中センターに関する脳卒中・診療の質指標」を策定した。策定した臨床指標を継続的にモニターするため、「Close The Gap - Stroke (CTGS)」と名付けた急性期脳卒中の医療の質評価プログラムを立ち上げた(AMED 研究との合同事業)。然し乍ら、CTGS で収集する指標は、学術的要素が強く、地域の自治体で収集するには、やや詳細に過ぎるとの指摘があった(CTGS については、日本脳卒中学会による脳卒中センター認定後の臨床指標の収集に活用することを検討中)。

脳梗塞急性期治療に関する臨床指標としては、地域や自治体などでも収集可能な指標として、以下のものを提唱し、J-ASPECT Study など既存のデータベースでの収集の実現可能性について検討した。本研究班からは、以下の指標を提案する。

- 1)脳卒中全体死亡率(30日以内、都道府県別)
- 2)脳卒中3病型別死亡率/患者数(脳梗塞、脳内出血、くも膜下出血別、30日以内、都道府県別)
- 3)脳卒中主要関連学会(日本脳卒中学会、脳神経外科学会、脳神経血管内治療学会など)専門医数(都道府県別)
- 4)脳卒中診療に従事する常勤医師数
- 5)rt-PA 静注療法実施数/率(都道府県別)
- 6)機械的血栓回収療法実施数/率(都道府県別)
- 7)ストローク・ユニット設置数(都道府県別)
- 8)rt-PA 静注療法 常時治療可能施設数
- 9)脳血管内治療 常時治療可能施設数
- 10)脳内出血治療数
- 11)再入院患者数

脳卒中全体90日後 mRankin Scale score(都道府県別)についても検討したが、CTGS の結果でも、収集率は低いため、自治体レベルでは実現可能性は低いと考えられる。集中治療室の設置数については、包括的脳卒中センターでの要件として検討する。

(3) rt-PA 療法の均てん化を目指した、rt-PA 静注療法適正治療指針の改訂に資するデータの蓄積:

(2)において検討した指標について、本研究班で得られた J-ASPECT のデータをもとに評価を行った。

平成30年度に行った第3診療施設調査の結果では、過去の施設調査からの経時推移については人的要因に関しては増加している項目(救急医、リハビリ医)も認めたが、その他の要項については大きな変化を認めなかった。また主要項目における都道府県別データを検討すると、都道府県ごとの脳卒中診療の実態が明らかになった。

厚生労働省の人口動態統計における脳梗塞の年齢調整死亡率と、J-ASPECT のデータにおける都道府県別のリスク調整死亡率(入院30日以内死亡)を比較した。この比較では死亡率の高い地域に相違があり、これは前者で脳梗塞患者の最終予後、後者で脳梗塞患者の急性期予後を反映しているものと考えられ、同じ患者集団であれば急性期医療と慢性期医療のギャップを示しており、治療のアウトカムを改善するための地域ごとの特色が可視化された。

また2015年における都道府県別の t-PA 静注療法および急性期血栓回収療法の実施率を算定した。5分位で評価すると、それぞれの治療に関して、実施率に地域差が見られ、特

にどちらも実施率の低い県に関しては積極的な格差是正の介入が必要であることが示唆された(投稿準備中)。

脳卒中急性期医療に関する評価指標のうち、構造指標として包括的脳卒中センターと死亡率の関係を評価した。包括的脳卒中センターに関する推奨要項の充足(CSCスコア)が高いほど死亡率や予後不良(mRS3-6)の割合が低く、CSCスコアの改善がアウトカムに寄与していることが明らかとなった。また、その中でも脳卒中に関する専門医のうち、脳神経外科専門医、脳卒中専門医、脳血管内治療専門医の在籍数が多いほど脳卒中における死亡率が低いことが示された(西村邦宏ら、投稿中)。

(倫理面への配慮)

1) 本研究において予測される危険性

本研究は患者の治療過程で得られる情報を整理、統合して構築する二次資料を用いるものであり、既存資料の利用にとどまり、研究対象者に身体的リスクを与えるものではない。

2) 被験者の利益および不利益

被験者にとっての直接的な利益は無い。集積される情報には個人識別情報を含まず、複数の情報から個人を推定できないように配慮している。さらに、情報の収集、蓄積に用いるシステムの厳格な管理、運用、目的を限定した情報の取り扱いにより、被験者に与える情報リスクを極小化しており、実質的な不利益は無い。

3) 費用負担

本研究に要する経費は平成28年度厚生労働科学研究費で負担する。本研究に参加する被験者に、本研究参加のために新たな費用の負担を求めることはない。

4) 倫理的事項

人を対象とする医学系研究に関する倫理指針に従い、公開すべき事項を含むポスターを各施設の外来および病棟の目につくところに掲示し、情報の公開と拒否の機会を設ける。

5) インフォームドコンセント

本研究は、公衆衛生上の重要性が高い研究であり、通常の診療において生成される診療情報を収集、匿名化して解析するものであり、研究目的の達成には悉皆性の担保が重要であることから、登録の際に患者個人から個別の同意は取得しない方針とし、各参加施設では研究の目的を含む研究の実施についての情報を院内掲示と入院時のお知らせ等により公開・広報し、登録の実施を周知する。併せて、何ら診療上の不利益を受けることなく、研究目的での協力を拒否できることを明示し、協力拒否の申し出があった患者については研究目的の情報登録の対象から除外する。

6) 個人情報の保護

レセプトデータ、DPCデータはすでに各施設で連結可能な匿名化となっている。データセットには個人を識別できる情報を含めない。

7) 知的所有権に関する事項

この研究の結果として特許権当科生じた場合、その権利は国、研究機関、民間企業を含む共同研究機関および研究遂行者などに属し、研究に参加した被験者には属さない。また特許権等に関して経済的利益が生じる可能性があるが、被験者はこれらについても権利はない。

D. 考察

本邦の代表的な大規模データベースなどを活用することによって、超急性期虚血性脳卒中の医療の実態把握を施行、それぞれの地域特性により急性脳動脈閉塞に対する再開通療

法としての rt-PA 静注療法、血管内治療が不均衡である実情が明らかとなった。

また、rt-PA 静注療法を適確に行うことを目的とした一次脳卒中センターの整備、血管内治療を含む、より高次の脳卒中治療を常時施行することが可能な包括的脳卒中センターの整備に向けて、脳梗塞急性期治療に関する地域や自治体などでも収集可能な臨床指標を提唱した。このデータを解析し、継続的にデータ収集することで、急性期脳梗塞の t-PA 静注療法の均てん化、血管内治療の集約化を図るための重要な提言ができるものと考えられる。

本研究で構築する医療施設のネットワークの枠組みは、脳卒中のみならず、広く急性心筋梗塞などの循環器病領域、救急医療、僻地・離島の医療にも応用されていくものと考えられ、今後の医療計画の策定に向けて、脳卒中超急性期医療に関する臨床指標を策定し、数値目標を可視化することで、二次医療圏の見直しなどに向けた PDCA サイクルの実現をもたらす、国民福祉の向上に向けての効果は計り知れない。

E. 結論

本研究において超急性期虚血性脳卒中の医療の実態を把握することで、歴然とした地域格差や不均衡が存在することが明らかとなった。また一次脳卒中センターおよび包括的脳卒中センターの整備に向けて、脳梗塞急性期治療に関する地域や自治体などでも収集可能な臨床指標を提唱した。

本研究により、rt-PA 静注療法の均てん化と血管内治療の集約化を目指した脳梗塞急性期医療のネットワークを、地理的条件やインフラの充足度などに応じて類型化して提言することが可能となる。rt-PA 静注療法を適確に行

うことを目的とした一次脳卒中センターの整備、血管内治療が常時可能な包括的脳卒中センターの整備に向けて基礎資料を提供し、医療圏の見直しなどに向けた PDCA サイクルの実現をもたらすことが期待される。

F. 健康危険情報

本研究において、患者の健康に危険が及ぶ事象は発生しない。

G. 研究発表

1. 論文発表

- 1) Kada A, Nishimura K, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Iihara K; J-ASPECT Study Collaborators. Development and validation of a score for evaluating comprehensive stroke care capabilities: J-ASPECT Study. *BMC Neurol.* 2017;17(1):46
- 2) Nishimura A, Nishimura K, Kada A, Iihara K; J-ASPECT Study GROUP. Status and Future Perspectives of Utilizing Big Data in Neurosurgical and Stroke Research. *Neurol Med Chir (Tokyo).* 2016 ;56(11):655-663.
- 3) Yoshimoto K, Kada A, Kuga D, Hatae R, Murata H, Akagi Y, Nishimura K, Kurogi R, Nishimura A, Hata N, Mizoguchi M, Sayama T, Iihara K. Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination

- Database (J-ASPECT Study-Brain Tumor).
Neurol Med Chir (Tokyo).
2016 ;56(11):664-673.
- 4) Lavine SD, Cockroft K, Hoh B, Bambakidis N, Khalessi AA, Woo H, Riina H, Siddiqui A, Hirsch JA, Chong W, Rice H, Wenderoth J, Mitchell P, Coulthard A, Signh TJ, Phatorous C, Khangure M, Klurfan P, Ter Brugge K, Iancu D, Gunnarsson T, Jansen O, et al. Training guidelines for endovascular stroke intervention: an international multi-society consensus document. *Neuroradiology*. 2016 ;58(6):537-41.
 - 5) Arimura K, Iihara K. Surgical Management of Intracranial Artery Dissection. *Neurol Med Chir (Tokyo)*. 2016;56(9):517-23.
 - 6) Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Nishimura A, Kurogi R, Sayama T, Iihara K; J-ASPECT Study Collaborators. Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). *BMJ Open*. 2016 ;6(3):e009942.
 - 7) Lavine SD, Cockroft K, Hoh B, Bambakidis N, Khalessi AA, Woo H, Riina H, Siddiqui A, Hirsch JA, Chong W, Rice H, Wenderoth J, Mitchell P, Coulthard A, Signh TJ, Phatorous C, Khangure M, Klurfan P, terBrugge K, Iancu D, Gunnarsson T, Jansen O, et al. Training Guidelines for Endovascular Ischemic Stroke Intervention: An International Multi-Society Consensus Document. *AJNR Am J Neuroradiol*. 2016;37(4):E31-4.
 - 8) 飯原 弘二. 【DPC の新展開】脳卒中医療の質向上に資する DPC データ活用. *病院* 76(2):114-118, 2017
 - 9) 黒木愛、飯原弘二. 知って得するワンポイントアドバイス 一次脳卒中センターと総合脳卒中センターの違い. *脳と循環* 22(1) :70-73, 2017
 - 10) 黒木亮太、飯原弘二. 【ビッグデータ解析に基づく臨床研究】 DPC 情報を活用した日本の脳卒中急性期医療の可視化 J-ASPECT study. *神経内科* 84(6) :572-577,2016
 - 11) 有村公一、飯原弘二. 【脳卒中-新時代の治療を求めて-】 臨床上の課題 脳血管内治療 新たなエビデンス. *日本臨床* 74(4):621-626, 2016
 - 12) Kurogi R, Kada A, Nishimura K, Kamitani S, Nishimura A, Sayama T, Nakagawara J, Toyoda K, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Matsuda S, Yoshimura S, Okuchi K, Suzuki A, Nakamura F, Onozuka D, Hagihara A, Iihara K, J-ASPECT Study Collaborators. Effect of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage: a nationwide study in Japan (J-ASPECT Study). *J Neurosurg*. 2018 May;128(5):1318-26. Epub 2017 May 26.
 - 13) Kurogi R, Nishimura K, Nakai M, Kada A,

- Kamitani S, Nakagawara J, Toyoda K, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Matsuda S, Yoshimura S, Okuchi K, Suzuki A, Nakamura F, Onozuka D, Ido K, Kurogi A, Mukae N, Nishimura A, Arimura K, Kitazono T, Hagihara A, Iihara K; J-ASPECT Study Collaborators. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. *Neurology*. 2018 Mar 27;90(13):e1143-9.
- 14) 黒木愛、飯原弘二. DPC・レセプトデータを活用した大規模データベースの現状と今後の展望. *医学の歩み* 264(10): 889-93, 2018
- 15) 黒木 愛、飯原弘二. ビッグデータから見た脳卒中救急医療. *Annual Review 神経* 2018 174-9
- 16) 黒木 愛、飯原弘二. 包括的脳卒中センターと J-ASPECT Study. *カレントセラピー* 35(12) :92, 2017
2. 学会発表
- 1) 嘉田晃子、西村邦宏、佐山徹郎、西村中、黒木亮太、奥地一夫、鈴木明文、飯原弘二. 包括的脳卒中センターの指標と4年間のアウトカム推移の関係 - J-ASPECT study. *STROKE2016*(シンポジウム) 4.14-16, 2016. 札幌
- 2) 迎 伸孝、荒田純平、郡 隆輔、岩田寛之、伊良皆啓治、瀧 雅子、井林雪郎、橋爪 誠、飯原弘二. *Smove* による在宅・施設融合型リハビリテーション・ロボットシステム. *STROKE2016*(シンポジウム) 4.14-16, 2016. 札幌
- 3) 荒川直紀、中村文明、西村邦宏、嘉田晃子、竹上未紗、北岡和代、飯原弘二. 脳卒中診療医における燃え尽き症候群と presenteeism の関係: J-ASPECT 研究. *STROKE2016* 4.14-16, 2016. 札幌
- 4) 黒木亮太、西村邦宏、嘉田晃子、佐山徹郎、西村 中、塩川芳昭、有賀 徹、飯原弘二. 年齢に応じたくも膜下出血患者における周術期管理と転帰の検討〜 J-ASPECT study〜. *STROKE2016* 4.14-16, 2016. 札幌
- 5) 黒木亮太、西村邦宏、嘉田晃子、佐山徹郎、西村 中、中川原譲二、豊田一則、飯原弘二. 脳卒中急性期医療の地域格差の可視化-J-ASPECT Study—. *STROKE2016* 4.14-16, 2016. 札幌
- 6) 佐山徹郎、西村 中、黒木亮太、西村邦宏、嘉田晃子、神谷 諭、飯原弘二. DPCデータからみた心疾患を合併した頸動脈治療 J-ASPECT study. *STROKE2016* 4.14-16, 2016. 札幌
- 7) 神谷 諭、中村文明、西村邦宏、嘉田晃子、佐山徹郎、西村 中、黒木亮太、小野塚大介、萩原明人、飯原弘二. 診療プロセス指標の実施率の差が症例数とアウトカムの関係に影響があるか: J-ASPECT Study. *STROKE2016* 4.14-16, 2016. 札幌
- 8) 西村 中、西村邦宏、嘉田晃子、佐山徹郎、黒木亮太、小笠原邦昭、小野純一、飯原弘二. J-ASPECT Study 4年間のデータに基づく本邦の脳卒中救急医療の年次的推移. *STROKE2016*(シンポジウム) 4.14-16, 2016. 札幌
- 9) 西村邦宏、嘉田晃子、佐山徹郎、西村中、黒木亮太、松田晋哉、吉村紳一、飯

- 原弘二. 包括的脳卒中ケアの院内死亡および後遺障害への効果について:J-ASPECT Study. STROKE2016(シンポジウム) 4.14-16, 2016. 札幌
- 10) 飯原弘二、西村邦宏、嘉田晃子、佐山徹郎、西村 中、黒木亮太、宮地茂、永田泉. 脳卒中医療におけるベンチマーキングの実際—医療の質の改善を目指して. STROKE2016(シンポジウム) 4.14-16, 2016. 札幌
- 11) 黒木亮太、西村邦宏、中村文明、嘉田晃子、神谷 諭、小笠原邦昭、塩川芳昭、豊田一則、中川原譲二、宮地 茂、吉村紳一、松田晋哉、奥地一夫、西村 中、佐山徹郎、飯原弘二. NOAC 投与中の非外傷性脳内出血の検討-J-ASPECT Study-. 第3回日本心血管脳卒中学会学術集会(シンポジウム) 6.17-18, 2016. 東京
- 12) 黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、井戸啓介、西村 中、有村公一、佐山徹郎、有賀 徹、豊田一則、吉村紳一、宮地 茂、塩川芳昭、小笠原邦昭、飯原弘二. J-ASPECT study における本邦の脳虚血急性期治療に関する検討. 一般社団法人日本脳神経外科学会第75回学術総会(シンポジウム) 9.29-10.1, 2016. 福岡
- 13) 飯原弘二. 脳卒中ビッグデータ活用の取り組み～J-ASPECT Study から～. 第23回東播磨脳卒中フォーラム(講演) 10.13, 2016. 明石
- 14) 飯原弘二. 脳卒中の医療体制の整備のための研究. 平成28年度循環器病研究振興財団研究成果発表会(研究者向け)(講演) 2.7, 2017. 東京
- 15) A Kurogi, D Onozuka, A Hagihara, A Kada, K Nishimura, S Kamitani, K Ogasawara, J Ono, Y Shiokawa, T Aruga, K Toyoda, S Miyachi,
- 16) S Yoshimura, K Okuchi, I Nagata, S Matsuda, F Nakamura, A Suzuki, K Ido, R Kurogi, A Nishimura, K Arimura, T Sayama, K Iihara. Temporal Trends of Intravenous Recombinant Tissue Plasminogen Activator Infusion and Endovascular Treatment for Acute Ischemic Stroke in Japan: J-ASPECT Study. International Stroke Conference 2017 2.22-24, 2017. Houston, Texas, U.S.A
- 17) A Nishimura, K Nishimura, A Kada, S Kamitani, K Ogasawara, J Ono, Y Shiokawa, T Aruga, K Toyoda, J Nakagawara, S Miyachi, S Yoshimura, K Okuchi, S Matsuda, F Nakamura, A Suzuki, T Sayama, K Arimura, A Kurogi, K Ido, K Iihara. Effects of Comprehensive Stroke Care Capabilities on Outcome of Carotid Endarterectomy and Carotid Artery Stenting (from the J-ASPECT Study [2013 to 2015]). International Stroke Conference 2017 2.22-24, 2017. Houston, Texas, U.S.A
- 18) K Arimura, K Nishimura, A Kada, S Kamitani, K Ogasawara, J Ono, Y Shiokawa, T Aruga, K Toyoda, J Nakagawara, S Miyachi, S Yoshimura, K Okuchi, I Nagata, S Matsuda, F Nakamura, D Onozuka, A Hagihara, A Suzuki, T Sayama, A Nishimura, R Kurogi, A Kurogi, K Ido, K Iihara. Geographical Disparity

- Of Acute Stroke Care Capabilities In Japan From A Nationwide Database: J-ASPECT Study. International Stroke Conference 2017 2.22-24, 2017. Houston, Texas, U.S.A
- 19) R Kurogi, K Nishimura, A Kada, S Kamitani, K Ogasawara, J Ono, Y Shiokawa, T Aruga, K Toyoda, J Nakagawara, S Miyachi, S Yoshimura, K Okuchi, I Nagata, S Matsuda, F Nakamura, D Onozuka, A Hagihara, A Suzuki, K Ido, A Kurogi, A Nishimura, K Arimura, T Sayama, K Iihara. A Nationwide Study Of Non-traumatic Intracranial Hemorrhage In Patients Receiving Direct Oral Anticoagulant TA19:B20herapy: J-Aspect Study. International Stroke Conference 2017 2.22-24, 2017. Houston, Texas, U.S.A
- 20) S Kamitani, K Nishimura, A Kada, T Sayama, K Arimura, A Nishimura, R Kurogi, A Kurogi, F Nakamura, Y Miyamoto, D Onozuka, A Hagihara, K Ogasawara, Y Shiokawa, S Miyachi, S Yoshimura, K Toyoda, J Nakagawara, S Matsuda, K Okuchi, T Aruga, J Ono, K Iihara. Comparison of Risk-Adjusted 30-day Mortality Models by Claims Data in Acute Ischemic Stroke With vs Without Adjustment for Stroke Severity : J-ASPECT Study. International Stroke Conference 2017 2.22-24, 2017. Houston, Texas, U.S.A
- 21) K Ido, A Kada, K Nishimura, S Kamitani, K Ogasawara, J Ono, S Yoshiaki, T Aruga, K Toyoda,
- 22) J Nakagawara, S Miyachi, S Yoshimura, K Okuchi, I Nagata, S Matsuda, F Nakamura, D Onozuka, A Hagihara, A Suzuki, R Kurogi, T Sayama, K Arimura, A Nishimura. Association Between Perioperative Management and Outcome in Aged SAH Patients. International Stroke Conference 2017 2.22-24, 2017. Houston, Texas, U.S.A
- 23) 黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、井戸啓介、西村 中、
- 24) 有村公一、佐山徹郎、有賀 徹、豊田一則、吉村紳一、宮地 茂、塩川芳昭、
- 25) 小笠原邦昭、飯原弘二. 本邦の脳虚血急性期治療に対する血管内治療の効果 -JASPECT study-. STROKE2017(シンポジウム) 3.16-19, 2017. 大阪
- 26) 黒木亮太、嘉田晃子、西村邦宏、小野塚大介、西村 中、井戸啓介、塩川芳昭、佐山徹郎、有村公一、飯原弘二. 年齢から見たくも膜下出血患者における破裂予防手術の選択が予後に与える影響 -J-ASPECT study-. STROKE2017 3.16-19, 2017. 大阪
- 27) 黒木亮太、西村邦宏、嘉田晃子、小笠原邦昭、塩川芳昭、豊田一則、中川原譲二、宮地 茂、吉村紳一、飯原弘二. NOAC内服中の非外傷性脳内出血の検討 -J-ASPECT Study -. STROKE2017 3.16-19, 2017. 大阪
- 28) 神谷 諭、西村邦宏、嘉田晃子、小笠原邦昭、西村 中、黒木 愛、井戸啓介、有村公一、佐山徹郎、飯原弘二. 脳梗塞のリスク調整死亡率の施設間格差に関する検討:J-ASPECT Study. STROKE2017 3.16-19, 2017. 大阪

- 29) 黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、井戸啓介、西村 中、有村公一、佐山徹郎、有賀 徹、豊田一則、吉村紳一、宮地 茂、塩川芳昭、小笠原邦昭、飯原弘二. 本邦の急性期脳梗塞に対する治療の現状-J-ASPECT study-. 第4回 日本心血管脳卒中学会学術集会(シンポジウム). 6.2-3, 2017. 福岡
- 30) 黒木亮太、西村邦宏、嘉田晃子、神谷諭、小笠原邦昭、塩川芳昭、豊田一則、中川原 讓二、宮地 茂、吉村紳一、松田晋哉、奥地一夫、永田 泉、小野塚大介、井戸啓介、黒木 愛、西村 中、有村公一、佐山徹郎、飯原弘二. DOAC 関連脳出血症例における臨床的特徴の検討、J-ASPECT Study. 第4回 日本心血管脳卒中学会学術集会. 6.2-3, 2017. 福岡
- 31) 井戸啓介、西村 中、西村邦宏、嘉田晃子、小笠原邦昭、豊田一則、中川原讓二、塩川芳昭、宮地 茂、吉村紳一、永田 泉、黒木 愛、有村公一、飯原弘二. 心疾患を合併した頸動脈狭窄症に対する外科治療-J-ASPECT Study-. 一般社団法人日本脳神経外科学会第76回学術総会. 10.12-14, 2017. 名古屋
- 32) 黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、井戸啓介、西村 中、有村公一、空閑太亮、有賀 徹、豊田一則、吉村紳一、宮地 茂、塩川芳昭、小笠原邦昭、飯原弘二. A study of the current situation for acute ischemic stroke in Japan: A national data linkage between Emergency Medical Services Data and J-ASPECT Data. 一般社団法人日本脳神経外科学会第76回学術総会(シンポジウム). 10.12-14, 2017. 名古屋
- 33) Kurogi R, Nishimura K, Nakai M, Nakagawara J, Toyoda K, Ogasawara K, Shiokawa Y, Yoshimura S, Kitazono T, Iihara K, J-ASPECT Study Collaborators. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin -J-ASPECT Study-. 第8回韓日合同脳卒中カンファレンス(The 8th Korea-Japan Joint Stroke Conference). 10.19-21, 2017. 新潟
- 34) 黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、井戸啓介、西村 中、有村公一、有賀 徹、豊田一則、吉村紳一、宮地 茂、塩川芳昭、小笠原邦昭、飯原弘二. 本邦の急性期脳梗塞に対する治療の現状-J-ASPECT study-. 第33回 NPO 法人日本脳神経血管内治療学会学術総会. 11.23-25, 2017. 東京
- 35) 黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、井戸啓介、西村 中、有村公一、空閑太亮、有賀 徹、豊田一則、吉村紳一、宮地 茂、塩川芳昭、小笠原邦昭、飯原弘二. 本邦の急性期脳梗塞における治療の現状と課題—J-ASPECT study と救急搬送データのデータリンケージによる検討. STROKE2018. 3.15-18, 2018. 福岡
- 36) 高岸 創、井戸啓介、黒木亮太、西村邦宏、嘉田晃子、有村公一、西村 中、黒木 愛、飯原弘二、J-ASPECT Study Investigators. 高齢者くも膜下出血患者の周術期管理と転帰の検討〜J-ASPECT study〜. STROKE2018. 3.15-18, 2018. 福岡

- 37) 井戸啓介、西村 中、西村邦宏、嘉田晃子、小笠原邦昭、豊田一則、中川原譲二、塩川芳昭、宮地 茂、吉村紳一、永田泉、黒木 愛、有村公一、飯原弘二. 心疾患を合併した頸動脈狭窄症に対する外科治療-J-ASPECT Study-. STROKE2018. 3.15-18, 2018. 福岡
- 38) 井戸啓介、西村 中、黒木 愛、有村公一、西村邦宏、小笠原邦昭、豊田一則、富永悌二、塩川芳昭、宮地 茂、北園孝成、飯原弘二. 頸動脈狭窄症の外科治療のアウトカムに対する心疾患合併の影響-J-ASPECT study. 第34回NPO法人日本脳神経血管内治療学会学術総会. 11.22-24, 2018. 仙台
- 39) 黒木 愛、西村邦宏、西村 中、有村公一、長谷川泰弘、豊田一則、吉村紳一、坂井信幸、北園孝成、飯原弘二、塩川芳昭、小笠原邦昭. 機械的血栓回収療法を施行された急性期脳梗塞患者において、年間手術数がアウトカムに与える影響 JASPECT Study からの検討. 第34回NPO法人日本脳神経血管内治療学会学術総会. 11.22-24, 2018. 仙台
- 40) 飯原弘二、北園孝成、小笠原邦昭、松丸祐司、吉村紳一、塩川芳昭、富永悌二、豊田一則、橋本洋一郎、坂井信幸、西村中、西村邦宏. Close The Gap-Stroke, J-ASPECT Study から見た血栓回収療法の地域格差. 第34回NPO法人日本脳神経血管内治療学会学術総会. 11.22-24, 2018. 仙台
- 41) 連 乃駿、黒木 愛、西村 中、有村公一、西村邦宏、豊田一則、鈴木倫保、北園孝成、塩川芳昭、坂井信幸、吉村紳一、飯原弘二. 本邦における急性期脳梗塞に対する機械的血栓回収療法の現状. 第34回NPO法人日本脳神経血管内治療学会学術総会. 11.22-24, 2018. 仙台
- 42) Nishimura K, Ogasawara K, Kitazono K, Yoneyama K, Shiokawa K, Toyoda T, Hashimoto Y, Suzuki M, Hasegawa Y, Kada A, Onozuka D, Nishimura A, Hagihara A, Iihara K. Impact of Physician Volume and Specialty on In-hospital Mortality of Ischemic and Hemorrhagic Stroke -j-aspect Study. International Stroke Conference 2019. 2.6-8, 2019. Honolulu, U.S.A
- 43) Nishimura A, Nishimura K, Matsuo R, Kada A, Kamitani S, Higashi T, Ogasawara K, Shimodozono M, Harada M, Hashimoto Y, Hirano T, Hishino H, Itabashi R, Itho Y, Iwama T, Kohriyama T, Matsumaru Y, Osato T, Sasaki M, Shiokawa Y, Shimizu H, Takegawa H, Nishi T, Uno M, Ido K, Kurogi A, Kurogi R, Arimura K, Kitazono T, Minematsu K, Iihara K. Development of the Close the Gap-stroke in the J-aspect Study: A Nationwide Quality Improvement Initiative of Japan. International Stroke Conference 2019. 2.6-8, 2019. Honolulu, U.S.A
- 44) 飯原弘二. 本邦の脳卒中医療提供体制の現状と課題-J-ASPECT Study. STROKE2019. 3.21-23, 2019. 横浜
- 45) 連 乃駿、黒木 愛、小野塚大介、萩原明人、嘉田晃子、西村邦宏、西村 中、有村公一、豊田一則、吉村紳一、宮地茂、塩川芳昭、小笠原邦昭、坂井信幸、飯原弘二. 本邦における急性期脳梗塞

に対する機械的血栓回収療法の現状
(J-ASPECT Study). STROKE2019.

3.21-23, 2019. 横浜

- 46) 黒木 愛、小野塚大介、萩原明人、嘉田
晃子、西村邦宏、有賀 徹、豊田一則、
吉村紳一、宮地 茂、塩川芳昭、小笠原
邦昭. 急性期脳梗塞治療に対する機械
的血栓回収療法の procedural volume の
影響:J-ASPECT Study からの検討.
STROKE2019. 3.21-23, 2019. 横浜

H. 知的財産権の出願・登録状況

(予定も含む)

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

「脳卒中の医療体制の整備のための研究」(厚労科研飯原班) 研究組織

氏名	所属 役職	
飯原 弘二	九州大学大学院医学研究院脳神経外科 教授	研究代表者
西村 邦宏	国立循環器病研究センター予防医学・疫学情報部 部長	研究分担者
吉村 紳一	兵庫医科大学脳神経外科 主任教授	研究分担者
塩川 芳昭	杏林大学医学部脳神経外科 教授	研究分担者
嘉田 晃子	名古屋医療センター臨床研究センター臨床試験研究部生物統計研究室 室長	研究分担者
小笠原 邦昭	岩手医科大学医学部脳神経外科 教授	研究分担者
豊田 一則	国立循環器病研究センター脳血管部門、脳血管内科 副院長	研究分担者
東 尚弘	国立がん研究センターがん対策情報センターがん登録センター センター長	研究分担者
坂井 信幸	神戸市立医療センター中央市民病院脳神経外科 部長	研究分担者
星野 晴彦	東京都済生会中央病院脳卒中センター 副院長 脳卒中センター長	研究分担者
長谷川 泰弘	聖マリアンナ医科大学神経内科 教授	研究分担者
橋本 洋一郎	熊本市民病院神経内科 首席診療部長	研究分担者
小川 彰	岩手医科大学 理事長	研究分担者
鈴木 倫保	山口大学大学院医学系研究科脳神経外科学 教授	研究分担者
辻野 彰	長崎大学病院脳神経内科 教授	研究分担者
北園 孝成	九州大学大学院医学研究院病態機能内科学 教授	研究分担者
松尾 龍	九州大学大学院医学研究院医療経営・管理学講座 助教	協力者
高木 俊範	兵庫医科大学脳神経外科 助教	協力者
天野 達雄	杏林大学脳卒中科 助教	協力者
高木 正仁	国立循環器病研究センター脳血管内科 医長	協力者
石原 秀行	山口大学大学院医学系研究科脳神経外科学 講師	協力者
中島 誠	熊本大学脳神経内科脳血管障害先端医療寄附講座 特任教授	協力者
伊佐早 健司	聖マリアンナ医科大学神経内科 助教	協力者
有村 公一	九州大学大学院医学研究院脳神経外科 助教	事務局
西村 中	九州大学大学院医学研究院脳神経外科 助教	事務局
黒木 愛	九州大学大学院医学研究院脳神経外科	事務局
井戸 啓介	九州大学大学院医学研究院脳神経外科	事務局
連 乃駿	九州大学大学院医学研究院脳神経外科	事務局
石床 亜里沙	九州大学大学院医学研究院脳神経外科 秘書	事務局

(順不同・敬称略)

Status and Future Perspectives of Utilizing Big Data in Neurosurgical and Stroke Research

Ataru NISHIMURA,¹ Kunihiro NISHIMURA,² Akiko KADA,³ Koji IIHARA,¹
and J-ASPECT Study GROUP

¹*Department of Neurosurgery, Graduate School of Medical Sciences,
Kyushu University, Fukuoka, Japan;*

²*Center for Cerebral and Cardiovascular Disease Information, National Cerebral
and Cardiovascular Center, Osaka, Japan;*

³*Department of Clinical Trials and Research, Clinical Research Center,
National Hospital Organization Nagoya Medical Center, Nagoya, Japan*

Abstract

The management, analysis, and integration of Big Data have received increasing attention in healthcare research as well as in medical bioinformatics. The J-ASPECT study is the first nationwide survey in Japan on the real-world setting of stroke care using data obtained from the diagnosis procedure combination-based payment system. The J-ASPECT study demonstrated a significant association between comprehensive stroke care (CSC) capacity and the hospital volume of stroke interventions in Japan; further, it showed that CSC capabilities were associated with reduced in-hospital mortality rates. Our study aims to create new evidence and insight from ‘real world’ neurosurgical practice and stroke care in Japan using Big Data. The final aim of this study is to develop effective methods to bridge the evidence-practice gap in acute stroke healthcare. In this study, the authors describe the status and future perspectives of the development of a new method of stroke registry as a powerful tool for acute stroke care research.

Key words: Big Data, neurosurgical research, stroke research, Diagnosis Procedure Combination

Introduction

The last decade has seen significant advances in the amount of data routinely generated and collected, as well as in our ability to use technology to analyze and understand this data. The intersection of these trends is called ‘Big Data’ and it is helping businesses in every industry achieve higher efficiency and productivity. Repeated observations over time and space generate most Big Data; examples include worldwide users’ Internet search engine queries (e.g., Google), e-commerce browsing and transactions (e.g., Amazon), and genomic sequencing in biomedical research.^{1,2)}

In the United States, the advanced bioinformatics technologies have led to the use of Big Data in many fields of healthcare. In stroke care, the use of Big Data has received considerable attention as an important source for creating new evidence.^{3–9)} Although the use of Big Data for healthcare is considered important in Japan, it is yet to be utilized effectively, including for stroke care research.

The nationwide survey of acute stroke care capacity for proper designation of comprehensive stroke centers in Japan (J-ASPECT study) is the first nationwide survey in Japan on the real-world setting of stroke using Big Data obtained from the diagnosis procedure combination (DPC) based payment system.^{10,11)} This review discusses the creation and analysis of Big Data using analytics and the current uses that are relevant to stroke and the J-ASPECT study that are challenges to using Big Data in stroke care research.

Big Data Analytics in Healthcare

A simple definition of Big Data is based on the concept of datasets whose sizes are beyond the management capabilities of typical relational database software. A more articulated definition of Big Data is based on the three V paradigm: volume, variety, and velocity.^{12,13)} The volume of the data requires novel storage scalability techniques and distributed approaches for information query and retrieval. The variety of the data source prevents the straightforward use of neat relational structures. Finally, the velocity, which is the increasing rate at

which data is generated, follows a similar pattern as the volume.¹⁴⁾ In the domain of healthcare, Big Data sources and techniques include structured electronic health record (EHR) data, unstructured clinical notes, medical imaging data,¹⁵⁾ genetic data,¹⁶⁾ and the other data (epidemiology and behavioral data).¹⁷⁾

Despite the inherent complexities of healthcare data, there is potential and benefit in developing and implementing Big Data solutions within this realm. A report by McKinsey Global Institute suggests that if the United States healthcare were to use Big Data creatively and effectively, the sector could create more than \$300 billion in value every year.¹⁸⁾ Two-thirds of the value would be in the form of reducing the United States healthcare expenditure.¹⁸⁾ Advances in computer and networking technology, patient monitoring systems, and EHR systems have allowed hospitals to collect and store a rapidly increasing volume and variety of patient data.^{19,20)} Increasing the recognition of the potential utility of Big Data in health outcomes research has created an impetus to collect and pool EHR data in national datasets. These large datasets provide access to information regarding rare conditions and outcomes that are otherwise difficult to study without robust sample sizes. The goal of Big Data analytics in healthcare is to build evidences and insights based on the 'real world,' and furthermore, to use these evidences to lower costs and improve outcomes through smarter decisions.

Bid Data Analyses about Stroke in the United States

An example of health-care-related Big Data efforts in the United States is the nationwide inpatient sample (NIS), which is structured inpatient EHR data. The NIS is one of the major databases compiled and maintained by the healthcare cost and utilization project (HCUP), which is funded by the agency for healthcare research and quality (AHRQ). Federal and state governments along with medical industry fund AHRQ.²¹⁾

The NIS is the largest all-payer database of inpatient discharge data, and hence, it is a useful dataset for outcomes research. Among hospitals participating in the survey, every discharge for the calendar year is included. The database contains discharge-level data instead of patient-level data, and there is no unique patient identifier to identify re-admissions. Several severity measures are also included in the NIS. Researchers can use these measures for risk-adjustment, or to develop their own risk-adjustment models using the diagnosis and procedure codes included in the data. The NIS does not currently identify conditions present on admission. The age, gender, socioeconomic factor and comorbidities index such as Charlson

comorbidities index is a typical adjustment factor for risk-adjustment. Propensity score matched analyses or mixed model analyses adjusted for hospital level variability of disease severity are typical statistical methods conducted in claims-based analysis.

NIS contains data on a stratified sample of over 1000 US hospitals with approximately 8 million hospital stays per year; weights are available to convert NIS data into national estimates.²¹⁾ Further, specialty hospitals (e.g., orthopedics or obstetrics-gynecology hospitals) are included, as are long-term acute care hospitals (since 2005). The data have been collected on an annual basis since 1988, and resources are available to facilitate the evaluation of time trends.

For the effective use of Big Data in stroke care, analyses using NIS have been reported in the United States since 1999; further, the number of articles increased rapidly after 2006. Chronological change in stroke care in the United States can be analyzed using NIS database as it provides not only overall nationwide data, but also continuous data per annum.

The NIS provides important information such as nationwide epidemiological and health economical information. In 1999, Williams et al. reported the estimation of the occurrence, incidence, and characteristics of total (first-ever and recurrent) stroke using the NIS database that is representative of all 1995 US inpatient discharges.³⁾ There were 682,000 occurrences of stroke with hospitalization and an estimated 68,000 occurrences of stroke without hospitalization. The overall incidence rate for the occurrence of total stroke (first-ever and recurrent) was 259 per 100,000 population (age- and sex-adjusted to 1995 US population). This new figure emphasized the importance of preventive measures for a disease that has identifiable and modifiable risk factors and of the development of new and improved treatment strategies and infrastructures that can reduce the consequences of stroke. The impact of new treatments for stroke was evaluated by examining the changes between 1990 to 1991 and 2000 to 2001 in in-hospital mortality rates and hospital charges in adult patients with stroke.⁴⁾ There had been an increase in the inflation-adjusted hospital charges for all patients with stroke and a reduction in mortality rates for all stroke subtypes, which was probably related to an increase in the proportion of patients with stroke admitted to urban teaching hospitals.

NIS data can provide clinical data such as clinical background or outcome; therefore, a researcher can analyze these data similar to a normal registry. Outcomes in acute stroke patients treated with thrombolysis were examined using the NIS database available in the United States for the years 1999–2002.⁵⁾ The thrombolysis cohort had a higher in-hospital mortality rate compared with nonthrombolysis patients (11.4%

vs. 6.8%). The rate of intracerebral hemorrhage was 4.4% for the thrombolysis cohort and 0.4% for nonthrombolysis patients. Multivariate logistic regression showed advanced age, Asian/Pacific Islander race, congestive heart failure, and atrial fibrillation/flutter to be independent predictors of in-hospital mortality after thrombolysis. Trends in therapy for cerebral aneurysms in the US were identified along with outcomes, using NIS data for the period 1993–2003.⁶⁾ Endovascular techniques for aneurysm occlusion have been increasingly used, while the use of surgical clipping procedures has remained stable. Toward the end of the study period, better overall outcomes were observed in the treatment of cerebral aneurysms, both ruptured and unruptured. Large academic centers were associated with better results, particularly for surgical clip placement. It was hypothesized that patients with ICH had a higher mortality risk if they were admitted to the hospital on the weekends than if they were admitted during the week.⁷⁾

One advantage of nationwide claim data such as NIS is that they can provide data about rare diseases or special treatments that are difficult to obtain from a single facility. The incidence, mortality, and risk factors for pregnancy-related stroke in the United States from 2000–2001 were estimated.⁸⁾ A total of 2,850 pregnancy-related discharges included a diagnosis of stroke for a rate of 34.2 per 100,000 deliveries. There were 117 deaths or 1.4 per 100,000 deliveries. African-American women are at an increased risk, as are women aged 35 years and older. Risk factors, not previously reported, include lupus, blood transfusion, and migraine headaches. The acute stroke hospitalization rates for children and young adults (aged 15–44 years) and the prevalence of stroke risk factors among children and young adults hospitalized for acute stroke⁹⁾ has been examined. The prevalence of hospitalizations of acute ischemic stroke increased among all age and gender groups except females aged 5–14 years. Hypertension, diabetes, obesity, lipid disorders, and tobacco use were among the most common coexisting conditions, and their prevalence increased during the period of study among adolescents and young adults hospitalized with acute ischemic stroke.

About 250 articles are published using the NIS database related to stroke. They become an important evidence for epidemiology or health economy about stroke.

Attempt using Big Data about Stroke in Japan—J-ASPECT study

The DPC is a mixed-case patient classification system that was launched in 2002 by the Ministry

of Health, Labor, and Welfare of Japan (MHLW) and was linked with a lump-sum payment system.²²⁾ This system collects important data during hospitalization in addition to the characteristics of the unique reimbursement system. Each patient's background information or discharge summary, which includes principal diagnosis, complications, comorbidities, and outcomes are recorded in the administrative database associated with the DPC system. These patient data are coded using the International Classification of Diseases and Injuries 10th Revision (ICD-10) code. The DPC project collects three types of information: Form 1 is a clinical summary that contains information on diagnosis and severity. The E file has information about the bundled charge of the procedure and the F-file indicates the detail of the bundled procedures. Form 1, E-file, and F-file are matched according to the ID number that is unique for each discharged case. Using these data, we can describe the process of each in-patient treatment. From the point of view of Big Data, the DPC is regarded as a large sample of the structured inpatient EHR data in Japan.

The J-ASPECT study was performed to examine the associations between PSC and CSC capabilities and the impact of CSC capabilities on the hospital volume of stroke interventions. This cross-sectional survey used the DPC discharge database from participating institutions in the J-ASPECT study.

Impact of Comprehensive Stroke Care Capacity on the Hospital Volume of Stroke Interventions¹⁰⁾

In 2000, the brain attack coalition discussed the concept of stroke centers and proposed two types of centers: comprehensive stroke centers (CSCs) and primary stroke centers (PSCs).^{23,24)} Most patients with stroke can be treated appropriately at a PSC, and the joint commission has established programs for certifying PSCs and evaluating their performance.²⁵⁾ The concept and recommended key components of CSCs enable intensive care and specialized techniques that are not available at most PSCs. A set of metrics and associated data elements that cover the major types of care distinguishing CSCs from PSCs have been published previously.^{23,24)}

In the J-ASPECT study, a 49-question survey was developed on hospital characteristics (i.e., number of beds, academic status, geographic location, and participation in the DPC payment system), PSC and CSC capacity, and hospital volume of stroke interventions. The questionnaire was mailed on February 2011 to 1369 certified training institutions of the Japan Neurosurgical Society, Japanese Society of Neurology, and Japan Stroke Society. This survey included 25 items related to the five

major components of CSCs (personnel, diagnostic programs, specific expertise, infrastructure, and educational components) and five items related to PSC certification (Table 1). CSC scores were divided with/without the availability of a t-PA protocol into quintiles and analyzed the trend with the

Table 1 Number (percentage) of responding hospitals (n = 749) with the recommended items of comprehensive stroke care capacity

Components	Items	n	%
Personnel	Neurologists	358	47.8
	Neurosurgeons	694	92.7
	Endovascular physicians	272	36.3
	Critical care medicine	162	21.6
	Physical medicine and rehabilitation	113	15.1
	Rehabilitation therapy	742	99.1
	Stroke rehabilitation nurses*	102	13.8
Diagnostic (24/7)	CT*	742	99.2
	MRI with diffusion	647	86.4
	Digital cerebral angiography*	602	80.8
	CT angiography*	627	84
	Carotid duplex ultrasound*	257	34.5
	TCD*	121	16.2
Specific expertise	Carotid endarterectomy*	603	80.6
	Clipping of IA	685	91.5
	Hematoma removal/drainage	689	91.9
	Coiling of IA	360	48.1
	Intra-arterial reperfusion therapy	498	66.5
Infrastructure	Stroke unit*	132	17.6
	Intensive care unit	445	59.4
	Operating room staffed 24/7*	451	60.4
	Interventional services coverage 24/7	279	37.3
	Stroke registry*	235	31.7
Education	Community education*	369	49.4
	Professional education*	436	58.6

CT: computed tomography, IA: intracranial aneurysm, MRI: magnetic resonance imaging, TCD: transcranial Doppler.

Data missing: stroke rehabilitation nurse, 9; CT, 1; digital cerebral angiography, 4; CT angiography, 3; carotid endarterectomy, 1; carotid duplex, 3; TCD, 3; stroke unit, 1; operating room staffed, 2; stroke registry, 7; community education, 2; professional education, 5. Reproduced from Iihara et al.¹⁰⁾ with permission from the publisher. Copyright © 2014 National Stroke Association.

Cochran-Armitage trend test and multivariable linear regressions for the hospital volume.

Approximately 749 hospitals responded to the survey. On performing multivariate analysis adjusted for hospital characteristics, the total CSC score, but not the availability of a t-PA protocol, was associated with the volume of all types of interventions with a clear increasing trend (P for trend < 0.001) (Fig. 1).

This study demonstrated a significant impact of comprehensive stroke care capacity represented by the total CSC score on the hospital volume of stroke interventions and unique aspects of comprehensive stroke care capacity in Japan.

Impact of CSC capabilities on in-hospital mortality in patients with stroke¹¹⁾

Among the institutions that responded to the questionnaire on CSC capacity, data on patients hospitalized for stroke between April 1 2010 and March 31 2011 were obtained from the Japanese DPC database. In-hospital mortality was analyzed with hierarchical logistic regression analysis adjusted for age, sex, level of consciousness on admission, comorbidities, and the number of fulfilled CSC items in each component and in total. Hierarchical logistic regression models were used to estimate odds ratios (ORs) for in-hospital mortality adjusting for institutional level difference. Each model had two levels of hierarchy (hospital and patient) while considering the random effects of hospital variation, as well as fixed effects of CSC score and patient effects of age, sex, and level of consciousness. The total score and each subcategory score were analyzed separately. CSC scores were divided into quintiles and analyzed the trend with the Cochran-Armitage trend test.

Data from 265 institutions and 53,170 emergency-hospitalized patients were analyzed (Table 2). Mortality adjusted for age, sex, and level of consciousness was significantly correlated with personnel, infrastructural, educational, and total CSC scores in patients with ischemic stroke. Mortality was significantly correlated with diagnostic, educational, and total CSC scores in patients with ICH and with specific expertise, infrastructural, educational, and total CSC scores in patients with SAH.

CSC capabilities were associated with reduced in-hospital mortality rates, and the relevant aspects of care were found to be dependent on stroke type (Fig. 2).

Problems and future perspectives of utilizing Big Data

There are some problems for the DPC-based clinical study. The most frequent problem is the accuracy of information.²⁶⁾ As DPC data is closely related to




Fig. 1 Associations between primary and comprehensive stroke care capabilities and case volume of stroke treatment in 2009 in Japan. The inclusion of total comprehensive stroke care (CSC) score, availability of a tissue-type plasminogen activator (t-PA) protocol, and other hospital characteristics in the model revealed that the total CSC score, but not the availability of a t-PA protocol, was significantly associated with the hospital volume of stroke interventions. Q, quintile. Reproduced from Iihara et al.¹⁰⁾ with permission from the publisher. Copyright © 2014 National Stroke Association.

the payment, there is a possibility that the medical staff may allocate inappropriate diagnosis in order to obtain more reimbursements. The second problem is the possibility of sampling bias. The current DPC database covers only acute in-patient cases.

Furthermore, DPC data do not provide detailed medical information in comparison with general large-scale cohort studies. Because DPC data are limited to hospitalized data, it can provide information about outcomes such as complications or hospitalized death; however, it cannot provide data such as foreign progress or long-term convalescence.

While DPC data have these limitations, the advantage compared with the other databases is that it can cover all types of diseases treated in acute care

facilities. Furthermore, we can obtain data about rare diseases or special treatments, which are difficult to obtain from a single facility.

There have been few academic papers on a large-scale clinical study originating in Japan. One of the reasons is that most Japanese clinical studies are small-scale studies based on close hospital groups, i.e., one university hospital and its associate facilities, and the case registry database is limited to some diseases and domains. Therefore, nationwide statistics about various diseases and treatments are insufficient in Japan. Because nationwide claim data such as DPC data can be obtained from multiple centers with the same format, it is expected as a valid solution to these problems.

Table 2 Demographics of the patient study cohort at the time of diagnosis and hospital characteristics according to stroke type

	Total (n = 53,170)	Ischemic stroke (n = 32,671)	Intracerebral hemorrhage (n = 15,699)	Subarachnoid hemorrhage (n = 4,934)
Male, n (%)	29,353 (55.2)	18,816 (57.6)	9,030 (57.5)	1,584 (32.1)
Age, mean years \pm SD	72.5 \pm 13.1	74.4 \pm 12.2	70.7 \pm 13.5	64.7 \pm 14.8
Hypertension, n (%)	39,918 (75.1)	22,531 (69.0)	13,281 (84.6)	4,229 (85.7)
Diabetes Mellitus, n (%)	13,725 (25.8)	9,318 (28.5)	3,278 (20.9)	1,174 (23.8)
Hyperlipidemia, n (%)	15,015 (28.2)	11,104 (34.0)	2,529 (16.1)	1,412 (28.6)
Medications during hospitalization				
Anti-renin-angiotensin system agent	34,136 (64.2)	17,694 (54.2)	12,537 (79.9)	4,019 (81.5)
Ca channel antagonist	25,984 (48.9)	10,469 (32.0)	11,719 (74.6)	3,903 (79.1)
Sympathetic antagonist	6,334 (11.9)	3,821 (11.7)	2,172 (13.8)	364 (7.4)
* β -blocker, α , β -blocker	4,357 (8.2)	3,048 (9.3)	1,133 (7.2)	188 (3.8)
α -blocker	2,374 (4.5)	953 (2.9)	1,232 (7.8)	200 (4.1)
Diuretic agent	9,950 (18.7)	5,860 (17.9)	3,074 (19.6)	1,049 (21.3)
Loop diuretic	7,434 (14.0)	4,609 (14.1)	1,912 (12.2)	940 (19.1)
Other diuretic	4,425 (8.3)	2,527 (7.7)	1,653 (10.5)	255 (5.2)
Antidiabetic agent	10,295 (19.4)	6,784 (20.8)	2,473 (15.8)	1,075 (21.8)
Insulin	7,654 (14.4)	4,597 (14.1)	2,044 (13.0)	1,046 (21.2)
Oral antidiabetic agent	5,749 (10.8)	4,459 (13.6)	1,110 (7.1)	197 (4.0)
Antihyperlipidemic agent	12,387 (23.3)	9,264 (28.4)	1,839 (11.7)	1,310 (26.6)
Statin	10,099 (19.0)	7,840 (24.0)	1,366 (8.7)	912 (18.5)
Antiplatelet agent	23,635 (44.5)	21,746 (66.6)	625 (4.0)	1,298 (26.3)
Aspirin	11,929 (22.4)	11,119 (34.0)	378 (2.4)	447 (9.1)
Japan Coma Scale				
0, n (%)	19,635 (36.9)	15,027 (46.0)	3,620 (23.1)	1,024 (20.8)
1-digit code, n (%)	19,371 (36.4)	12,375 (37.9)	5,934 (37.8)	1,117 (22.6)
2-digit code, n (%)	6,937 (13.0)	3,396 (10.4)	2,705 (17.2)	852 (17.3)
3-digit code, n (%)	7,227 (13.6)	1,873 (5.7)	3,440 (21.9)	1,941 (39.3)
Emergency admission by ambulance, n (%)	31,995 (60.2)	17,336 (53.1)	10,909 (69.5)	3,830 (77.6)
Average days in hospital (range)	21 (11–40)	20 (12–38)	22 (10–43)	30 (12–54)
Hospital characteristics (CSC scores)				
Total score (25 items)		16.7 \pm 3.8	16.8 \pm 3.4	17.1 \pm 3.4
Personnel (7 items)		3.7 \pm 1.2	3.7 \pm 1.2	3.8 \pm 1.2
Diagnostic techniques (6 items)		4.4 \pm 1.1	4.5 \pm 1.0	4.5 \pm 1.0
Specific expertise (5 items)		4.4 \pm 1.0	4.4 \pm 0.9	4.5 \pm 0.8
Infrastructure (5 items)		2.8 \pm 1.3	2.9 \pm 1.3	2.9 \pm 1.3
Education (2 items)		1.4 \pm 0.8	1.4 \pm 0.8	1.4 \pm 0.8

CSC: comprehensive stroke center. *A composite variable with a pure beta antagonist and a mixed alpha/beta adrenergic antagonist (e.g., labetalol). Reproduced from Iihara et al.¹¹⁾ with permission.




Fig. 2 Associations between total comprehensive stroke care scores separated into quintiles (Q) and in-hospital mortality of patients after all types of stroke. Odds ratios (ORs) and 95% confidence intervals (CIs) of in-hospital mortality for each quintile are depicted compared with that of Q1 as the control (Q1, 4–12 points; Q2, 13–14 points; Q3, 15–17 points; Q4, 18 points; Q5, 19–23 points). Reproduced from Iihara et al.¹¹⁾ with permission.

As for J-ASPECT study, it is advantage that the overall database about stroke can be established and important information can be provided effectively without bothering stroke physicians. Furthermore, the facilities that participated can feedback their medical treatment process and the outcome of stroke compared to other Japanese hospitals; this benchmark promotes improvements in the quality of the stroke care in each facility.

To make up for the shortcomings of the DPC data and realize a higher quality clinical epidemiologic study, it will be important to link the DPC database with other databases. In the United States, the surveillance, epidemiology, and end results (SEER)-Medicare database is constructed for cancer research. The SEER-Medicare data reflect the linkage of two large population-based sources

of data that provide detailed information about Medicare beneficiaries with cancer. The data come from the SEER program of cancer registries that collect clinical, demographic, and the cause of death information for persons with cancer and the Medicare claims for covered health care services from the time of a person's Medicare eligibility until death.²⁷⁾

In the field of stroke care, claim data and registry is expected to be linked. In Japan, the construction of the nationwide stroke registry has been planned in order to foresee the development of the basic law for stroke measures. In the future, the linkage of this stroke registry and DPC database can result in a unique population-based source of information that can be used for an array of epidemiological and health services research. Furthermore, it can help

discard the manual work required to enter the data in each facility and reduce the burden on prostrate stroke physicians.

Conclusion

The use of Big Data is expected as an effective modality that establishes new evidence about stroke care. The J-ASPECT study demonstrated the importance of the impact of CSC capacity and CSC capabilities on in-hospital mortality in stroke using the DPC database, one of the Big Data databases in Japan. The advantages of applying Big Data such as DPC to stroke care are that the overall database about stroke can be established without bothering stroke physicians and it can become a large-scale clinical study originating in Japan. The development of a new method of stroke registry using Big Data is expected as it would greatly improve future stroke care.

Disclosures

The J-ASPECT study was supported by the grants-in-aid from the Ministry of Health, Labour, and Welfare of Japan (principal investigator, KI). AN, KN and AK have no conflicts of interests to declare. KI received grants from Nihon Medi-Physics, Otsuka Pharmaceutical Co., Ltd., AstraZeneca K.K.

Acknowledgement

We thank Prof. Nobuo Hashimoto (National Cerebral and Cardiovascular Center) and Prof. Takamasa Kayama (Yamagata University) for collaboration with the Japan Neurosurgical Society and Profs. Akira Ogawa (Iwate Medical College) and Norihiro Suzuki (Keio University) for collaboration with the Japan Stroke Society. We also thank Dr. Manabu Hasegawa (Shimonoseki City Health Care Center) and Dr. Yasuhiro Nishijima and Dr. Kei Takayama (Ministry of Health, Labour and Welfare) for the helpful discussion, and Arisa Ishitoko for secretarial assistance.

References

- 1) Laney D: 3D data management: controlling data volume, velocity, and variety. <https://blogs.gartner.com/doug-laney/files/2012/01/ad949-3D-Data-Management-Controlling-Data-Volume-Velocity-and-Variety.pdf>
- 2) Mayer-Schonberger V, Cukier K: Chapter 1: Now. In: Mayer-Schonberger V, Cukier K, eds. Big data: A revolution that will transform how we live, work, and think. *Boston: Boston Houghlin Mifflin Harcourt* 1–18, 2013
- 3) Williams GR, Jiang JG, Matchar DB, Samsa GP: Incidence and occurrence of total (first-ever and recurrent) stroke. *Stroke* 30: 2523–2528, 1999
- 4) Qureshi AI, Suri MF, Nasar A, Kirmani JF, Ezzeddine MA, Divani AA, Giles WH: Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. *Stroke* 38: 2180–2184, 2007
- 5) Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J: Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. *Stroke* 37: 440–446, 2006
- 6) Andaluz N, Zuccarello M: Recent trends in the treatment of cerebral aneurysms: analysis of a nationwide inpatient database. *J Neurosurg* 108: 1163–1169, 2008
- 7) Crowley RW, Yeoh HK, Stukenborg GJ, Medel R, Kassell NF, Dumont AS: Influence of weekend hospital admission on short-term mortality after intracerebral hemorrhage. *Stroke* 40: 2387–2392, 2009
- 8) James AH, Bushnell CD, Jamison MG, Myers ER: Incidence and risk factors for stroke in pregnancy and the puerperium. *Obstet Gynecol* 106: 509–516, 2005
- 9) George MG, Tong X, Kuklina EV, Labarthe DR: Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008. *Ann Neurol* 70: 713–721, 2011
- 10) Iihara K, Nishimura K, Kada A, Nakagawara J, Toyoda K, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Matsuda S, Ishikawa KB, Suzuki A, Mori H, Nakamura F: J-ASPECT Study Collaborators: The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: a nationwide study in Japan: J-ASPECT study. *J Stroke Cerebrovasc Dis* 23: 1001–1018, 2014
- 11) Iihara K, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Miyamoto Y, Suzuki A, Ishikawa KB, Kataoka H, Nakamura F, Kamitani S: Effects of comprehensive stroke care capabilities on in-hospital mortality of patients with ischemic and hemorrhagic stroke: J-ASPECT study. *PLoS One* 9: e96819, 2014
- 12) McAfee A, Brynjolfsson E: Big data: the management revolution. *Harv Bus Rev* 90: 60–66, 68, 128, 2012
- 13) Lynch C: Big data: How do your data grow? *Nature* 455: 28–29, 2008
- 14) Merelli I, Perez-Sanchez H, Gesing S, D'Agostino D: Managing, analysing, and integrating Big Data in medical bioinformatics: open problems and future perspectives. *Biomed Res Int* 2014: 1–13, 2014
- 15) Tempany CM, Jayender J, Kapur T, Bueno R, Golby A, Agar N, Jolesz FA: Multimodal imaging for improved diagnosis and treatment of cancers. *Cancer* 121: 817–827, 2015
- 16) Cain AA, Kosara R, Gibas CJ: GenoSets: visual analytic methods for comparative genomics. *PLoS One* 7: e46401, 2012

- 17) Chui KK, Wenger JB, Cohen SA, Naumova EN: Visual analytics for epidemiologists: understanding the interactions between age, time, and disease with multi-panel graphs. *PLoS One* 6: e14683, 2011
 - 18) Manyika J, Chui M, Brown B, Bughin J, Dobbs R, Roxburgh C, Byers AH: Big Data: The next frontier for innovation, competition, and productivity. *McKinsey Global Institute*, 2011
 - 19) Wolfe PJ: Making sense of Big Data. *Proc Natl Acad Sci U S A* 110: 18031–18032, 2013
 - 20) Costa FF: Big Data in biomedicine. *Drug Discov Today* 19: 433–440, 2014
 - 21) Databases. Healthcare Cost and Utilization Project (HCUP). November 2015. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.hcup-us.ahrq.gov/nisoverview.jsp>.
 - 22) Yasunaga H, Ide H, Imamura T, Ohe K: Impact of the Japanese diagnosis procedure combination-based payment system on cardiovascular medicine-related costs. *Int Heart J* 46: 855–866, 2005
 - 23) Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O'Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD: Brain Attack Coalition: Recommendations for comprehensive stroke centers: a consensus statement from the brain attack coalition. *Stroke* 36: 1597–1616, 2005
 - 24) Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girgus M, Shephard T, Emr M, Shwayder P, Walker MD: Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. *JAMA* 283: 3102–3109, 2000
 - 25) Reeves MJ, Parker C, Fonarow GC, Smith EE, Schwamm LH: Development of stroke performance measures: definitions, methods, and current measures. *Stroke* 41: 1573–1578, 2010
 - 26) Matsuda S, Fujimori K, Kuwabara K, Ishikawa KB, Fushimi K: Diagnosis procedure combination as an infrastructure for the clinical study. *Asian Pac J Dis Manag* 5: 81–87, 2011
 - 27) National Cancer Institute. SEER-Medicare Linked Database. <http://healthcaredelivery.cancer.gov/seer-medicare/>
-
- Address reprint requests to:* Koji Iihara, MD, PhD, Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
e-mail: kiihara@ns.med.kyushu-u.ac.jp

Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor)

Koji YOSHIMOTO,¹ Akiko KADA,² Daisuke KUGA,¹ Ryusuke HATAE,¹ Hideki MURATA,¹ Yojiro AKAGI,¹ Kunihiro NISHIMURA,³ Ryota KUROI,¹ Ataru NISHIMURA,¹ Nobuhiro HATA,^{1,4} Masahiro MIZOGUCHI,^{1,5} Tetsuro SAYAMA,¹ and Koji IHARA¹

¹Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

²Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan;

³Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Suita, Japan;

⁴Department of Neurosurgery, National Kyushu Medical Center, Fukuoka, Japan;

⁵Department of Neurosurgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

Abstract

We conducted this study to clarify the current trends and healthcare resource usage in the treatment of inpatients with primary malignant brain tumors. The Diagnostic Procedure Combination (DPC) data of all inpatients treated between 2013 and 2014 in the 370 core and branch hospitals enrolled in the Japanese Neurosurgical Society training program were collected. DPC is a discharge abstract and administrative claims database of inpatients. We assessed 6,142 primary, malignant brain tumor patients. Patient information, diagnostic information, treatment procedure, and healthcare resource usage were analyzed. Chemotherapy was the most frequent treatment (27% of cases), followed by surgery (13%) and surgery + chemo-radiotherapy (11%). Temozolomide (TMZ), the most frequently used chemotherapeutic drug, was administered to 1,236 patients. Concomitant TMZ and radiotherapy was administered to 816 patients, and was performed according to the Stupp regimen in many cases. The mean length of hospital stay (LOS) was 16 days, and the mean medical cost was 1,077,690 yen. The average medical cost of TMZ-only treatment was 1,138,620 yen whilst it was 4,424,300 yen in concomitant TMZ patients. The LOS was significantly shorter in high-volume than in low-volume hospitals, and the medical cost was higher in hospitals treating 21–50 patients compared to those treating 1–10 patients. However, the direct medical cost of TMZ treatment was the same across different volume hospitals. This is the first report of current trends and healthcare resource usage in the treatment of primary malignant brain tumor inpatients in the TMZ era in Japan.

Key words: malignant brain tumor, DPC, temozolomide, medical cost

Introduction

Malignant brain tumors are amongst the most lethal types of cancer. Its incidence is increasing, and hence, a growing number of patients are being treated in the clinic.^{1–4)} The current incidence of primary brain tumors is 10–20 cases per 100,000

of the general population. Primary malignant brain tumors can be classified into a number of histological subtypes, but are mostly gliomas with a World Health Organization (WHO) grade between I and IV. Treatment consists of surgery, radiotherapy (RT), and chemotherapy (CTX), either alone or in combination, depending on the tumor histology and the patient's condition. Temozolomide (TMZ) is an oral alkylating agent, and has been widely

used to treat primary malignant glioma patients in Japan since 2006 when it was first covered by health insurance. After the publication of Stupp et al's influential study, the standard initial treatment strategy for malignant glioma became concomitant RT and TMZ-based CTX.⁵⁾ However, as TMZ is an expensive drug compared to carmustine and procarbazine, the economic burden of TMZ usage for the treatment of malignant glioma has been a matter of debate. For example, Wasserfallen et al reported that TMZ usage in concomitant and adjuvant treatment increased medical costs eight fold in a single institution cohort in Switzerland.⁶⁾ Nevertheless, several studies demonstrated the cost-effectiveness of TMZ treatment in malignant brain tumor treatment.⁷⁻⁹⁾ In this context, there is no data as to how many primary brain tumor patients are treated in Japanese hospitals, and how often TMZ is administered overall and in single hospitals. Given that concomitant TMZ treatment after surgery is considered the standard treatment internationally for malignant glioma, the medical economics of TMZ usage should be evaluated in individual countries because the health insurance system is different in each country.

In 2002, the Japanese government introduced a per diem prospective payment system with a Diagnosis-Related Groups (DRG)-like grouping, which is called Diagnostic Procedure Combination (DPC).¹⁰⁾ Data for practices can be obtained from DPC, and an attending physician is responsible for clinical data entry for each patient. Using this database, we have previously reported the discharge outcomes of cerebrovascular disease patients in a nationwide retrospective analysis (the J-ASPECT study).¹¹⁻¹³⁾ In this study, we collected and analyzed all the DPC data for patients treated in 370 core and branch hospitals from a total of 847 hospitals participating in the Japan Neurosurgical Society training program. Brain tumor patients are treated in neurosurgical hospitals in Japan, and this treatment includes CTX and RT. Therefore, this dataset may include the majority of data for patients treated in Japan during the designated period.

The first aim of this study was to reveal what kind of therapeutic modality is administered, and the difference of modality based on patient age, focusing particularly on TMZ usage in the Japanese clinical setting. The second aim was to evaluate healthcare resource usage based on measures such as length of hospital stay (LOS) and direct medical cost using an exhaustive patient administrative claim database. Our findings clarify the current trends in the treatment of primary malignant brain tumor patients, and its associated medical economics in Japan.

Materials and Methods

Data acquisition

Of the 847 hospitals participating in the Japan Neurosurgical Society training program, 392 agreed to participate in this study. We obtained data between April 2013 and March 2014 from 392 hospitals, but 22 hospitals were excluded from the analysis because insufficient data are available. In total, the data from 370 hospitals were analyzed, including the DPC data of 501,609 patients admitted to neurosurgical hospitals. This dataset included background patient information such as age, sex, Charlson score, and Japan Coma Scale (JCS) score: 1, 2, 3-digit, and we could acquire information about the treatment procedure and modality, and the administered drug. In addition, we could obtain healthcare resource usage information such as the LOS and direct medical cost. Direct medical costs include hospitalization, medications, imaging examinations, surgery, CTX, and RT. Analysis of indirect medical costs is not included in this study. As mentioned above, the DPC reimbursement system pays for the surgery, RT, and CTX as fee-for-service (FFS), while other costs for hospitalization, medications, blood examination, imaging examination, and physician time are inclusive. As the cost of chemotherapeutic drugs is inclusive, the dose and duration of CTX are not reflected in DPC reimbursement. The medical cost was converted into US dollars based on an exchange rate at 103 Japanese Yen per US dollar.

Patient extraction

In this study, we focused on patients with primary malignant brain tumors of neuroepithelial origin. The DPC database does not include diagnostic histological information. The ICD-10 codes denote different intracranial primary malignant tumors as follows: C71, malignant brain tumor; C70, malignant intracranial tumor originating in the meninges; and C72, malignant intracranial tumor originating in the cranial nerves. In order to extract information on primary malignant brain tumors of neuroepithelial origin, we used C71 as the DPC ICD-10 code. Using this code, we assumed that we could extract data on astrocytic, oligodendroglial, ependymal, pineal, embryonal, germ cell, and other neuroepithelial tumors. Primary central nervous system lymphomas were not included as they are specified by a different code. We also assumed that no malignant meningeal, mesenchymal, or peripheral nerve sheath tumors were included in the analysis. Patients with malignant tumors in the sellar region and pituitary tumors were also excluded. In total, data for 6,142 patients with a primary malignant brain tumor were retrieved using code C71. Data analysis was performed for these patients.

Evaluation of treatment modalities

The DPC database includes sub-codes that specify the surgical procedures and adjuvant therapy used, allowing demographic data to be stratified according to the treatment modalities described below.

Surgery

The type of surgical treatment is specified by a K-code. In this study, we aimed to extract data on surgical procedures related directly to tumor treatment. We used codes K169 (tumor removal by craniotomy), K171 (transsphenoidal tumor removal), and K151-2 (tumor removal by extended skull base craniotomy) to extract data for patients who had a tumor removed by craniotomy. In addition, to extract data on biopsies, we used codes K148 (only craniotomy), K1541 (functional stereotactic surgery [hemilateral]), and K164-4 (stereotactic hematoma evacuation) because stereotactic tumor biopsy was not K-coded as of the end of this study period. We also included codes K1492 (decompressive craniectomy), K145 (extra-ventricle drainage), and K174 (operation for hydrocephalus). Collectively, to extract data for malignant brain tumor patients who underwent surgery, we used codes K-169, K148, K1541, K164-4, K171, K151-2, K1492, K145, and K174 (Table 1).

CTX

In order to evaluate the use of chemotherapeutic drugs, we selected the following agents that are used in the neurosurgical clinic: TMZ, nimustine (ACNU),

interferon, bevacizumab, methotrexate, carmustine, ifosfamide, cisplatin, carboplatin, vincristine, cyclophosphamide, and procarbazine. We considered that CTX had been administered when there was a code for CTX and one of these drugs were listed.

RT

In Japan, payments for RT are classified and coded according to the treatment modality. External beam therapy (EBT) is coded as M001, and stereotactic radiosurgery (SRS) and stereotactic RT (SRT) are coded as M001-2 and M001-3, respectively. In this study, we identified patients treated with RT and sub-categorized them by modality using these codes.

Statistical analysis

LOS and medical cost were treated by log transformed value. Geometric means and their 95% confidence intervals were calculated. A general linear mixed model analysis was performed to determine statistically significant differences in mode of therapy on LOS or medical cost adjusted for age, sex, and the Charlson and JCS scores as a fixed effect and the hospital as a random effect. The differences in the number of patients per hospital were also determined. Reference population was set on male, average age (46.28), JCS = 0, and average Charlson score = 4.28, and then estimates and their 95% confidence interval for LOS and medical cost were presented. A value of $p < 0.05$ was considered statistically significant. The reference category for the number of patients per hospital was 1–10, and the JCS score had a value of 0, 1, 2, or 3. The analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Table 1 Number of extracted patients according to K-code

K-code	Description	Number of patients (%)
K1691	Tumor removal by craniotomy (pineal region)	18 (0.9)
K1692	Tumor removal by craniotomy	1688 (79.8)
K148	Craniotomy only	34 (1.6)
K1541	Functional stereotactic surgery (hemilateral)	83 (3.9)
K164-4	Stereotactic hematoma evacuation	45 (2.1)
K145	Extraventricular drainage	66 (3.1)
K174	Operation for hydrocephalus	129 (6.1)
K1492	Decompressive craniectomy	22 (1.0)
K151-2	Tumor removal by extended skull base craniotomy	13 (0.6)
K171	Transsphenoidal tumor removal	6 (0.3)
K171-2	Endoscopic transsphenoidal tumor removal	11 (0.5)

Ethical statement

The research plan was designed by the authors and approved by the Institutional Review Board of Kyushu University. The requirement for individual informed consent was waived.

Results

Patient demographics

Of 6,142 primary malignant brain tumor patients, 57% were male and 43% were female. With regard to age, 18% of the patients were children aged 15 years or younger, 65% were adult patients aged between 16 and 70 years, and 17% were elderly patients aged over 71 years. The tumor type was unknown in 3% of the patients; 58% of patients had a primary tumor and 39% of patients had recurrent disease (Table 2). The number of patients treated in a single institution varied between 1 and 277, with a median of 7 (Fig. 1), indicating that many hospitals treated less

Table 2 Demographics and clinical characteristics of patients included in this study

Total, n	6,142
Male, n (%)	3,489 (56.8)
Age	
≤15, n (%)	1,091 (17.8)
16–70, n (%)	3,984 (64.9)
≥71, n (%)	1,067 (17.4)
Primary, n (%)	3,549 (57.8)
Japan Coma scale	
0, n (%)	4,211 (68.6)
1-digit code, n (%)	1,592 (25.9)
2-digit code, n (%)	240 (3.9)
3-digit code, n (%)	99 (1.6)
Charlson score	
2, n (%)	1,948 (31.7)
3, n (%)	733 (11.9)
4, n (%)	757 (12.3)
5, n (%)	962 (15.7)
6–10, n (%)	1643 (26.8)
11–15, n (%)	99 (1.6)

than 20 primary malignant brain tumor patients (small-volume hospitals), and a few hospitals treated more than 100 patients (high-volume hospital).

Surgery

Of 6,142 primary malignant brain tumor patients, 2,236 were assigned a surgical K-code, and of these, 1,963 patients had a K-code related to surgery to treat the tumor (Fig. 2A, Table 1). The remaining 273 patients underwent procedures not directly related to the tumor, such as brain abscess evacuation, tracheostomy, or central venous catheter insertion. According to data from the Japan Neurosurgical Society, there were 25,160 brain tumor surgeries in neurosurgical hospitals in 2013. Therefore, the number of surgical cases analyzed in this study is equivalent to 7.8% of all brain tumor surgeries in Japan for a period of one year.

Radiation

A total of 1,510 primary brain tumor patients underwent RT (Fig. 2A), of whom, 1,203 were treated using EBT, 90 using SRS, and 217 using SRT. EBT was the most popular radiation modality followed by SRT and SRS in all age groups (Fig. 2B), and the frequency of these modalities were very similar.




Fig. 1 The distribution of the number of primary malignant brain tumor patients treated at each hospital

CTX

CTX was administered to 3,079 of the 6,142 patients with a primary brain tumor (Fig. 2A), using a total of 4,728 different regimens. As shown in Fig. 3A, the most frequently used drugs were TMZ (41%), followed by etoposide (11%), interferon-β (9%), and carboplatin (9%). Bevacizumab and carmustine were rarely used because they were not covered by health insurance at the start of this study period. With respect to age group, pediatric patients were less frequently administered TMZ compared to adults, but were more frequently treated using etoposide, carboplatin, methotrexate, vincristine, cisplatin, or cyclophosphamide (Fig. 3B). We also investigated the frequency with which combinations of drugs were administered to different age groups (Table 3). In total, combination therapy was used in 871 cases, and combined carboplatin and etoposide (CARE), or combined TMZ and interferon-β, were both commonly used in the adult group. In contrast, combined cisplatin and vincristine was most frequently used for pediatric patients, followed by combinations of carboplatin and etoposide, or ifosfamide, cisplatin, and etoposide (ICE) at a similar frequency. Combined cyclophosphamide, cisplatin, and vincristine therapy (Packer regimen) was also commonly used in the pediatric group.

We focused our analysis on TMZ, as it is the most commonly used chemotherapeutic drug for the treatment of malignant glioma. The most common duration of TMZ administration for initial cases (816 cases) was between 40 and 45 days, which is consistent with the standard concomitant TMZ treatment protocol of 42 days for initial malignant gliomas (Fig. 3C). In addition, in the concomitant TMZ treatment protocol, TMZ therapy and RT were initiated on the same day for most patients (Fig. 3D).




Fig. 2 (A) Frequency of each treatment modality (B) The ratio of different radiotherapy modalities in age groups (C) The distribution of types of therapy for all patients, and (D) by age group

Mode of therapy

The 6,142 primary malignant brain tumor patients were classified into eight groups depending on whether they underwent surgery alone, surgery + RT, surgery + CTX, surgery + chemo-radiotherapy (CRT), RT, CTX, CRT, or none of these (Fig. 2A, C). Pediatric patients less frequently underwent surgical treatment and were more often treated using CTX compared to adults. Hence, the type of therapy varied between adult and pediatric patients (Fig. 2D).

LOS

We analyzed the LOS with respect to the mode of therapy. The mean LOS of all the patients was 16 days. When we stratified the data according to the mode of therapy, primary tumor patients who underwent surgery had longer hospital stays compared to non-surgically treated patients (Table 4). In the subgroup of primary tumor patients who underwent surgery, the mean LOS was long amongst

those who underwent surgery + CRT (73.8 days), followed by surgery + RT (65.5 days), surgery + CTX (38 days), and surgery alone (23.2 days). CRT was the most common treatment administered to patients who did not undergo surgery. When we

Table 3 Combination of chemotherapeutic drug according to the patient age group

Chemotherapeutic drug (n = 871)	≤15 yr (%)	16–70 yr (%)	≥71 yr (%)
Carboplatin + Etoposide	69 (25.7)	253 (43.7)	5 (20.8)
Temozolomide + Interferon-β	22 (8.2)	229 (39.6)	16 (66.7)
Cisplatin + Vincristine	90 (33.6)	19 (3.3)	0
Ifosfamide + Cisplatin + Etoposide	60 (22.4)	46 (7.9)	0
Cyclophosphamide + Cisplatin + Vincristine	27 (10.1)	7 (1.2)	0
Procarbazine + Nimustine + Vincristine	0	25 (4.3)	3 (12.5)




Fig. 3 Frequency with which each type of chemotherapeutic drug was administered for primary malignant brain tumor patients (for a total of 4,728 regimens) in (A) all patients and (B) patients in different age groups (C) The distribution of the duration of temozolomide (TMZ) administration for primary malignant brain tumor patients undergoing initial treatment (D) Relationship between the time between surgery and the start of TMZ or radiotherapy for primary malignant brain tumor patients undergoing initial treatment

stratified the patients according to the number of primary malignant brain tumor patients treated by their hospital, the LOS was significantly shorter in high-volume hospitals than in low-volume hospitals (Table 5).

Direct medical cost

The DPC dataset also lists inpatient direct medical costs including surgery, CTX, RT, hospital stay, and other diagnostic and treatment modalities. The average direct medical cost for treating the patients was 1,077,690 yen. Consistent with the LOS, surgical treatment was much more expensive than non-surgical therapy (Table 4). Surgery + CRT was the most expensive treatment, at 5,926,220 yen, followed by surgery + RT (4,757,000 yen) and

surgery + CTX (3,937,540 yen). The mean cost of surgery was 2,752,300 yen. We found that medical cost was higher in hospitals treating 21–50 patients compared to those treating 1–10 patients (Table 6). However, although the medical cost was lower in high-volume hospitals than in small-volume hospitals, this difference was not statistically significant. In the DPC system, days and dose of TMZ administration for the primary patients are not translated in the medical expenditure, which means that medical cost depends on whether TMZ is administered. We analyzed medical expenditure for TMZ only patients (420 cases) and concomitant TMZ patients (816 cases) according to the number of the patients per hospital. In TMZ only patients, the average medical cost was 1,138,620 yen, whilst for concomitant TMZ

Table 4 Length of hospital stay and medical cost depending on therapeutic modalities

Modalities	n	Length of stay (days)		n	Medical cost (10 thousand yen)	
		Geometric mean	95% CI		Geometric mean	95% CI
None	1893	8.0	0.6–101.3	1774	39.1	4.1–369.1
CTX	1672	11.0	1.3–93.7	1640	64.5	11.3–370.1
RT	321	11.9	1.4–98.4	302	97.1	32.8–287.8
CRT	414	37.9	7.8–183.6	408	230.5	69.8–761.4
Surgery	779	23.2	7.4–73.2	763	275.2	132.5–571.5
Surgery + CTX	313	38.0	9.7–148.2	309	393.8	181.3–855.3
Surgery + RT	70	65.5	26.5–162.4	68	475.7	264.3–856.1
Surgery + CRT	680	73.8	35.0–155.7	672	592.6	341.3–1029.0

Table 5 Length of hospital stay according to the patient volume of the hospital

Patient volume	n	Length of stay (days)		p value	Analysis of mixed model	
		Geometric mean	95% CI		Estimates for reference population	
					Estimates	95% CI
1–10	998	24.6	2.7–227.5	–	18.1	16.4–20.0
11–20	863	20.8	2.2–194.4	0.256	16.6	14.5–18.9
21–50	1109	18.4	1.5–221.1	0.854	18.4	15.8–21.5
51–100	1480	16.0	1.4–182.9	0.181	15.8	13.2–18.9
≥101	1692	10.0	0.8–124.5	0.001	11.5	8.9–14.9

patients it was 4,424,300 yen, indicating that the direct medical cost increases more than two fold when it includes RT in Japan. In both groups, the medical cost was not statistically different among hospitals with different patient volumes (Table 6).

Discussion

In this study, we analyzed the current status of malignant brain tumor treatment using the DPC database in Japan. The advantage of using DPC data is that patient and hospital information, diagnosis, procedures, and administrative claim data are completely enumerated for all of the patients in the participating hospitals. Another benefit is that all of these data can be collected from the administrative claims database of inpatients without additional effort by medical staff. This study covered 370 hospitals (44%) out of all 847 Japanese Neurosurgical Society training program core and branch hospitals. Thus, we think that our study is a good representation of the current trends in malignant brain tumor treatment in Japan. Approximately 24,000 patients

are newly diagnosed with primary malignant brain cancer annually in the United States.^{3,4)} In this study, 3,562 (58%) of the 6,142 malignant tumor patients had primary disease, which is equivalent to 15% of all the patients in the United States.

Our analysis revealed that many of the hospitals treated less than 20 patients with primary malignant brain tumors in a single year. There are very few high-volume centers treating more than 100 malignant brain tumor patients per year in Japan, in contrast with the USA, Europe, Korea, and China, where malignant brain tumor patients are treated in high-volume core center hospitals. Regarding the use of cytotoxic chemotherapeutic drugs, we found that TMZ was administered to approximately 40% of patients, and that the next most frequently used drug was administered to less than 10% of patients, indicating that TMZ is the most widely prescribed drug for treating primary malignant brain tumors. However, amongst pediatric patients, TMZ was less frequently administered than platinum-based drugs, etoposide, vincristine, and ifosfamide. This may be because TMZ offers no significant benefit in pediatric

Table 6 Direct medical cost according to the patient volume of the hospital

Patient volume	Medical cost (10 thousand yen)			p value	Analysis of mixed model	
	n	Geometric mean	95% CI of geometric mean		Estimates for reference population	
					Estimates	95% CI
1–10	977	133.5	13.5–1318.3	–	110.1	99.2–122.1
11–20	795	135.6	13.4–1373.9	0.334	119.3	103.7–137.3
21–50	1063	134.0	11.6–1549.2	0.011	139.7	119.0–163.9
51–100	1472	110.2	8.2–1475.4	0.655	115.2	96.1–138.1
≥101	1629	72.0	5.5–941.0	0.224	92.9	71.7–120.3

TMZ only

Patient volume	Medical cost (10 thousand yen)		
	n	Geometric mean	95% CI
1–10	82	162.2	27.4–958.9
11–20	55	107.6	11.8–984.2
21–50	82	137.1	17.4–1080.5
51–100	105	101.7	11.3–918.6
≥101	93	83.1	12.5–554.3

TMZ + RT (concomitant)

Patient volume	Medical cost (10 thousand yen)		
	n	Geometric mean	95% CI
1–10	149	463.7	160.3–1341.1
11–20	125	460.3	159.3–1329.6
21–50	169	460.2	161.5–1311.3
51–100	226	410.6	116.4–1449.0
≥101	140	437.0	146.9–1300.2

Reference population means male, average age(46.28), JCS = 0, and average Charlson score = 4.28

patients,¹⁴⁾ or, in part, because germ cell and embryonal tumors occur frequently in pediatric patients. Indeed, combination CTX, which is usually administered for germ cell and embryonal tumors, was most frequently used to treat pediatric tumors.

According to the standard protocol, RT consists of fractionated focal irradiation at a dose of 2 Gy per fraction for a total dose of 60 Gy, which is administered once daily 5 days per week over a period of 6 weeks. Concomitant CTX consisted of TMZ at a dose of 75 mg per square meter per day, administered 7 days per week from the first day of RT until the

last day of RT. We found that TMZ administration most frequently lasted 40–45 days for many of the initial primary malignant brain tumor patients. In addition, RT and TMZ administration often started at the same time postoperatively, suggesting that concomitant CTX and RT is the current trend for initial primary malignant brain tumors in Japan. Taken together, our findings demonstrate that TMZ treatment for initial primary malignant brain tumor patients was undertaken according to the international standard protocol in Japanese neurosurgical hospitals.

We also evaluated the frequency with which different therapies were used to treat the patients. The most frequent treatment was CTX (27%), followed by surgery (13%), and surgery + CRT (11%). No single treatment type was used for more than 30% of patients. This differs from findings using the Brain Tumor Registry dataset,¹⁵⁾ where surgery + CRT was most frequently used (51%), followed by surgery (18%) and surgery + RT (18%). Observation alone and other treatments accounted for only 2% of patients. There are a number of possible reasons for this discrepancy between the datasets. First, because tumor histology is not included in the DPC dataset, it is possible that this varies significantly between the datasets, which would be reflected in the different therapies used. Second, the TMZ administration for malignant glioma was covered by Japanese health insurance in 2006, which means that Brain Tumor Registry data were collected before the TMZ era between 2001 and 2004. This might explain why CTX (possibly involving TMZ) was used more frequently for patients included in our dataset. Third, actively treated patients in the university and national center (core) hospitals might have been selectively included in the Brain Tumor Registry. Given that our data are collected from all of the patients in registered hospitals including branch hospitals, our results reflect the current situation

regarding malignant brain tumor treatment after admission to Japanese neurosurgical hospitals.

Sub-analysis of therapy type for primary tumor patients demonstrated that pediatric patients less frequently underwent surgical treatment, including surgery alone or combined with CRT, compared with adult and elderly patients. However, pediatric patients more frequently underwent CTX. This suggests that pediatric patients are more often treated using CTX than RT, and indeed the prevalence of RT regardless of surgery and CTX was 7.5%, 18%, and 25% in pediatric, adult, and elderly patients, respectively. Regarding the type of RT used, SRS/SRT accounted for a quarter of all RT used to treat primary brain tumors.

Our analysis also revealed novel findings regarding health care data in Japan. Japan sustains full and equal health insurance coverage with a single reimbursement fee system for all physicians and patients.¹⁶⁾ Under this system, the mean LOS for primary malignant brain tumor patients was 16 days. Hospital stays generally get longer with increasingly complex modes of therapy. According to the 2011 data of the Ministry of Health, Labour and Welfare in Japan, the mean LOS of all cancer patients was 19.5 days.¹⁷⁾ The mean LOS in our dataset was closer to this value (16 days). Accordingly, the mean LOS in the surgically treated groups was 46 days. The Ministry of Health, Labour and Welfare data also reveal that patients who undergo craniotomy have the longest stay in hospital (mean 48.5 days) among all patients undergoing surgery. As data for patients with benign tumors are also included in the Ministry of Health, Labour and Welfare dataset, this study is the first to demonstrate that the LOS of malignant brain tumor patients depends on the mode of therapy. Given that CTX or RT is more likely to be administered as an inpatient treatment in Japan, we need to be careful in comparing healthcare resource usage between countries.

In this study, we first evaluated the direct medical cost for the treatment of inpatient primary malignant brain tumor patients in Japan. The mean medical cost of all 6,142 patients was 1,077,690 yen, which is equivalent to 10,463 US dollars at the exchange rate of 103 Japanese yen per US dollar. A recent publication showed that the total direct cost for surgery and RT ranged from 50,600 to 92,700 US dollars in the United States.⁹⁾ We found that the medical cost of patients undergoing both surgery and RT was 4,757,000 yen (46,184 dollars) in this study. Although the direct medical cost cannot be compared between countries with different health insurance systems, it seems clear that the direct medical expenditure for combined surgery and RT is within the same range

in both countries. As expected, the medical costs are greater for patients undergoing surgery, RT, and CTX, at 5,926,220 yen (57,536 dollars). Concerning TMZ treatment, the cost of treating patients undergoing concomitant TMZ therapy after surgery was 4,424,300 yen (42,541 dollars). A previous study found that the medical cost of inpatients with concomitant TMZ therapy was 59,121 US dollars in the United States,¹⁸⁾ which indicates that medical costs including TMZ treatment is lower than that in the United States. Furthermore, our results showed that the direct medical cost of patients undergoing surgery with only TMZ and concomitant TMZ is similar among the hospitals regardless of patient volume. This indicates that the same level of treatment is administered for primary malignant brain tumor patients across all hospitals in Japan, which may partly be because TMZ use is included in the DPC system, and thus, the dose and duration of TMZ administration is not reflected in the direct medical cost.

A limitation of this study is that detailed information concerning the tumor site, histology, and extent of resection was not available in the DPC data set. Furthermore, because the DPC dataset only includes mortality data for the corresponding admission period, information on patient outcomes after discharge is not included. Thus, the survival rate cannot be calculated. Moreover, outpatient data are not included. Nevertheless, this study provides a clear picture of the current trend of treatment for malignant brain tumors in Japan. If we can link this population-based dataset to the standard registration database, we could obtain very useful information regarding the treatment of malignant brain tumor patients.

In summary, we have assessed the current treatment and healthcare resource usage of malignant brain tumor patients in Japan using exhaustive claim data from 6,142 patients. This study could act as a road map towards the establishment of a better health care policy.

Acknowledgement

This study was conducted as the Joint Project of the 34th annual meeting of the Japanese Congress of Neurosurgeons (President K.I.) and the Japan Neurosurgical Society. We also thank Profs. Takamasa Kayama and Nobuo Hashimoto for their supervision of this collaborative project with the Japan Neurosurgical Society.

Conflict of Interest

The authors declare that there are no potential conflicts of interest in relation to this study.

References

- 1) Wrensch M, Minn Y, Chew T, Bondy M, Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. *Neuro-oncology* 4: 278–299, 2002
- 2) Nakamura H, Makino K, Yano S, Kuratsu J, Kumamoto Brain Tumor Research Group: Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan—20-year study. *Int J Clin Oncol* 16: 314–321, 2011
- 3) Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. *Neuro-oncology* 16 Suppl 4: iv1–iv63, 2014
- 4) SEER Cancer Statistics Factsheets: Brain and Other Nervous System Cancer. National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/statfacts/html/brain.html>
- 5) Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10: 459–466, 2009
- 6) Wasserfallen JB, Ostermann S, Pica A, Mirimanoff RO, Leyvraz S, Villemure JG, Stupp R: Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. *Cancer* 101: 2098–2105, 2004
- 7) Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA: EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. *Cancer* 112: 1337–1344, 2008
- 8) Messali A, Hay JW, Villacorta R: The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. *Neuro-oncology* 15: 1532–1542, 2013
- 9) Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM: Economics of Malignant Gliomas: A Critical Review. *J Oncol Pract* 2014
- 10) Hamada H, Sekimoto M, Imanaka Y: Effects of the per diem prospective payment system with DRG-like grouping system (DPC/PDPS) on resource usage and healthcare quality in Japan. *Health Policy* 107: 194–201, 2012
- 11) Iihara K, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Miyamoto Y, Suzuki A, Ishikawa KB, Kataoka H, Nakamura F, Kamitani S: Effects of comprehensive stroke care capabilities on in-hospital mortality of patients with ischemic and hemorrhagic stroke: J-ASPECT study. *PLoS one* 9: e96819, 2014
- 12) Iihara K, Nishimura K, Kada A, Nakagawara J, Toyoda K, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Matsuda S, Ishikawa KB, Suzuki A, Mori H, Nakamura F: J-ASPECT Study Collaborators. The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: a nationwide study in Japan: J-ASPECT study. *J Stroke Cerebrovasc Dis* 23: 1001–1018, 2014
- 13) Kamitani S, Nishimura K, Nakamura F, Kada A, Nakagawara J, Toyoda K, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Matsuda S, Miyamoto Y, Iwata M, Suzuki A, Ishikawa KB, Kataoka H, Morita K, Kobayashi Y, Iihara K: Consciousness level and off-hour admission affect discharge outcome of acute stroke patients: a J-ASPECT study. *J Am Heart Assoc* 3: e001059, 2014
- 14) MacDonald TJ, Aguilera D, Kramm CM: Treatment of high-grade glioma in children and adolescents. *Neuro-oncology* 13: 1049–1058, 2011
- 15) Japan TCoBTRo: Report of brain tumor registry of Japan (2001–2004). 13th edition. *Neurol Med Chir (Tokyo)* suppl 1(54): 1–102, 2014
- 16) Reich MR, Shibuya K: The Future of Japan's Health System—Sustaining Good Health with Equity at Low Cost. *N Eng J Med* 373: 1793–1797, 2015
- 17) Statistical survey conducted by Ministry of health, Labour and Welfare. <http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/index.html>, 2011
- 18) Ray S, Bonafede MM, Mohile NA: Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. *Am Health Drug Benefits* 7: 140–149, 2014

Address reprint requests to: Koji Yoshimoto, MD, PhD, Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan. Tel: +81-92-642-5524; Fax: +81-92-642-5526. e-mail: kyoshimo@ns.med.kyushu-u.ac.jp

RESEARCH ARTICLE

Open Access



Development and validation of a score for evaluating comprehensive stroke care capabilities: J-ASPECT Study

Akiko Kada^{1*}, Kunihiro Nishimura², Jyoji Nakagawara³, Kuniaki Ogasawara⁴, Junichi Ono⁵, Yoshiaki Shiokawa⁶, Toru Aruga⁷, Shigeru Miyachi⁸, Izumi Nagata⁹, Kazunori Toyoda¹⁰, Shinya Matsuda¹¹, Akifumi Suzuki¹², Hiroharu Kataoka¹³, Fumiaki Nakamura², Satoru Kamitani¹⁴, Koji Iihara¹⁵ and the J-ASPECT Study Collaborators

Abstract

Background: Although the Brain Attack Coalition recommended establishing centers of comprehensive care for stroke and cerebrovascular disease patients, a scoring system for such centers was lacking. We created and validated a comprehensive stroke center (CSC) score, adapted to Japanese circumstances.

Methods: Of the selected 1369 certified training institutions in Japan, 749 completed an acute stroke care capabilities survey. Hospital performance was determined using a 25-item score, evaluating 5 subcategories: personnel, diagnostic techniques, specific expertise, infrastructure, and education. Consistency and validity were examined using correlation coefficients and factorial analysis.

Results: The CSC score (median, 14; interquartile range, 11–18) varied according to hospital volume. The five subcategories showed moderate consistency (Cronbach's $\alpha = 0.765$). A strong correlation existed between types of available personnel and specific expertise. Using the 2011 Japanese Diagnosis Procedure Combination database for patients hospitalized with stroke, four constructs were identified by factorial analysis (neurovascular surgery and intervention, vascular neurology, diagnostic neuroradiology, and neurocritical care and rehabilitation) that affected in-hospital mortality from ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. The total CSC score was related to in-hospital mortality from ischemic stroke (odds ratio [OR], 0.973; 95% confidence interval [CI], 0.958–0.989), intracerebral hemorrhage (OR, 0.970; 95% CI, 0.950–0.990), and subarachnoid hemorrhage (OR, 0.951; 95% CI, 0.925–0.977), with varying contributions from the four constructs.

Conclusions: The CSC score is a valid measure for assessing CSC capabilities, based on the availability of neurovascular surgery and intervention, vascular neurology, diagnostic neuroradiology, and critical care and rehabilitation services.

Keywords: Ischemia, Stroke, Hemorrhage, Cerebrovascular circulation, Risk factors

Background

Stroke is the fourth leading cause of mortality and the most common cause of permanent morbidity in Japan, causing an enormous socioeconomic burden. The public health implications of stroke care globally, including in Japan, are profound. Despite accelerating progress in stroke therapy, implementation of appropriate acute

treatment remains essential for decreasing the associated mortality and permanent morbidity. In 2000, the Brain Attack Coalition discussed the concept of primary stroke centers and later proposed the design of comprehensive stroke centers (CSCs) [1, 2]. Most stroke patients can be adequately treated at a primary stroke center (PSC), and the Joint Commission established programs for the certification and performance measurement of PSCs [3]. The concept and recommended key components of a CSC enable intensive patient care and the use of specialized techniques that are not available at most PSCs [1, 4]. To continuously monitor the efficiency of care, reliable

* Correspondence: akiko.kada@nnh.go.jp

¹Department of Clinical Trials and Research, Clinical Research Center, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan

Full list of author information is available at the end of the article



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

measures of hospital capabilities and performance are needed. Although the Joint Commission and several US states have started certification processes for PSCs and CSCs [5–8], an established, simple scoring system does not exist to evaluate the comprehensive acute stroke care capabilities of CSCs. To this end, a simple tool for assessing CSC capabilities would be useful for monitoring service quality and enabling its improvement [4]. In 2010, we started the J-ASPECT study (Nationwide survey of Acute Stroke care capacity for Proper designation of Comprehensive stroke center in Japan) to establish optimal nationwide implementation of stroke centers to improve acute stroke outcomes. We modified the above recommendations to reflect the specific circumstances in Japan and developed a CSC score; this tool was validated using the nationwide Diagnosis Combination Procedure (DPC) database, created during the first year of this study.

Methods

Content validity

In the first step of the J-ASPECT study, we investigated the current conditions of stroke hospitals in Japan. We created a 49-item questionnaire examining various aspects of stroke care, including medical systems, emergency systems, stroke rehabilitation, education, and medical performance. Some recommended items, such as ventriculostomy availability, were excluded from our questionnaire for the sake of simplicity and to increase the survey response rate since the items seemed identical to the recommendations of board-certified (BC) neurosurgeons in Japan. Other items, such as availability of transesophageal echocardiography, were excluded because of their very low expected usage, which would make an evaluation of their impact on mortality rates difficult. In February 2011, the questionnaire was mailed to 1369 certified training institutions belonging to the Japan Neurosurgical Society, the Japanese Society of Neurology, and the Japan Stroke Society. Based on this questionnaire, the overall organizational and staffing levels of the hospitals, in terms of CSC capacity, were scored following the Brain Attack Coalition recommendations, after reviewing the literature describing CSCs and conducting a thorough discussion with an expert panel [9]. Advanced acute stroke care capabilities were assessed based on 25 items divided into 5 subcategories (listed in Table 1). One point was assigned for each recommended item that the hospital met, resulting in a maximum total score of 25; subcategory scores were also calculated.

Consistency

Cronbach's α was calculated to evaluate the consistency between the 5 CSC score subcategories used for

Table 1 The availability of comprehensive stroke center score components

Components	Items	Item No	Number	Percent	
Personnel	Neurologists	1	358	47.8	
	Neurosurgeons	2	694	92.7	
	Endovascular physicians	3	272	36.3	
	Critical care medicine	4	162	21.6	
	Physical medicine and rehabilitation	5	113	15.1	
	Rehabilitation therapy	6	742	99.1	
	Stroke rehabilitation nurses	7	102	13.6	
	Diagnostics (24/7)	CT ^a	8	742	99.1
		MRI ^b with diffusion	9	647	86.4
		Digital cerebral angiography	10	602	80.4
		CT angiography	11	627	83.7
		Carotid duplex ultrasound	12	257	34.3
		TCD ^c	13	121	16.2
	Specific expertise	Carotid endarterectomy	14	603	80.5
		Clipping of intracranial aneurysm	15	685	91.5
		Hematoma removal/draining	16	689	92.0
		Coiling of intracranial aneurysm	17	360	48.1
		Intra-arterial reperfusion therapy	18	498	66.5
Infrastructure	Stroke unit	19	132	17.6	
	Intensive care unit	20	445	59.4	
	Operating room staffed 24/7	21	451	60.2	
	Interventional services coverage 24/7	22	279	37.2	
	Stroke registry	23	235	31.4	
Education	Community education	24	369	49.3	
	Professional education	25	436	58.2	

^acomputed tomography; ^bmagnetic resonance imaging; ^ctranscranial Doppler

assessing CSC capabilities. To determine the influence of each subcategory, α -values were also calculated for all combinations of the four subcategories. Correlations between the 25 CSC score items were determined using tetrachoric correlation coefficients to evaluate individual items measured with different constructs.

Construct validity

Factorial analysis, based on tetrachoric correlation coefficients [10], was performed using principal factor analysis to explore possible potential groupings of the 25 items into a more limited number of components. The selection of the number of components was based on the Eigen values. To understand the meaning of the components, promax rotation was used.

Predictive validity

Using the Japanese DPC database for patients hospitalized with strokes during the 2011 fiscal year, we examined the differential effects of the items on mortality and poor outcomes (modified Rankin Scale: 3–6, at discharge) associated with ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). This cross-sectional survey used the DPC discharge database for the institutions participating in the J-ASPECT study. The DPC database is a mixed-case classification system that is linked with the lump-sum payment system, launched in 2002 by the Ministry of Health, Labor and Welfare of Japan [11]. In 2010, approximately 1388 acute care hospitals, representing about 50% of the total hospital beds, had adopted the DPC data system. Data regarding practices were obtained from the DPC database; the attending physician is responsible for each patient's clinical data entry. The details of this database have been described elsewhere [12].

Of the 749 hospitals that responded to the institutional survey of advanced stroke care capabilities, 256 agreed to participate in the DPC discharge database study. Consecutive patients, hospitalized between April 1, 2010 and March 31, 2011, were identified in the annual discharge database using the International Classification of Diseases (ICD)-10 diagnosis codes related to IS (I63.0-9), nontraumatic ICH (I61.0-9, I62.0-1, I62.9), and SAH (I60.0-9). Patients with scheduled admissions were excluded from analysis. This research was approved by the Institutional Review Board of the National Cerebral and Cardiovascular Center and, if required, by the participating hospitals.

We used hierarchical logistic regression models to determine relationships between hospital CSC scores, reflecting the capacities they were equipped with, and mortality. Each model had two levels of hierarchy (hospital and patient), and considered the random effects of hospital variables as well as the fixed effects of CSC scores, patient age and sex, and Japan Coma Scale (JCS) scores. Interactions such as those between the JCS and CSC scores were not included in the model. The analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC, USA), and R, version 3.2.0 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria).

Results

Of the selected 1369 certified training institutions, 749 (55%) responded to the acute stroke care capability survey. Among the surveyed hospitals, 62% had more than 300 beds, and 51% had more than 200 acute patients (Table 2). Clipping of intracranial aneurysms (IAs) was performed more frequently than any other procedure (median/hospital, 15), followed by craniotomy removal

Table 2 Hospital characteristics

Beds per hospital, n (%)	
20–49	16 (2.1)
50–99	30 (4.0)
100–299	232 (31.0)
300–499	260 (34.7)
> 500	207 (27.6)
Unknown	4 (0.5)
Acute stroke patients per hospital, n (%)	
≤ 49	51 (6.8)
50–99	78 (10.4)
100–199	199 (26.6)
200–299	155 (20.7)
> 300	228 (30.4)
Unknown	38 (5.1)
Treated patients per hospital, median (IQR) ^a	
Tissue plasminogen activator	5 (2–10)
Intra-arterial thrombolysis/percutaneous angioplasty	0 (0–2)
Carotid endarterectomy	1 (0–4)
Carotid stenting	1 (0–7)
Extracranial-intracranial bypass surgery	1 (0–5)
Clipping of intracranial aneurysm	15 (6–27)
Coiling of intracranial aneurysm	3 (0–11)
Craniotomy hematoma removal	6 (2–12)
Stereotactic hematoma removal	0 (0–3)
Endoscopic hematoma removal	0 (0–0)

^ainterquartile range

of ICH (6), intravenous infusion of recombinant tissue plasminogen activator (5), and coiling of IAs (3). The availability of each item is shown in Table 1. Even within the same component, the availability of each item varied. Low availability values were noted for IA coiling (48.1%) in the specific expertise component and for stroke units (17.6%) in the infrastructure component.

The distribution of CSC score components, by hospital, is shown in Table 3. The median CSC score was 14 (interquartile range, 11–18). These components showed moderate consistency (Cronbach's $\alpha = 0.765$, for the total score). Removal of any one component resulted in Cronbach's α falling in the range of 0.668–0.776, indicating the absence of substantial influence of individual components. High correlations between the survey components pertaining to personnel and specific expertise were observed (Table 4). For example, there were high correlations between neurosurgeon availability and carotid endarterectomy ($r = 0.821$; items 2 and 14), clipping of IAs ($r = 0.936$; items 2 and 15), and hematoma removal/drainage ($r = 0.949$; items 2 and 16). Similarly, endovascular physician availability was strongly correlated with

Table 3 The distribution of comprehensive stroke center score components and their consistency

Components	Mean	SD	Median	IQR ^a	Cronbach's α
Personnel	3.26	1.25	3	2–4	0.724
Diagnostic	4.00	1.28	4	4–5	0.741
Specific expertise	3.79	1.48	4	3–5	0.668
Infrastructure	2.06	1.43	2	1–3	0.674
Education	1.07	0.83	1	0–2	0.776
Total Score	14.18	4.57	14	11–18	0.765

^aInterquartile range

coiling of IAs ($r = 0.932$; items 3 and 17) and intra-arterial reperfusion therapy ($r = 0.842$; items 3 and 18). Other relationships regarding diagnostics, infrastructure, and education did not stand out.

Factorial analysis, based on promax rotation, revealed four constructs (Table 5). The first pattern contained items pertaining to neurovascular surgery and intervention, such as endovascular physician availability, coiling of IAs, intra-arterial reperfusion therapy, 24/7 interventional services coverage, carotid endarterectomy, hematoma removal/drainage, clipping of IAs, neurosurgeon availability, rehabilitation therapy, 24/7 operating room staffing, and stroke rehabilitation nurse availability. The first pattern had the largest explained variance (43% of total variance). The second pattern included imaging modalities mainly associated with diagnostic neuroradiology (e.g., computed tomography, computed tomography angiography, digital cerebral angiography, and diffusion-weighted magnetic resonance imaging) and intensive care units. The third pattern contained items related to vascular neurology: transcranial Doppler, carotid duplex ultrasound, professional education, community education, stroke registry, and available stroke units. The fourth pattern represented neurocritical care and rehabilitation, and included the availability of neurologists, physical medicine and rehabilitation, and critical care medicine.

A total of 53,170 patients in the cohort were analyzed; the in-hospital mortality was 7.8% for IS, 16.8% for ICH, and 28.1% for SAH (Table 6). Table 7 shows the impact of hospital capacity for each of the 25 items on mortality. Among the four constructs obtained using factorial analysis, the availability of neurologists in neurocritical care and rehabilitation was significantly associated with reduced mortality of patients with IS ($P < 0.05$). The 24/7 availability of interventional service coverage in neurovascular surgery and intervention ($P < 0.05$), availability of intensive care units in diagnostic neurology, and physical medicine and rehabilitation in neurocritical care and rehabilitation ($P < 0.05$) were related to SAH mortality. The total CSC score was related to the mortality associated with IS (OR, 0.973; 95% CI, 0.958–0.989), ICH (OR,

0.970; 95% CI, 0.950–0.990), and SAH (OR, 0.951; 95% CI, 0.925–0.977).

The proportions of poor outcomes (modified Rankin Scale, 3–6) were 49.2% for IS, 65.3% for ICH, and 56.4% for SAH (Table 6). In contrast to mortality, the total CSC score was not significantly associated with poor outcomes in patients having any type of stroke (Table 8). The impact of hospital capacity for each of the 25 items on poor outcomes differed from that for mortality in some aspects. For example, among patients with IS, stroke unit availability were significantly associated with a reduced proportion of poor outcomes ($P < 0.05$). Among patients with ICH and SAH, no significant association was observed between the availability of any item and poor outcomes.

Discussion

We evaluated the consistency and validity of the CSC score; based on the Cronbach's α value of 0.765, the five components were moderately consistent [13]. The validity of the score was evaluated using factorial analysis, which revealed four major constructs. Although the four constructs were determined by the five components: personnel, diagnostic techniques, specific expertise, infrastructure, and education, this study showed a high correlation between the survey components pertaining to personnel and specific expertise. The unique fact that BC neurosurgeons comprise more than 95% of BC endovascular physicians, in Japan, may explain why personnel, specific expertise, and infrastructure components closely related to these different treatment aspects were grouped into the same construct (neurovascular surgery and intervention). Considering their influence on the variance of the CSC scores, temporal trends and geographical disparities focused on this construct may provide critical information for proper accreditation and implementation of CSCs.

With regard to the predictive validity of the CSC score, the four constructs had different effects on mortality and poor outcomes in patients with IS, ICH, and SAH. The availability of neurologists involved in neurocritical care and rehabilitation was significantly associated with reduced in-hospital mortality in patients with IS. Recently, the treatment paradigm for acute IS has been changing rapidly, such that the critical role of endovascular intervention following tissue plasminogen activator infusion, for acute IS, has been established by several recent randomized controlled trials (MR Clean, ESCAPE, EXTEND-IA) [14–16]. Of note, however, the acute stroke care survey used in this study and the DPC database were both implemented before these evidences were published in 2015. The availability of BC neurosurgeons at more than 90% of the participating hospitals suggests the importance of multidisciplinary acute stroke care [17].

Table 5 Factor analysis

	Factor 1 Neurovascular surgery and intervention	Factor 2 Diagnostic neuroradiology	Factor 3 Vascular neurology	Factor 4 Neurocritical care and rehabilitation	
	Proportion explained	0.43	0.25	0.19	0.14
Item No	Items	Standardized loadings (pattern matrix)			
3	Endovascular physicians	0.91^d	-0.07	-0.04	0.12
17	Coiling of intracranial aneurysm	0.89	-0.11	0.04	0.15
18	Intra-arterial reperfusion therapy	0.88	0.00	0.10	-0.05
22	Interventional services coverage 24/7	0.80	-0.09	0.05	0.23
14	Carotid endarterectomy	0.76	0.24	-0.01	-0.10
16	Hematoma removal/draining	0.75	0.37	0.06	-0.16
15	Clipping of intracranial aneurysm	0.73	0.37	0.08	-0.16
2	Neurosurgeons	0.69	0.43	0.02	-0.22
6	Rehabilitation therapy	0.59	0.07	-0.63	0.18
21	Operating room staffed 24/7	0.59	0.28	0.00	0.18
7	Stroke rehabilitation nurses	0.34	-0.36	0.21	0.20
8	CT ^a	-0.03	0.89	-0.21	0.34
11	CT angiography	0.08	0.84	0.06	-0.17
10	Digital cerebral angiography	0.36	0.70	0.08	-0.10
9	MRI ^b with diffusion	0.03	0.59	0.23	-0.06
20	Intensive care unit	-0.06	0.50	0.17	0.22
13	TCD ^c	0.02	0.15	0.71	0.04
12	Carotid duplex ultrasound	-0.31	0.26	0.72	0.16
25	Professional education	0.23	-0.15	0.63	-0.23
24	Community education	0.21	-0.17	0.56	0.07
23	Stroke registry	0.24	-0.08	0.52	0.10
19	Stroke unit	0.23	-0.05	0.49	0.06
1	Neurologists	-0.02	-0.02	0.02	0.85
5	Physical medicine and rehabilitation	0.10	-0.09	0.00	0.72
4	Critical care medicine	-0.09	0.25	0.14	0.55

^acomputed tomography; ^bmagnetic resonance imaging; ^ctranscranial Doppler; ^dvalues > 0.300 are shown in bold font

The association between the availability of a stroke care unit and the increased proportion of favorable outcomes after IS, observed in this study, is consistent with a 2009 Cochrane review conducted by the Stroke Unit Trialists' Collaboration that showed the benefits of stroke unit care in terms of reducing death, dependency, and institutional care [18].

The SAH-associated mortality was higher than that associated with IS or ICH, and the condition of the patients with SAH was also more severe and required more urgent intervention. Accordingly, the availability of items representing SAH treatment, such as 24/7 interventional service coverage, intensive care unit, and BC physical medicine and rehabilitation, showed the greatest effects on mortality. The critical role of endovascular coil embolization for ruptured IAs was previously

established by the International Subarachnoid Aneurysms Trial [19]. Using Nationwide Inpatient Survey data, Qureshi et al. reported a significant increase in endovascular treatment as well as a decrease in in-hospital mortality (2000–2002, 27%; 2004–2006, 24%) in patients with SAH after publication of the International Subarachnoid Trial (ISAT) in 2002 [20]. However, whether the ISAT results can be generalized to all patients with SAH is questionable because most of the patients enrolled in the study were patients with good clinical grades, having small, anterior circulation aneurysms.

The second common cause of SAH-related death and poor functional outcome is rebleeding [21], and early treatment of the ruptured aneurysm is known to lower the incidence of rebleeding. Intensive care unit and 24/7

Table 4 Correlation coefficients between the 25 survey items

Item No ^a	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	
1	1.000																									
2	-0.071	1.000																								
3	0.201	0.671	1.000																							
4	0.282	0.243	0.244	1.000																						
5	0.520	0.063	0.259	0.476	1.000																					
6	0.334	0.282	0.239	-0.190	0.140	1.000																				
7	0.171	0.072	0.248	0.054	0.117	0.125	1.000																			
8	0.300	0.451	0.265	0.202	0.037	0.392	0.007	1.000																		
9	-0.018	0.500	0.325	0.054	-0.025	0.043	0.047	0.636	1.000																	
10	-0.027	0.827	0.490	0.255	0.058	0.132	-0.005	0.616	0.594	1.000																
11	-0.132	0.701	0.264	0.201	-0.050	0.017	0.055	0.632	0.614	0.830	1.000															
12	0.120	0.215	0.118	0.198	0.016	-0.196	0.158	0.306	0.357	0.332	0.295	1.000														
13	0.155	0.435	0.361	0.156	0.036	-0.142	0.102	0.194	0.287	0.492	0.372	0.713	1.000													
14	0.095	0.821	0.639	0.238	0.155	0.234	0.138	0.281	0.363	0.694	0.492	0.196	0.305	1.000												
15	0.029	0.936	0.669	0.208	0.073	0.253	0.123	0.414	0.405	0.840	0.675	0.253	0.521	0.885	1.000											
16	0.010	0.949	0.709	0.227	0.053	0.263	0.105	0.431	0.429	0.831	0.663	0.256	0.512	0.865	0.987	1.000										
17	0.215	0.648	0.932	0.283	0.270	0.228	0.373	0.262	0.288	0.486	0.243	0.220	0.386	0.648	0.695	0.729	1.000									
18	0.092	0.784	0.842	0.209	0.226	0.215	0.289	0.234	0.407	0.646	0.391	0.247	0.418	0.754	0.793	0.821	0.874	1.000								
19	0.185	0.378	0.277	0.109	0.045	0.049	0.373	0.197	0.333	0.340	0.193	0.206	0.260	0.345	0.408	0.395	0.307	0.357	1.000							
20	0.154	0.358	0.256	0.237	0.086	-0.230	0.012	0.451	0.197	0.416	0.374	0.187	0.229	0.325	0.403	0.416	0.265	0.243	0.291	1.000						
21	0.291	0.599	0.603	0.205	0.155	0.314	0.180	0.484	0.287	0.583	0.429	0.193	0.386	0.714	0.756	0.718	0.564	0.515	0.443	0.382	1.000					
22	0.273	0.515	0.912	0.226	0.218	0.229	0.376	0.347	0.277	0.464	0.224	0.217	0.400	0.538	0.594	0.626	0.895	0.762	0.321	0.283	0.697	1.000				
23	0.203	0.314	0.360	0.145	0.210	0.014	0.213	0.059	0.342	0.357	0.253	0.287	0.406	0.373	0.425	0.451	0.385	0.405	0.381	0.165	0.369	0.362	1.000			
24	0.193	0.346	0.298	0.080	0.134	0.188	0.104	0.179	0.219	0.234	0.079	0.249	0.414	0.266	0.337	0.334	0.293	0.314	0.408	0.174	0.303	0.344	0.315	1.000		
25	0.038	0.425	0.230	0.025	0.073	-0.114	0.055	0.012	0.312	0.292	0.260	0.193	0.289	0.373	0.422	0.395	0.267	0.359	0.417	0.101	0.282	0.221	0.311	0.576	1.000	

^aItem No in Table 1

Table 6 Demographics of the patient cohort at diagnosis, mortality, and severe disability at discharge

	Total (n = 53170)		IS ^a (n = 32671)		ICH ^b (n = 15699)		SAH ^c (n = 4934)	
	N	%	N	%	N	%	N	%
Male	29353	55.2	18816	57.6	9030	57.5	1584	32.1
Age (years)								
18–50	3515	6.6	1328	4.1	1271	8.1	927	18.8
51–60	5824	11.0	2742	8.4	2171	13.8	934	18.9
61–70	11744	22.1	6894	21.1	3640	23.2	1242	25.2
71–80	15825	29.8	10342	31.7	4466	28.4	1048	21.2
81–106	16262	30.6	11365	34.8	4151	26.4	783	15.9
Hypertension	39918	75.1	22531	69.0	13281	84.6	4229	85.7
Diabetes mellitus	13725	25.8	9318	28.5	3278	20.9	1174	23.8
Hyperlipidemia	15015	28.2	11104	34.0	2529	16.1	1412	28.6
Smoking (n = 44842)	12761	24.0	8188	25.1	3540	22.5	1074	21.8
Japan Coma Scale								
0	19635	36.9	15027	46.0	3620	23.1	1024	20.8
1-digit code	19371	36.4	12375	37.9	5934	37.8	1117	22.6
2-digit code	6937	13.0	3396	10.4	2705	17.2	852	17.3
3 digit code	7227	13.6	1873	5.7	3440	21.9	1941	39.3
Emergency admission by ambulance	31995	60.2	17336	53.1	10909	69.5	3830	77.6
Mortality	6522	12.3	2535	7.8	2630	16.8	1384	28.1
Poor outcome (modified Rankin Scale 3–6) at discharge. (N = 51719)	28238	54.6	15566	49.2	10044	65.3	2721	56.4

^aischemic stroke; ^bintracerebral hemorrhage; ^csubarachnoid hemorrhage

interventional coverage availability were significant factors associated with decreasing in-hospital mortality after SAH. These findings are explained by the importance of early obliteration of ruptured aneurysms for preventing rebleeding and by the early detection and appropriate treatment of vasospasms, another important cause of morbidity and mortality in patients with SAH. The study provided additional evidence that the availability of endovascular treatment and surgical clipping may reduce in-hospital mortality in patients with SAH [22]. Another recent study also showed that an early mobilization program for patients with aneurysmal SAH is feasible and safe [23]. In addition, appropriate nutritional care from the acute stage is reported to be essential for improving functional outcomes and reducing post-SAH mortality [24]. Taken together, the significant association between the availability of BC physical medicine and rehabilitation and reduced mortality observed in our study reinforces the importance of comprehensive care capabilities, including early rehabilitation and nutritional care for patients with SAH, to prevent complications. Further investigation is required to understand the role of BC physical medicine and rehabilitation in reducing SAH-associated mortality.

Finally, the total CSC score correlated with reduced mortality for all types of stroke, supporting the usefulness of this score as a comprehensive measure of acute stroke care capabilities. Another study showed that hemorrhagic stroke patients admitted to CSCs were more likely to receive neurosurgical and endovascular treatments and to be alive at 90 days than patients admitted to other hospitals. The authors used certification by the New Jersey Department of Health and Senior Services to identify CSCs. The impacts of CSCs on mortality determined in that study are similar to the results obtained using our simple scoring system [25].

In contrast to its impact on in-hospital mortality, the total CSC score did not show a significant impact on poor functional outcomes in patients with any type of stroke. Similarly, no specific item had a significant impact on poor outcomes in patients with hemorrhagic stroke. In patients with IS, the significant role of the presence of a stroke unit in reducing poor outcomes, observed in the present study, was consistent with the results of a previous report [26]. A validation study investigating functional outcomes using the DPC database may be necessary to explain the disparities between the total CSC scores (and specific items) on mortality and poor functional outcomes.

Table 7 The effect of items on mortality

Item No	Items	IS ^a			ICH ^b			SAH ^c		
		(n = 32671)			(n = 15699)			(n = 4934)		
		OR ^d	95% CI ^e		OR	95% CI		OR	95% CI	
3	Endovascular physicians	0.832	0.653	1.060	0.896	0.671	1.198	1.309	0.906	1.891
17	Coiling of intracranial aneurysm	1.062	0.832	1.355	1.075	0.797	1.451	0.982	0.667	1.444
18	Intra-arterial reperfusion therapy	1.155	0.931	1.434	0.919	0.706	1.194	0.854	0.608	1.201
22	Interventional services coverage 24/7	1.071	0.831	1.379	1.145	0.844	1.555	0.674 ^j	0.458	0.992
14	Carotid endarterectomy	0.945	0.708	1.262	0.833	0.595	1.165	0.789	0.503	1.237
15 and 16	Clipping of intracranial aneurysm and hematoma removal/draining	0.798	0.465	1.368	0.537	0.266	1.088	0.359	0.082	1.564
2	Neurosurgeons	0.905	0.530	1.546	1.513	0.744	3.077	0.840	0.230	3.071
6	Rehabilitation therapy	1.000			1.000			1.000		
21	Operating room staffed 24/7	0.986	0.826	1.176	0.956	0.769	1.187	1.217	0.921	1.610
7	Stroke rehabilitation nurses	1.021	0.831	1.253	1.019	0.803	1.293	1.074	0.803	1.436
8	CT ^f	0.963	0.208	4.462	0.515	0.035	7.590	1.000		
11	CT angiography	1.127	0.877	1.449	0.820	0.608	1.107	0.978	0.662	1.446
10	Digital cerebral angiography	0.840	0.652	1.082	1.243	0.917	1.684	1.068	0.722	1.580
9	MRI ^g with diffusion	1.117	0.849	1.471	0.844	0.605	1.176	0.897	0.581	1.383
20	Intensive care unit	1.032	0.897	1.188	0.964	0.813	1.144	0.795 ^j	0.640	0.988
13	TCD ^h	0.852	0.699	1.038	0.879	0.700	1.105	1.222	0.930	
12	Carotid duplex ultrasound	1.039	0.889	1.215	1.021	0.849	1.228	1.119	0.891	1.406
25	Professional education	0.907	0.765	1.076	1.061	0.868	1.296	0.954	0.751	1.212
24	Community education	0.948	0.810	1.109	0.908	0.753	1.094	0.800	0.636	1.006
23	Stroke registry	0.895	0.781	1.026	0.861	0.732	1.013	0.915	0.749	1.118
19	Stroke unit	0.993	0.838	1.177	0.887	0.724	1.086	0.871	0.679	1.118
1	Neurologists	0.854 ^j	0.742	0.982	1.043	0.881	1.234	1.110	0.901	1.367
5	Physical medicine and rehabilitation	1.025	0.844	1.245	0.976	0.777	1.225	0.746 ^j	0.562	0.991
4	Critical care medicine	0.967	0.825	1.134	0.993	0.823	1.200	0.895	0.712	1.126
	Total CSC ⁱ score	0.973 ^j	0.958	0.989	0.970 ^j	0.950	0.990	0.951 ^j	0.925	0.977

^aischemic stroke; ^bintracerebral hemorrhage; ^csubarachnoid hemorrhage; ^dOR odds ratio adjusted by hierarchical logistic model including patient age, sex, Japan Coma Scale scores, and hospital variables; ^eCI confidence interval; ^fcomputed tomography; ^gmagnetic resonance imaging; ^htranscranial Doppler; ⁱcomprehensive stroke center; ^jP < 0.05 (hierarchical logistic model)

Strengths and limitations of the present study

First, this study is limited by a possible selection bias because hospitals actively working to improve stroke care were more likely to respond to the questionnaire. However, the coverage of the J-ASPECT Study group, which collaborates with the Japan Neurosurgical Society and the Japanese Congress of Neurological Surgeons, was broad enough to provide a reliable study sample. Second, information bias might have existed (self-reporting, recall, and nonresponse). Third, the CSC score mainly evaluated structural measures and did not consider their utilization, supported with real data. To assess clinical practice quality, the use of process measures is preferred [27], but process measures, such as electrocardiogram monitoring and pulse oximetry, were not considered in this scoring system [4, 28]. However,

strong correlations between survey components pertaining to personnel and specific expertise (e.g., availability of neurosurgeons and carotid endarterectomy) were observed in this study, suggesting that these items may not be considered as purely structural, but may have characteristics of both structural and process measures. We are planning to develop a new registry system in the J-ASPECT Study to include key metrics required for certification of CSCs in the US, in addition to the DPC database, to study and monitor the association of such quality metrics on mortality and morbidity of acute stroke patients, in Japan. Fourth, in-hospital mortality was selected as an outcome measure to test the validity of the CSC score. A recent systematic review showed that hospital mortality does not necessarily reflect the quality of clinical practice because mortality is affected

Table 8 The effect of items on poor outcome (modified Rankin Scale 3–6)

Item No	Items	IS ^a			ICH ^b			SAH ^c		
		(n = 31640)			(n = 15391)			(n = 4821)		
		OR ^d	95% CI ^e		OR	95% CI		OR	95% CI	
3	Endovascular physicians	1.180	0.890	1.563	0.896	0.671	1.198	1.267	0.856	1.875
17	Coiling of intracranial aneurysm	0.838	0.634	1.106	1.075	0.797	1.451	0.933	0.618	1.407
18	Intra-arterial reperfusion therapy	0.990	0.777	1.261	0.919	0.706	1.194	0.704	0.487	1.017
22	Interventional services coverage 24/7	0.969	0.725	1.295	1.145	0.844	1.555	0.928	0.615	1.400
14	Carotid endarterectomy	1.293	0.946	1.768	0.833	0.595	1.165	0.838	0.511	1.376
15 and 16	Clipping of intracranial aneurysm and hematoma removal/draining	0.763	0.427	1.364	0.537	0.266	1.088	0.553	0.065	4.693
2	Neurosurgeons	1.026	0.582	1.807	1.513	0.744	3.077	4.449	0.987	20.041
6	Rehabilitation therapy	1.000	.	.	1.000	.	.	1.000	.	.
21	Operating room staffed 24/7	0.883	0.723	1.078	0.956	0.769	1.187	0.959	0.712	1.290
7	Stroke rehabilitation nurses	0.874	0.693	1.101	1.019	0.803	1.293	0.877	0.641	1.200
8	CT ^f	1.328	0.296	5.956	0.515	0.035	7.590	1.000	.	.
11	CT angiography	1.227	0.931	1.617	0.820	0.608	1.107	0.877	0.579	1.329
10	Digital cerebral angiography	0.912	0.685	1.213	1.243	0.917	1.684	1.274	0.842	1.928
9	MRI ^g with diffusion	0.940	0.706	1.252	0.844	0.605	1.176	0.793	0.490	1.284
20	Intensive care unit	0.987	0.842	1.156	0.964	0.813	1.144	1.000	0.795	1.259
13	TCD ^h	0.966	0.773	1.208	0.879	0.700	1.105	1.152	0.858	1.547
12	Carotid duplex ultrasound	1.183	0.988	1.415	1.021	0.849	1.228	1.206	0.945	1.538
25	Professional education	0.892	0.737	1.079	1.061	0.868	1.296	1.015	0.782	1.317
24	Community education	1.144	0.957	1.368	0.908	0.753	1.094	0.871	0.680	1.116
23	Stroke registry	0.981	0.840	1.146	0.861	0.732	1.013	0.860	0.695	1.065
19	Stroke unit	0.783 ^j	0.645	0.952	0.887	0.724	1.086	0.878	0.676	1.141
1	Neurologists	1.137	0.969	1.335	1.043	0.881	1.234	1.096	0.877	1.370
5	Physical medicine and rehabilitation	1.163	0.934	1.449	0.976	0.777	1.225	0.979	0.725	1.322
4	Critical care medicine	1.113	0.929	1.334	0.993	0.823	1.200	1.062	0.830	1.360
	Total CSC ⁱ score	0.995	0.977	1.014	1.007	0.984	1.030	0.978	0.950	1.008

^aischemic stroke; ^bintracerebral hemorrhage; ^csubarachnoid hemorrhage; ^dOR odds ratio adjusted by hierarchical logistic model including patient age, sex, Japan Coma Scale scores, and hospital variables; ^eCI: confidence interval; ^fcomputed tomography; ^gmagnetic resonance imaging; ^htranscranial Doppler; ⁱcomprehensive stroke center; ^jP < 0.05 (hierarchical logistic model)

to a greater extent by the patients' condition rather than by the quality of practice [29]. Possible correlations between specific items and mortality in patients with IS may have been missed because of the relatively low in-hospital mortality associated with these patients; a larger study is necessary to resolve this issue. Fifth, the DPC-based payment system contains limited information regarding patient condition severity beyond post-discharge data and the National Institute of Health Stroke (NIHSS) Scale, Glasgow Coma Scale (GCS), ICH-, or Hunt-Hess severity scores, upon admission. Nevertheless, the JCS is a useful tool for evaluating stroke severity. Notably, the importance of the JCS, published in 1974, for predicting stroke outcomes has been recently reconfirmed [9, 30]. Further study is necessary to validate the results of the present study with other

patient-level measurements, such as the NIHSS, GCS, etc. Despite the above limitations, clear correlations were revealed between the CSC score and in-hospital mortality in patients with all types of strokes. In future work, the score's components should be weighted according to stroke type, based on their influence on patient outcomes.

Conclusions

The CSC score is a valid measure for assessing the capabilities of CSCs with regard to the availability of neurovascular surgery and intervention, vascular neurology, diagnostic neuroradiology, and neurocritical care and rehabilitation. The total CSC score was associated with mortality in patients with IS, ICH, and SAH, with varying contributions from the four abovementioned constructs.

Abbreviations

BC: Board-certified; CI: Confidence interval; CSC: Comprehensive stroke center; DPC: Diagnosis combination procedure; GCS: Glasgow coma scale; IA: Intracranial aneurysm; ICH: Intracerebral hemorrhage; IS: Ischemic stroke; ISAT: International subarachnoid trial; JCS: Japan coma scale; NIHSS: National institute of health stroke; OR: Odds ratio; PSC: Primary stroke center; SAH: Subarachnoid hemorrhage

Acknowledgements

We thank Drs. Manabu Hasegawa, Tomoatsu Tsuji, and Yasuhiro Nishijima for their helpful discussions, Profs. Takamasa Kayama and Nobuo Hashimoto for their supervision of the Japan Neurosurgical Society collaboration, and Ms. Arisa Ishitoko for her secretarial assistance.

Funding

This work was supported by Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan and JSPS KAKENHI Grant Number 25293314 (principal investigator: KI). This research was partially supported by the Practical Research Project for Life-Style related Diseases, including Cardiovascular Diseases and Diabetes Mellitus, from the Japan Agency for Medical Research and Development.

Availability of data and materials

The datasets for this manuscript will not be shared, based on agreements between the principal investigator and the presidents of the participating hospitals.

Authors' contributions

KI initiated the collaborative project. AK, KN, SK, and KI designed the study, drafted and revised the article. AK, KN, SK monitored data collection and analyzed the data. JN, KO, JO, YS, TA, SM, IN, KT, SM, AS, HK, FN designed the study, and validated the survey questions from the views of physicians and experts. All authors read and approved the final manuscript.

Competing interests

KI has received grants from Nihon Medi-Physics, AstraZeneca, and Otsuka Pharmaceutical. JN has received an unrestricted research grant from Nihon Medi-Physics. IN has received lecture honoraria from Otsuka Pharmaceutical and Sanofi.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Ethical approval was provided by National Cerebral and Cardiovascular Center in Japan.

Author details

¹Department of Clinical Trials and Research, Clinical Research Center, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan. ²Center for Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, Suita, Japan. ³Integrative Stroke Imaging Center, National Cerebral and Cardiovascular Center, Suita, Japan. ⁴Department of Neurosurgery, Iwate Medical University, Morioka, Japan. ⁵Chiba Cardiovascular Center, Ichihara, Japan. ⁶Department of Neurosurgery, Kyorin University, Mitaka, Japan. ⁷Showa University, Tokyo, Japan. ⁸Department of Neurosurgery, Osaka Medical College, Takatsuki, Japan. ⁹Kokura Memorial Hospital, Fukuoka, Japan. ¹⁰Departments of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. ¹¹Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Kita-Kyushu, Japan. ¹²Akita Prefectural Hospital Organization Research Institute for Brain and Blood Vessels, Akita, Japan. ¹³Department of Neurosurgery, National Cerebral and Cardiovascular Center, Suita, Japan. ¹⁴Department of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. ¹⁵Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Received: 25 July 2016 Accepted: 8 February 2017

Published online: 28 February 2017

References

- Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. *JAMA*. 2000;283:3102–9.
- Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. *Stroke*. 2005;36:1597–616.
- Reeves MJ, Parker C, Fonarow GC, Smith EE, Schwamm LH. Development of stroke performance measures: definitions, methods, and current measures. *Stroke*. 2010;41:1573–8.
- Leifer D, Bravata DM, Connors 3rd JJ, Hinchey JA, Jauch EC, Johnston SC, et al. Metrics for measuring quality of care in comprehensive stroke centers: detailed follow-up to Brain Attack Coalition comprehensive stroke center recommendations: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011;42:849–77.
- Markovchick VJ, Moore EE. Optimal trauma outcome: trauma system design and the trauma team. *Emerg Med Clin North Am*. 2007;25:643–54.
- Joint Commission on Accreditation of Healthcare Organizations. Updated Primary Stroke Center Certification appendix for the disease-specific care manual. *Jt Comm Perspect*. 2005;25:3–6.
- Gropen TI, Gagliano PJ, Blake CA, Sacco RL, Kwiatkowski T, Richmond NJ, et al. Quality improvement in acute stroke: the New York State Stroke Center Designation Project. *Neurology*. 2006;67:88–93.
- Stradling D, Yu W, Langdorf ML, Tsai F, Kostanian V, Hasso AN, et al. Stroke care delivery before vs after JCAHO stroke center certification. *Neurology*. 2007;68:469–70.
- Iihara K, Nishimura K, Kada A, Nakagawara J, Toyoda K, Ogasawara K, et al. The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: a nationwide study in Japan: J-ASPECT Study. *J Stroke Cerebrovasc Dis*. 2014;23:1001–18.
- Kubinger KD. On artificial results due to using factor analysis for dichotomous variables. *Psychol Sci*. 2003;45:106–10.
- Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese Diagnosis Procedure Combination-based Payment System on cardiovascular medicine-related costs. *Int Heart J*. 2005;46:855–66.
- Iihara K, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, et al. Effects of comprehensive stroke care capabilities on in-hospital mortality of patients with ischemic and hemorrhagic stroke: J-ASPECT Study. *PLoS ONE*. 2014;9:e96819.
- Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaire. *J Clin Epidemiol*. 2007;60:34–42.
- Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. 2015;372:11–20.
- Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*. 2015;372:1019–30.
- Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*. 2015;372:1009–18.
- Decker C, Chhatrwalla E, Gialde E, Garavalia B, Summers D, Quinlan ME, et al. Patient-centered decision support in acute ischemic stroke: Qualitative study of patients' and providers' perspectives. *Circ Cardiovasc Qual Outcomes*. 2015;8 Suppl 3:S109–16.
- Sun Y, Paulus D, Eysen M, Maervoet J, Saka O. A systematic review and meta-analysis of acute stroke unit care: what's beyond the statistical significance? *BMC Med Res Methodol*. 2013;13:132.
- Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effect on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet*. 2005;366:809–17.
- Qureshi AI, Vazquez G, Tariq N, Suri MF, Lakshminarayan K, Lanzino G. Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States. *Clinical article. J Neurosurg*. 2011;114:834–41.

21. Broderick JP, Brott TG, Duldner JE, Tomsick T, Leach A. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. *Stroke*. 1994;25:1342–7.
22. Spetzler RF, McDougall CG, Albuquerque FC, Zabramski JM, Hills NK, Partovi S, et al. The Barrow Ruptured Aneurysm Trial: 3-year results. *J Neurosurg*. 2013;119:146–57.
23. Olkowski BF, Devine MA, Slotnick LE, Veznedaroglu E, Liebman KM, Arcaro ML, et al. Safety and feasibility of an early mobilization program for patients with aneurysmal subarachnoid hemorrhage. *Phys Ther*. 2013;93:208–15.
24. Nagano A, Yamada Y, Miyake H, Dornen K, Koyama T. Increased resting energy expenditure after endovascular coiling for subarachnoid hemorrhage. *J Stroke Cerebrovasc Dis*. 2016;25:813–8.
25. McKinney JS, Cheng JQ, Rybinnik I, Kostis JB, for the Myocardial Infarction Data Acquisition System Study Group. Comprehensive stroke centers may be associated with improved survival in hemorrhagic stroke. *J Am Heart Assoc*. 2015;4:e001448.
26. Minematsu K, Uehara T, Yasui N, Hata T, Ueda T, Okada Y, et al. Effects of stroke unit on patient outcome: a prospective multicenter study in Japan. *Jpn J Stroke*. 2007;29:59–64.
27. Lilford RJ, Brown CA, Nicholl J. Use of process measures to monitor the quality of clinical practice. *BMJ*. 2007;335:648–50.
28. Uehara T, Yasui N, Okada Y, Hasegawa Y, Nagatsuka K, Minematsu K. Which should be the essential components of stroke centers in Japan? A survey by questionnaires sent to the directors of facilities certified by the Japan Stroke Society. *Cerebrovasc Dis*. 2014;37:409–16.
29. Pitches DW, Mohammed AM, Lilford RJ. What is the empirical evidence that hospitals with higher-risk adjusted mortality rates provide poorer quality care? A systematic review of the literature. *BMC Health Serv Res*. 2007;7:91.
30. Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome—reintroduction of Japan Coma Scale: A cohort study. *BMJ Open*. 2013;3:e002736.

Submit your next manuscript to BioMed Central
and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit



Effect of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage: a nationwide study in Japan (J-ASPECT Study)

*Ryota Kurogi, MD,¹ Akiko Kada, MPH,² Kunihiro Nishimura, MD, PhD,³ Satoru Kamitani, MD,⁴ Ataru Nishimura, MD,¹ Tetsuro Sayama, MD, PhD,¹ Jyoji Nakagawara, MD, PhD,⁵ Kazunori Toyoda, MD, PhD,⁶ Kuniaki Ogasawara, MD, PhD,⁷ Junichi Ono, MD, PhD,⁸ Yoshiaki Shiokawa, MD, PhD,⁹ Toru Aruga, MD, PhD,¹⁰ Shigeru Miyachi, MD, PhD,¹¹ Izumi Nagata, MD, PhD,¹² Shinya Matsuda, MD, PhD,¹³ Shinichi Yoshimura, MD, PhD,¹⁴ Kazuo Okuchi, MD, PhD,¹⁵ Akifumi Suzuki, MD, PhD,¹⁶ Fumiaki Nakamura, MD, PhD,⁴ Daisuke Onozuka, PhD,¹⁷ Akihito Hagihara, DMSc, MPH,¹⁷ Koji Iihara, MD, PhD,¹ and the J-ASPECT Study Collaborators

¹Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka; ²Department of Clinical Trials and Research, National Hospital Organization Nagoya Medical Centre, Nagoya; ³Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Centre, Suita; ⁴Department of Public Health/Health Policy, Graduate School of Medicine, University of Tokyo; ⁵Integrative Stroke Imaging Centre; ⁶Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Centre, Suita; ⁷Department of Neurosurgery, Iwate Medical University, Morioka; ⁸Department of Neurosurgery, Chiba Cerebral and Cardiovascular Centre, Chiba; ⁹Department of Neurosurgery, Kyorin University, Mitaka; ¹⁰Department of Emergency and Critical Care Medicine, Showa University Hospital, Shinagawa; ¹¹Department of Neurosurgery, Osaka Medical College, Takatsuki; ¹²Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu; ¹³Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; ¹⁴Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya; ¹⁵Department of Emergency and Critical Care Medicine, Nara Medical University, Kashihara; ¹⁶Department of Surgical Neurology, Research Institute for Brain and Blood Vessels-Akita; and ¹⁷Department of Health Communication, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

OBJECTIVE Although heterogeneity in patient outcomes following subarachnoid hemorrhage (SAH) has been observed across different centers, the relative merits of clipping and coiling for SAH remain unknown. The authors sought to compare the patient outcomes between these therapeutic modalities using a large nationwide discharge database encompassing hospitals with different comprehensive stroke center (CSC) capabilities.

METHODS They analyzed data from 5214 patients with SAH (clipping 3624, coiling 1590) who had been urgently hospitalized at 393 institutions in Japan in the period from April 2012 to March 2013. In-hospital mortality, modified Rankin Scale (mRS) score, cerebral infarction, complications, hospital length of stay, and medical costs were compared between the clipping and coiling groups after adjustment for patient-level and hospital-level characteristics by using mixed-model analysis.

RESULTS Patients who had undergone coiling had significantly higher in-hospital mortality (12.4% vs 8.7%, OR 1.3) and a shorter median hospital stay (32.0 vs 37.0 days, $p < 0.001$) than those who had undergone clipping. The respective proportions of patients discharged with mRS scores of 3–6 (46.4% and 42.9%) and median medical costs (thousands US\$, 35.7 and 36.7) were not significantly different between the groups. These results remained robust after further adjustment for CSC capabilities as a hospital-related covariate.

ABBREVIATIONS BRAT = Barrow Ruptured Aneurysm Trial; CCI = Charlson Comorbidity Index; CSC = comprehensive stroke center; DPC = Diagnosis Procedure Combination; HAC = hospital-acquired condition; ISAT = International Subarachnoid Aneurysm Trial; JCS = Japan Coma Scale; mRS = modified Rankin Scale; PPV = positive predictive value; PSI = patient safety indicator; RCT = randomized controlled trial; SAH = subarachnoid hemorrhage.

SUBMITTED April 22, 2016. **ACCEPTED** December 9, 2016.

INCLUDE WHEN CITING Published online May 26, 2017; DOI: 10.3171/2016.12.JNS161039.

* Dr. Kurogi and Ms. Kada contributed equally to this work.

CONCLUSIONS Despite the increasing use of coiling, clipping remains the mainstay treatment for SAH. Regardless of CSC capabilities, clipping was associated with reduced in-hospital mortality, similar unfavorable functional outcomes and medical costs, and a longer hospital stay as compared with coiling in 2012 in Japan. Further study is required to determine the influence of unmeasured confounders.

<https://thejns.org/doi/abs/10.3171/2016.12.JNS161039>

KEY WORDS subarachnoid hemorrhage; clipping; coiling; nationwide database study; comprehensive stroke center; vascular disorders

NUMEROUS studies have compared outcomes between clipping and coiling procedures for patients with subarachnoid hemorrhage (SAH).^{7,17–21,26,28,30,31} The International Subarachnoid Aneurysm Trial (ISAT), a large randomized controlled trial (RCT) that compared neurosurgical clipping with endovascular coiling in patients with SAH, demonstrated the superiority of coiling.²⁰ This finding of the ISAT led to a prominent shift in the pattern of treatment for SAH, with the number of coiling procedures steadily increasing following publication.²⁸ However, it remains questionable whether the results of the ISAT can be generalized to all patients with SAH because most participants enrolled in the study were high-clinical-grade patients with small anterior circulation aneurysms.²³ While patient demographics and SAH severity remain the strongest predictors of outcome following treatment, interhospital, interregional, and cross-national disparities may also contribute to differences in patient outcomes. For example, fatality rates in patients with SAH in Japan are substantially lower than those in other regions.²⁴ Such differences may be explained by the varied expertise of the treating physician, the SAH case volumes at different institutions, and a hospital's propensity to use endovascular therapy.^{3,11,13} Recently, using the Japanese Diagnosis Procedure Combination (DPC) database, we established that high comprehensive stroke center (CSC) capability scores were associated with reduced in-hospital mortality in patients with ischemia and hemorrhage.¹⁵

Researchers have increasingly relied on the use of administrative databases of hospital admissions to assess clinical outcomes. Despite several limitations, studies using nationwide databases produce more generalizable results than those of RCTs because of the elimination of potential selection and referral biases.^{7,17,26} Previous large database studies that have compared outcomes following clipping and coiling in patients with SAH have been conducted in the US, yielding mixed results.^{7,17}

To address these discrepancies, we used the nationwide DPC database (JASPECT Study) to identify patients urgently hospitalized for SAH between April 1, 2012, and March 31, 2013. We then performed a mixed-model analysis adjusted with patient-level and hospital-level covariates to compare outcomes for patients with SAH who had undergone clipping and coiling procedures.

Methods

The DPC Database

The DPC database is a mixed-case classification sys-

tem linked with a lump-sum payment system that was launched in 2002 by the Ministry of Health, Labor, and Welfare of Japan.³⁴ In 2010, an estimated 1388 acute care hospitals, representing about 50% of all hospital beds, adopted the DPC system. Data on practices can be obtained from the DPC database, and the attending physician is responsible for clinical data entry for each patient. The DPC system includes all patients admitted to participating hospitals. Compared with other registry databases, the DPC database has strength in enabling researchers to conduct nationwide studies of descriptive or analytical epidemiology in the real-world setting of clinical practice. The Japanese DPC database includes data on the following elements: each patient's profile (that is, age, sex, height, weight, smoking index); principal diagnoses (coded according to the *International Classification of Diseases and Injuries, 10th revision*); comorbidities at admission (coded similarly); complications after admission (coded similarly); and procedures, including surgery, medications, and devices used during hospitalization; length of stay; discharge status; and medical expense.^{22,34,35} Institutions using the DPC system encompass a wide variety of centers, including academic, large, urban, and rural hospitals.¹⁵ Of the 847 certified training institutions of the Japan Neurosurgical Society, 393 agreed to participate in the J-ASPECT Study. This cross-sectional survey used DPC discharge data from the participating institutions.

Assessment of CSC Capabilities

We investigated whether the effect of treatment modality on outcomes in patients with SAH was influenced by CSC capabilities. The CSC capabilities questionnaire was completed by 266 of the 393 participating institutions. This institutional survey has been described in detail elsewhere.¹⁵ The CSC capabilities were assessed using 25 items specifically recommended for CSC,¹ which were divided into 5 categories: 1) personnel (7 items: board-certified neurologists, board-certified neurosurgeons, board-certified endovascular physicians, board-certified physicians in critical care medicine, board-certified physicians in physical medicine and rehabilitation, personnel in rehabilitation therapy, and stroke rehabilitation nurses); 2) diagnostic techniques (6 items: 24 hours/day, 7 days/week [24/7] availability of CT, MRI with diffusion-weighted imaging, digital cerebral angiography, CT angiography, carotid duplex ultrasound, and transcranial Doppler ultrasonography); 3) specific expertise (5 items: carotid endarterectomy, clipping of intracranial aneurysms [IAs], re-

moval of intracerebral hemorrhage, coiling of IAs, and intraarterial reperfusion therapy); 4) infrastructure (5 items: stroke unit, intensive care unit, operating room staffed 24/7, interventional services coverage 24/7, and stroke registry); and 5) educational components (2 items: community education and professional education). One point was assigned for each recommended item, with a maximum possible CSC score of 25.

Sampling Strategy

Computer software was developed to identify patients hospitalized for SAH from the de-identified discharge database using the ICD-10 diagnosis codes related to SAH (I60.0–9). We extracted data from the Japanese DPC database for patients who had been urgently hospitalized for SAH in the period from April 1, 2012, to March 31, 2013. Patients with a scheduled admission were excluded from our study.

The DPC database includes the following data: hospitals' unique identifiers and CSC scores; patients' age, sex, height, and weight; diagnoses; comorbidities on admission, including those based on the Charlson Comorbidity Index (CCI);⁶ Brinkman Index;⁴ level of consciousness on admission according to the Japan Coma Scale (JCS); admission source; days between admission and treatment; in-hospital mortality; modified Rankin Scale (mRS) score at discharge; cerebral infarction after admission; complications after admission according to patient safety indicators (PSIs) and hospital-acquired conditions (HACs);¹⁰ length of hospital stay; medical costs; and procedures coded with Japanese original K-codes. The extent of smoking was assessed based on the Brinkman Index (daily number of cigarettes \times years).⁴ The JCS is the most widely used grading scale for assessing impaired consciousness in Japan (Supplementary Table S1).^{14,29} This scale represented levels of consciousness upon admission regardless of whether patients had subsequently undergone ventriculostomy or CSF shunt placement.

Validation Study

We collected a 1% representative sample from among 501,609 patients at the 393 institutions included in the DPC discharge database from April 1, 2012, to March 31, 2013, by using 2-stage random sampling. Admissions were randomly drawn from among the 393 included institutions, after which patients with SAH were randomly selected using ICD-10 codes. The primary diagnosis, treatment modality, in-hospital mortality, mRS score at discharge, and JCS score on admission were verified based on the discharge summary, hospital records of the clinical presentation according to neurosurgeons or neurologists, and CT or MRI evidence. Validation of the attending physician's contemporary assessment was equivalent to that of a retrospective chart review. The sensitivity, specificity, and positive predictive value (PPV) of SAH as the primary diagnosis were calculated using the sample set. The sensitivities, specificities, and PPVs of treatment modality, in-hospital mortality, mRS score at discharge, and JCS score on admission were calculated using the ICD-10 diagnosis codes related to SAH (I60.0–9) in the sample set.

Statistical Analysis

For statistical analysis, the mRS score at discharge was dichotomized into score groups 0–2 and 3–6. The JCS score was treated as a categorical variable of 0, 1, 2, or 3. Differences in patient demographics between the clipping and coiling groups were analyzed using the Wilcoxon rank-sum and chi-square tests. We used mixed-model analysis to estimate odds ratios for in-hospital mortality, mRS score at discharge, cerebral infarction, and complications and to estimate differences in length of hospital stay and medical costs. Odds ratios and differences were adjusted using a mixed model with sex, age, JCS score, and CCI score as fixed effects and hospital as a random effect (full cohort). To examine whether patient outcomes were affected by the CSC capabilities of each institution, the CSC score was applied as a fixed effect in addition to the aforementioned variables (subgroup with CSC scores). After conducting stratified analysis by JCS 0, 1-digit, 2-digit, and 3-digit codes, odds ratios and differences were adjusted using a mixed model with sex, age, CCI scores, and treatment modalities (clipping or coiling) as fixed effects and hospital as a random effect. We estimated odds ratios and differences for outcomes after 1:1 propensity score matching to account for differences in baseline characteristics between groups. Propensity scores for coiling were estimated using a probit model with age, sex, JCS score, and CCI score. To match patients, we used an automated matching procedure in the STATA software package that randomly selected a patient with clipping and a patient with coiling from the pool of potential patients within a propensity score caliper of ± 0.001 . Successfully matched pairs were removed, and the procedure was repeated until all patients were matched to one comparator or until no further patients that could be matched were available within the caliper. Analyses were performed using SAS version 9.3 (SAS Institute Inc.), STATA version 12 (STATA Corp.), and SPSS version 12 (SPSS Inc.). A *p* value < 0.05 was considered statistically significant.

Ethics Statement

This research was designed by us and approved by the institutional review board of Kyushu University, which waived the requirement for individual informed consent.

Results

Patient Demographics

A total of 5214 patients with SAH (clipping 3624, coiling 1590) at 393 institutions were identified based on ICD-10 codes (full cohort). Of the 4327 patients (83%) with SAH who were hospitalized at the 266 institutions that participated in the CSC capabilities survey and assigned a CSC score (subgroup with CSC scores), 2996 had undergone clipping and 1331 had undergone coiling. Table 1 shows the demographics of the full cohort and the subgroup with CSC scores.

In the full cohort, significant differences in some characteristics were observed between patients who had undergone clipping and those who had undergone coiling. Specifically, patients who underwent coiling were significantly older (mean age: clipping 62.0 years, coiling 63.5

TABLE 1. Demographics of the full cohort and the subgroup with CSC scores

Parameter	Full Cohort			Subgroup w/ CSC Scores		
	Clipping	Coiling	p Value	Clipping	Coiling	p Value
Total	3624	1590		2996	1331	
Patients						
Male	1147 (31.6)	480 (30.2)	0.294	955 (31.9)	388 (29.2)	0.074
Age in yrs	62.0 ± 13.9	63.5 ± 15.3	0.003	62.1 ± 13.9	63.3 ± 15.3	0.025
Height in cm	157.9 ± 9.2	157.4 ± 9.6	0.080	157.9 ± 9.2	157.3 ± 9.6	0.066
Weight in kg	57 ± 12.4	56.2 ± 13.3	0.005	57.0 ± 12.5	56.1 ± 13.3	0.004
Brinkman Index	215.4 ± 376.7	164.9 ± 387.4	<0.001	220.5 ± 384.7	158.4 ± 351.5	<0.001
Comorbidities						
CCI score	4.0 ± 1.0	4.1 ± 1.6	0.034	4.0 ± 1.5	4.1 ± 1.6	0.166
Hypertension	1993 (55.0)	852 (53.6)	0.347	1658 (55.3)	709 (53.3)	0.206
Diabetes mellitus	352 (9.7)	133 (8.4)	0.123	278 (9.3)	109 (8.2)	0.246
Hyperlipidemia	565 (15.6)	236 (14.8)	0.491	455 (15.2)	190 (14.3)	0.437
Hyperuricemia	12 (0.3)	9 (0.6)	0.218	11 (0.4)	8 (0.6)	0.283
JCS score on admission			<0.001			<0.001
0	834 (23.0)	285 (17.9)		663 (22.1)	245 (18.4)	
1-digit code	1120 (30.9)	450 (28.3)		951 (31.7)	371 (27.9)	
2-digit code	811 (22.4)	363 (22.8)		673 (22.5)	320 (24.0)	
3-digit code	859 (23.7)	492 (30.9)		709 (23.7)	395 (29.7)	
Admission source						
Ambulance	2837 (78.3)	1244 (78.2)	0.971	2369 (79.1)	1045 (78.5)	0.671
Days btwn admission & treatment	2.0 ± 3.3	2.0 ± 4.1	0.141	2.0 ± 3.4	2.0 ± 3.7	0.076
Surgery for hydrocephalus						
Ventriculostomy	182 (5.0)	322 (20.3)	<0.001	160 (5.3)	267 (20.1)	<0.001
CSF shunt	802 (22.1)	270 (17.0)	<0.001	682 (22.8)	225 (16.9)	<0.001
Hospital characteristics (CSC scores)						
Total score	NA	NA	NA	16.8 ± 3.6	17.9 ± 2.8	<0.001
Personnel	NA	NA	NA	3.9 ± 1.3	4.2 ± 1.1	<0.001
Diagnostic techniques	NA	NA	NA	4.4 ± 1.0	4.4 ± 1.0	0.286
Specific expertise	NA	NA	NA	4.3 ± 0.9	4.8 ± 0.6	<0.001
Infrastructure	NA	NA	NA	2.8 ± 1.4	3.2 ± 1.3	<0.001
Educational components	NA	NA	NA	1.3 ± 0.8	1.3 ± 0.8	0.971

NA = not applicable.

Values expressed as the mean ± standard deviation or number (%).

years, $p = 0.003$). The proportion of patients with impaired consciousness was significantly higher in the coiling group (for example, comatose patients: clipping 23.7%, coiling 30.9%, $p < 0.001$). The mean CCI score was also significantly higher in the coiling group (clipping 4.0 ± 1.0 , coiling 4.1 ± 1.6 , $p = 0.034$). No significant differences in other comorbidities, such as hypertension, diabetes mellitus, hyperlipidemia, and hyperuricemia, were noted between the groups. The mean weight (clipping 57.0 ± 12.4 kg, coiling 56.2 ± 13.3 kg, $p = 0.005$) and mean Brinkman Index (clipping 215.4 ± 376.7 , coiling 164.9 ± 387.4 , $p < 0.001$) were significantly lower in the coiling group.

In the subgroup with CSC scores, the corresponding differences between the 2 treatment groups were also significant except in the mean CCI score (clipping 4.0 ± 1.5 , coiling 4.1 ± 1.6 , $p = 0.166$). Regarding hospital charac-

teristics, the mean CSC total (clipping 16.8 ± 3.6 , coiling 17.9 ± 2.8 , $p < 0.001$), personnel (clipping 3.9 ± 1.3 , coiling 4.2 ± 1.1 , $p < 0.001$), specific expertise (clipping 4.3 ± 0.9 , coiling 4.8 ± 0.6 , $p < 0.001$), and infrastructure subgroup scores (clipping 2.8 ± 1.4 , coiling 3.2 ± 1.3 , $p < 0.001$) were significantly higher in the coiling group.

Mixed-Model Analysis

Table 2 shows outcomes in the full cohort and the subgroup with CSC scores. In the full cohort, rates of in-hospital mortality (clipping 8.7%, coiling 12.4%), cerebral infarction (clipping 16.7%, coiling 18.1%), mRS score of 3–6 at discharge (clipping 42.9%, coiling 46.4%), and PSIs ≥ 1 (clipping 48.5%, coiling 63.1%) were higher in the coiling group. However, the proportion of HACs ≥ 1 was higher in the clipping group (7.9% vs 7.0%). The median hospital

TABLE 2. Outcomes in the full cohort and the subgroup with CSC scores

Parameter	Full Cohort		Subgroup w/ CSC Scores	
	Clipping	Coiling	Clipping	Coiling
Total	3624	1590	2996	1331
In-hospital mortality	315 (8.7)	198 (12.4)	257 (8.6)	152 (11.4)
Discharge mRS Scores 3–6	1555 (42.9)	738 (46.4)	1307 (43.6)	618 (46.4)
Cerebral infarction	607 (16.7)	288 (18.1)	500 (16.7)	237 (17.8)
PSIs ≥1	1757 (48.5)	1003 (63.1)	1442 (48.1)	856 (64.3)
HACs ≥1	288 (7.9)	111 (7.0)	240 (8.0)	97 (7.3)
Length of hospital stay in days	37.0 ± 33.7	32.0 ± 30.7	38.0 ± 33.9	32.0 ± 30.7
Medical costs in thousands US\$	36.7 ± 14.1	35.7 ± 14.9	36.7 ± 14.1	36.0 ± 14.5

Values expressed as the median ± standard deviation or number (%).

stay was longer in the clipping group (median days: clipping 37.0, coiling 32.0), whereas the median medical costs were similar between the groups (thousands US\$: clipping 36.7, coiling 35.7). Similar results were obtained for the subgroup with CSC scores.

Table 3 shows patient outcomes in the full cohort and the subgroup with CSC scores according to the mixed-model analysis. In the full cohort, after adjusting for sex, age, JCS and CCI scores as fixed effects and hospital as a random effect, in-hospital mortality was significantly higher in the coiling group (OR 1.30, $p = 0.013$). Rates of cerebral infarction (OR 1.19, $p = 0.066$) and mRS scores of 3–6 at discharge (OR 0.98, $p = 0.761$) were not significantly different between the treatment groups. The proportion of PSIs ≥ 1 was significantly higher in the coiling group (OR 1.3, $p = 0.003$), whereas that of HACs ≥ 1 was significantly higher in the clipping group (OR 0.73, $p = 0.021$). The median hospital stay was significantly longer in the clipping group ($\beta = -7.18$, $p < 0.001$), whereas the medical costs were not significantly different between the groups ($\beta = -144.64$, $p = 0.742$). Analysis of the subgroup with CSC scores revealed similar results regarding in-hospital mortality (OR 1.27, $p = 0.046$), cerebral infarction (OR 1.18, $p = 0.124$), mRS scores of 3–6 at discharge (OR 0.96, $p = 0.657$), PSIs ≥ 1 (OR 1.33, $p = 0.003$), length of hospital stay ($\beta = -6.98$, $p < 0.001$), and medical costs ($\beta = -603.15$, $p = 0.210$). Although the proportion of HACs ≥ 1

was no longer significantly different between the groups, the odds ratio exhibited a similar tendency to that in the full cohort (OR 0.78, $p = 0.105$).

Because we suspected the JCS score to be the most important confounder, we also conducted stratified analyses by JCS 0, 1-digit, 2-digit, and 3-digit codes (Supplementary Tables S2 and 3). Although coiling did not have a significant effect on discharge mRS scores of 3–6 in patients with JCS 0, 1-digit, and 2-digit codes, rates of discharge mRS scores of 3–6 in the coiling group were significantly lower in patients with 3-digit codes in both the full cohort (OR 0.74, $p = 0.038$) and the subgroup with CSC scores (OR 0.70, $p = 0.024$). Although coiling did not have a significant effect on cerebral infarction in patients with JCS 0, 1-digit, and 2-digit codes, rates of cerebral infarction in the coiling group were significantly higher in patients with 3-digit codes in both the full cohort (OR 1.57, $p = 0.008$) and the subgroup with CSC scores (OR 1.69, $p = 0.006$). Regarding in-hospital mortality, PSIs ≥ 1, HACs ≥ 1, hospital stay, and medical costs, the influence of treatment modality seemed similar between the clipping and coiling groups in patients with each JCS score.

Propensity Score Analysis

Following 1:1 matching, 1556 patients who had undergone clipping and 1556 who had undergone coiling fol-

TABLE 3. Outcomes of patients with SAH according to mixed-model analysis

Parameter	Full Cohort			Subgroup w/ CSC Scores		
	OR*	95% CI	p Value	OR*	95% CI	p Value
In-hospital mortality	1.3	1.06–1.59	0.013	1.27	1.01–1.60	0.046
Discharge mRS Scores 3–6	0.98	0.85–1.14	0.761	0.96	0.81–1.14	0.657
Cerebral infarction	1.19	0.99–1.43	0.066	1.18	0.96–1.45	0.124
PSIs ≥1	1.3	1.10–1.53	0.003	1.33	1.10–1.60	0.003
HACs ≥1	0.73	0.55–0.95	0.021	0.78	0.58–1.05	0.105
Length of hospital stay	-7.18*†	-9.14 to -5.21	<0.001	-6.98*†	-9.15 to -4.80	<0.001
Medical costs	-144.64*†	-1008.17 to 718.88	0.742	-603.15*†	-1546.05 to 339.75	0.21

* Odds ratios and differences were adjusted by a mixed model with sex, age, JCS scores, and CCI scores as fixed effects and hospital as a random effect. Clipping was used as the reference.

† Number represents the β value.

lowing aneurysm rupture were matched based on demographic similarities. All covariates between the clipping and coiling groups were statistically indistinguishable after matching. Outcomes for patients with SAH after matching according to propensity score are shown in Table 4. In-hospital mortality was significantly higher in the coiling group (OR 1.25, $p = 0.047$). Rates of cerebral infarction (OR 0.97, $p = 0.745$) and mRS scores of 3–6 at discharge (OR 0.94, $p = 0.409$) were not significantly different between the groups. The proportion of PSIs ≥ 1 was significantly higher in the coiling group (OR 1.77, $p < 0.001$), whereas that of HACs ≥ 1 was not significantly different between the groups (OR 0.83, $p = 0.16$). The median hospital stay was significantly longer in the clipping group ($\beta = -6.71$, $p < 0.001$), whereas the medical costs were not significantly different between the groups ($\beta = 754.04$, $p = 0.086$). Compared with the results of the mixed-model analysis, except for the proportion of HACs ≥ 1 , a similar tendency was observed for the odds ratios and differences for the other factors.

Validation of Diagnosis, Treatment Modality, and Outcomes

Our sample, selected using 2-stage random sampling, consisted of 495 patients at 68 institutions. The sensitivity, specificity, and PPV of SAH as the primary diagnosis were 100%, 99.0%, and 95.1%, respectively. Among the 495 patients, 82 were identified using the ICD-10 diagnosis codes related to SAH (I60.0–9). The sensitivities, specificities, and PPVs of treatment modality and in-hospital mortality were all 100%. The sensitivity, specificity, and PPV of mRS Scores 3–6 at discharge were 97.2%, 87.0%, and 85.4%, respectively. The κ coefficient of the JCS score on admission was 0.683. The results of the validation study are summarized in Table 5.

Discussion

In Japan, the incidence of SAH is higher,⁸ and the associated mortality is lower,²⁴ than in other countries, possibly because of differences in genetic backgrounds, socioeconomic indicators,¹³ and national medical systems, including centralization of neurosurgical and acute stroke care capabilities. Therefore, international, national, and

TABLE 5. Results of the validation study

Parameter	Sensitivity	Specificity	PPV
SAH as primary diagnosis	100%	99.0%	95.1%
Treatment modality	100%	100%	100%
In-hospital mortality	100%	100%	100%
Discharge mRS Scores 3–6	97.2%	87.0%	85.4%

longitudinal comparisons of outcomes for patients with SAH treated using different therapeutic modalities should be discussed in light of socioeconomic indicators, acute stroke care capabilities at the specific time,^{13,14,26,28,31} and patient-level characteristics such as SAH severity.²⁷ The present study is the first to compare outcomes for SAH patients treated with clipping and coiling via a mixed-model analysis of a large nationwide discharge database (DPC database) after adjustment for patient-level characteristics including age, sex, level of consciousness (JCS score), CCI score, and hospital-level CSC capabilities (CSC score).^{14,15} Our results revealed that patients who had undergone coiling exhibited significantly higher in-hospital mortality (12.4% vs 8.7%) and shorter hospital stays (32.0 vs 37.0 days) than those in patients who had undergone clipping. The proportion of patients discharged with mRS scores of 3–6 (coiling 46.4%, clipping 42.9%) and median medical costs (thousands US\$: coiling 35.7, clipping 36.7) were not significantly different between the groups. Furthermore, the high accuracy of diagnoses, treatment modalities, and outcomes of the DPC cohort in the present study were confirmed using a 2-stage sampling method.

Discrepancies in the Results of Comparative Studies

Our results were partly consistent with those of 2 previous RCTs—the ISAT and the Barrow Ruptured Aneurysm Trial (BRAT)—with regard to functional outcomes, although rates of in-hospital mortality differed significantly.^{18,20} One possible explanation for this discrepancy is that almost 80% of all eligible aneurysms were excluded from the ISAT cohort, calling into question the general applicability of the results. In the BRAT, a relatively small number of patients were randomized and treated by highly experienced surgeons and endovascular physicians at a single high-volume center. The merits of using an electronic hospital claim database are associated with decreases in the risk of selection biases. Such biases may largely account for the differences between results of the present study and those of previous RCTs.

Researchers have increasingly relied on administrative databases of hospital admissions to assess clinical outcomes in patients with SAH. Three nationwide database studies were conducted to compare outcomes for patients with SAH who had undergone clipping or coiling, yielding mixed results.^{7,17,26} Using administrative claim data from Canada entered between 1995 and 2004, authors of one study found that endovascular coiling was associated with a significantly increased risk of death or SAH readmission.²⁶ The results were confirmed by propensity score-matched analysis. Authors of another study, who used the National (Nationwide) Inpatient Sample from 1998 to 2003 in the US, reported higher in-hospital mortality after coil-

TABLE 4. Outcomes of patients with SAH according to propensity score analysis

Parameter	OR*	95% CI	p Value
In-hospital mortality	1.25	1.00–1.57	0.047
Discharge mRS Scores 3–6	0.94	0.82–1.08	0.409
Cerebral infarction	0.97	0.81–1.16	0.745
PSIs ≥ 1	1.77	1.53–2.04	<0.001
HACs ≥ 1	0.83	0.64–1.08	0.16
Length of hospital stay	-6.70*†	-8.64 to -4.77	<0.001
Medical costs	754.04*†	-106.89 to 1614.96	0.086

* Odds ratios and differences were estimated for outcomes after 1:1 propensity score matching to account for differences in baseline characteristics between groups. Clipping was used as the reference.

† Number represents the β value.

ing than after clipping (16.6% vs 12.7%).⁷ These 2 studies, both conducted relatively soon after the publication of the ISAT, produced results similar to ours in terms of the case volume ratio, mortality, and functional outcomes of clipping and coiling.^{7,26} Qureshi et al. revealed that, after the publication of the ISAT in 2002, there was a significant increase in endovascular treatment as well as a decrease in in-hospital mortality in patients with SAH.²⁸ A third nationwide database study used the Premier database, which is a voluntary, fee-supported collection of data developed to assess the quality and resource utilization of health care delivery in the US.¹⁷ In contrast to findings in the present and aforementioned studies, the Premier database study revealed no significant differences in mortality between the groups (clipping 12%, coiling 13%, OR 0.94, 95% CI 0.73–1.21), though functional outcomes were significantly better in the coiling group (discharge to long-term care: clipping 42%, coiling 36%).¹⁷ Except for the present study, the only other study to use an administrative database in the analysis of patients treated relatively late after the publication of the ISAT was a US study in which patients admitted from 2006 to 2011 demonstrated higher in-hospital mortality after clipping (11.9% vs 8.7%) and similar in-hospital mortality after coiling (12.6% vs 12.5%), relative to patients in the present study.¹⁷ Since age is a predictor of a poor outcome,^{7,24} it is important to note that the patients with SAH who had undergone clipping (mean age 62.0 years) and coiling (63.5 years) in our Japanese cohort were almost 10 years older than those in the US and Canadian studies.^{7,17,26} Nonetheless, in-hospital mortality rates after clipping were much lower in Japan than the corresponding rates in the other countries, whereas rates after coiling remained similar.

Unmeasured Confounders

Discrepancies between findings of the present and previous large-scale database studies may be explained by the influence of unmeasured confounders. In general, the most common cause of death and poor functional outcomes following SAH is the initial bleeding.^{5,16} In fact, we revealed that the influence of treatment modalities on rates of discharge mRS scores of 3–6 and cerebral infarction differs between patients with 0 to 2-digit JCS scores and those with 3-digit JCS scores. Although McDonald et al. performed propensity score analysis to minimize potential selection bias, SAH severity was not included in the patient variables used to generate propensity scores, making interpretation of the results difficult.¹⁷ On the other hand, SAH severity was adjusted by the JCS score^{14,25,29} in the present study, minimizing its confounding effects. Notably, the importance of the JCS, first developed in 1974 for the prediction of stroke outcomes, has recently been validated.²⁹ The second most common cause of SAH-related death and poor functional outcome is rebleeding.^{5,16} Earlier treatment of ruptured aneurysms reduces the incidence of rebleeding.³³ However, no significant difference in the mean preoperative period (2 days) between clipping and coiling was observed in the present study. Intracranial aneurysm size and location are also important clinical variables used to guide treatment decisions. However, details regarding these variables are unavailable in administrative databases and represent potentially important unmeasured

confounders. In this regard, the Prospective Registry of Subarachnoid Aneurysms Treatment (PRESAT) trial provided reasonable estimates of the differences in ruptured aneurysm size and location in patients treated with clipping versus coiling.³¹ The PRESAT trial was undertaken from 2006 to 2007 at 29 tertiary care referral centers in Japan where both clipping and coiling were available for ruptured cerebral aneurysms, and the treatment choice was based on both patient and aneurysm characteristics.³¹ Clipping was mostly performed for small aneurysms with wide necks and for middle cerebral artery aneurysms, whereas coiling was preferred for larger, internal carotid artery and posterior circulation aneurysms. Authors of the study concluded that treatment modality, aneurysm size, and aneurysm location did not influence outcomes at tertiary care referral hospitals with high CSC capabilities.

Ideally, ruptured cerebral aneurysms should be treated at centers offering high-quality treatment with open surgical procedures as well as endovascular techniques. Our study demonstrated that high-quality surgical clipping remains available as both a first-line and a complementary treatment option for ruptured cerebral aneurysms in Japan: Our results were similar regardless of whether total CSC scores were adjusted in the mixed-model analysis. The optimal balance between clipping and coiling to maximize the overall proportion of favorable outcomes in patients with SAH will vary somewhat among centers, regions, and countries, depending on local expertise and CSC capabilities.

After CSC capabilities (total CSC scores) were adjusted in the mixed model, the odds ratios of in-hospital mortality and unfavorable outcomes of coiling compared with clipping remained almost unchanged. Although coiling was performed in hospitals with significantly higher CSC scores, the effect of treatment modality on outcomes in patients with SAH was unaffected by CSC capabilities. This finding is unexpected since higher CSC capabilities were found to be significantly associated with reduced in-hospital mortality in patients with SAH in our previous analysis of the J-ASPECT study.¹⁴ Rather than the CSC capabilities, surgeon-related factors such as technical skill and patient-related factors such as aneurysm location, size, and morphology may primarily influence the association between treatment modality and outcome. Further study is required to assess the influence of surgical skill and aneurysm characteristics.

In Japan, the official designation of primary stroke centers or CSCs has not yet begun, although the clear correlation between comprehensive stroke care capabilities and in-hospital mortality for all types of stroke revealed using the J-ASPECT Study database has had a significant impact on national policy. Given recently established evidence for the efficacy of mechanical thrombectomy in patients with acute ischemic stroke, a task force headed by the Japan Stroke Society and the Japan Neurosurgical Society has initiated an active discussion regarding the recommended items and criteria for the designation of primary stroke centers and CSCs in Japan, such as the CSC score.¹⁴

Study Strengths and Limitations

In light of the possible selection bias, the present study

can be considered a snapshot of the state of ruptured aneurysm treatment in Japan rather than a direct comparison between the safety and efficacy of both treatments. Given that heterogeneity in patient outcomes following stroke has been observed across different hospitals in the same country,¹⁴ considering the patients within each hospital as a cluster in a mixed model may be superior to conventional regression, which views all participants as independent. The present study is the first in which outcomes in patients with SAH treated with clipping and coiling have been compared using a mixed-model analysis of a large nationwide discharge database (DPC database), after adjustment for important patient and hospital characteristics.^{14,15} In addition, we added a propensity score analysis to verify the results of the mixed-model analysis. Findings of the propensity score analysis were mostly consistent with those of the mixed-model analysis. Therefore, we consider the results of our study to be highly reliable.

Our study has several limitations. First, the DPC database lacks several types of data such as cause of death and aneurysm characteristics. As previously mentioned, such confounders peculiar to Japan may underlie the differences in outcomes compared with other countries. Second, as a measure of SAH severity, we used the JCS score rather than the Hunt and Hess grade or the World Federation of Neurological Surgeons (WFNS) grade. The JCS is widely used for the assessment of impaired consciousness in patients with SAH in Japan.^{2,12,14,25,32} Although the JCS cannot assess neurological impairment other than diminished consciousness, the JCS score on admission had the greatest impact on the outcomes of patients with SAH.⁹ In addition, JCS scores have been reported to correlate with stroke outcomes.²⁹ Therefore, we believe that the JCS is sufficient for clinical grade assessment in patients with SAH. However, as an increasing number of stroke researchers have used JCS scores in recent Japanese DPC database studies,^{2,9,12,14,25,30,33} it may be necessary to compare the JCS scoring system with more typical grading scales. Third, the DPC database includes information collected only during hospitalization; thus, we were unable to evaluate long-term outcomes. However, the ISAT reported that the probability of death or dependency at 2 months, 1 year, and 10 years after treatment were higher in the clipping group.^{19,20} Results of the ISAT suggest that short-term outcomes regarding mRS scores and mortality may serve as reasonable predictive markers for long-term outcomes. Fourth, the external validity of the CSC grading system has not been confirmed. External validation is necessary to increase the reliability of self-assessment; therefore, we aim to validate information regarding hospital characteristics and outcomes using a small sample set from the validation cohort of the present study.

Conclusions

Clipping remains the standard treatment for SAH in Japan. Compared with coiling, clipping was associated with reduced in-hospital mortality, longer hospital stay, and similar unfavorable functional outcomes and medical costs in Japan in 2012. These findings were independent of CSC capabilities. Further study is required to determine

the effects of unmeasured confounders on the outcomes of clipping and coiling.

Acknowledgments

We thank the J-ASPECT study collaborators for their important contributions. The names of the 393 participating hospitals and representatives are listed in the online-only data supplement. We also thank Drs. Manabu Hasegawa, Tomoatsu Tsuji, and Yasuhiro Nishijima for their helpful discussions; Profs. Takamasa Kayama and Nobuo Hashimoto for their supervision of the collaboration with the Japan Neurosurgical Society; and Ms. Arisa Ishitoko for her secretarial assistance.

This work was supported by Grants-in-Aid from the Ministry of Health, Labor, and Welfare of Japan and JSPS KAKENHI Grant No. 25293314 (K.I.). This research is partially supported by the Practical Research Project for Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for Medical Research and development, AMED.

References

1. Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, et al: Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. *Stroke* **36**:1597–1616, 2005
2. Asano S, Hara T, Haisa T, Okamoto K, Kato T, Ohno H, et al: Outcomes of 24 patients with subarachnoid hemorrhage aged 80 years or older in a single center. *Clin Neurol Neurosurg* **109**:853–857, 2007
3. Berman MF, Solomon RA, Mayer SA, Johnston SC, Yung PP: Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. *Stroke* **34**:2200–2207, 2003
4. Brinkman GL, Coates EO Jr: The effect of bronchitis, smoking, and occupation on ventilation. *Am Rev Respir Dis* **87**:684–693, 1963
5. Broderick JP, Brott TG, Duldner JE, Tomsick T, Leach A: Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. *Stroke* **25**:1342–1347, 1994
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* **40**:373–383, 1987
7. Cowan JA Jr, Ziewacz J, Dimick JB, Upchurch GR Jr, Thompson BG: Use of endovascular coil embolization and surgical clip occlusion for cerebral artery aneurysms. *J Neurosurg* **107**:530–535, 2007
8. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ: Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. *J Neurol Neurosurg Psychiatry* **78**:1365–1372, 2007
9. Deruty R, Pelissou-Guyotat I, Mottolèse C, Amat D, Bogner L: Level of consciousness and age as prognostic factors in aneurysmal SAH. *Acta Neurochir (Wien)* **132**:1–8, 1995
10. Fargen KM, Neal D, Rahman M, Hoh BL: The prevalence of patient safety indicators and hospital-acquired conditions in patients with ruptured cerebral aneurysms: establishing standard performance measures using the Nationwide Inpatient Sample database. *J Neurosurg* **119**:1633–1640, 2013
11. Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, et al: Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. *JAMA* **311**:1632–1640, 2014
12. Gotoh O, Tamura A, Yasui N, Nihei H, Manaka S, Suzuki A, et al: [Japan Coma Scale in the prediction of outcome after early surgery for aneurysmal subarachnoid hemorrhage.] *No To Shinkei* **47**:49–55, 1995 (Jpn)

13. Guha D, Ibrahim GM, Kertzer JD, Macdonald RL: National socioeconomic indicators are associated with outcomes after aneurysmal subarachnoid hemorrhage: a hierarchical mixed-effects analysis. **J Neurosurg** **121**:1039–1047, 2014
14. Iihara K, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, et al: Effects of comprehensive stroke care capabilities on in-hospital mortality of patients with ischemic and hemorrhagic stroke: J-ASPECT study. **PLoS One** **9**:e96819, 2014
15. Iihara K, Nishimura K, Kada A, Nakagawara J, Toyoda K, Ogasawara K, et al: The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: a nationwide study in Japan: J-ASPECT study. **J Stroke Cerebrovasc Dis** **23**:1001–1018, 2014
16. Le Roux PD, Elliott JP, Newell DW, Grady MS, Winn HR: Predicting outcome in poor-grade patients with subarachnoid hemorrhage: a retrospective review of 159 aggressively managed cases. **J Neurosurg** **85**:39–49, 1996
17. McDonald JS, McDonald RJ, Fan J, Kallmes DF, Lanzino G, Cloft HJ: Comparative effectiveness of ruptured cerebral aneurysm therapies: propensity score analysis of clipping versus coiling. **AJNR Am J Neuroradiol** **35**:164–169, 2014
18. McDougall CG, Spetzler RF, Zabramski JM, Partovi S, Hills NK, Nakaji P, et al: The Barrow Ruptured Aneurysm Trial. **J Neurosurg** **116**:135–144, 2012
19. Molyneux AJ, Birks J, Clarke A, Sneade M, Kerr RS: The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT). **Lancet** **385**:691–697, 2015 (Erratum in **Lancet** **385**:946, 2015)
20. Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al: International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. **Lancet** **360**:1267–1274, 2002
21. Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al: International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. **Lancet** **366**:809–817, 2005
22. Nakamura K: Diagnosis procedure combination database would develop nationwide clinical research in Japan. **Circ J** **80**:2289–2290, 2016
23. Nichols DA, Brown RD Jr, Meyer FB: Coils or clips in subarachnoid haemorrhage? **Lancet** **360**:1262–1263, 2002
24. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ: Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. **Lancet Neurol** **8**:635–642, 2009
25. Ohta T, Kikuchi H, Hashi K, Kudo Y: Nifedipine administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study. **J Neurosurg** **64**:420–426, 1986
26. O’Kelly CJ, Kulkarni AV, Austin PC, Wallace MC, Urbach D: The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms: an administrative data analysis. Clinical article. **J Neurosurg** **113**:795–801, 2010
27. Pegoli M, Mandrekar J, Rabinstein AA, Lanzino G: Predictors of excellent functional outcome in aneurysmal subarachnoid hemorrhage. **J Neurosurg** **122**:414–418, 2015
28. Qureshi AI, Vazquez G, Tariq N, Suri MF, Lakshminarayan K, Lanzino G: Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States. Clinical article. **J Neurosurg** **114**:834–841, 2011
29. Shigematsu K, Nakano H, Watanabe Y: The eye response test alone is sufficient to predict stroke outcome—reintroduction of Japan Coma Scale: a cohort study. **BMJ Open** **3**:e002736, 2013
30. Spetzler RF, McDougall CG, Albuquerque FC, Zabramski JM, Hills NK, Partovi S, et al: The Barrow Ruptured Aneurysm Trial: 3-year results. **J Neurosurg** **119**:146–157, 2013
31. Taki W, Sakai N, Suzuki H: Determinants of poor outcome after aneurysmal subarachnoid hemorrhage when both clipping and coiling are available: Prospective Registry of Subarachnoid Aneurysms Treatment (PRESAT) in Japan. **World Neurosurg** **76**:437–445, 2011
32. Todo T, Usui M, Takakura K: Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase. **J Neurosurg** **74**:81–86, 1991
33. Whitfield PC, Moss H, O’Hare D, Smielewski P, Pickard JD, Kirkpatrick PJ: An audit of aneurysmal subarachnoid haemorrhage: earlier resuscitation and surgery reduces inpatient stay and deaths from rebleeding. **J Neurol Neurosurg Psychiatry** **60**:301–306, 1996
34. Yasunaga H, Ide H, Imamura T, Ohe K: Impact of the Japanese Diagnosis Procedure Combination-based Payment System on cardiovascular medicine-related costs. **Int Heart J** **46**:855–866, 2005
35. Yasunaga H, Matsui H, Horiguchi H, Fushimi K, Matsuda S: [Application of the diagnosis procedure combination (DPC) data to clinical studies.] **J UOEH** **36**:191–197, 2014 (Jpn)

Disclosures

Dr. Yoshimura has participated in the speaker’s bureau and/or has received honoraria from Bayer, Sanofi, Boehringer-Ingelheim, and Otsuka Pharmaceutical Co. and has received grants from Terumo and Takeda Pharmaceutical Co.

Author Contributions

Conception and design: Iihara. Acquisition of data: Iihara, Nakagawara, Toyoda, Ogasawara, Ono, Shiokawa, Aruga, Miyachi, Nagata, Matsuda, Yoshimura, Okuchi, Suzuki, Nakamura. Analysis and interpretation of data: all authors. Drafting the article: Kurogi. Critically revising the article: Iihara. Reviewed submitted version of manuscript: Kurogi, A Nishimura, Sayama, Nakagawara, Toyoda, Ogasawara, Ono, Shiokawa, Aruga, Miyachi, Nagata, Matsuda, Yoshimura, Okuchi, Suzuki, Nakamura, Onozuka, Hagihara. Statistical analysis: K Nishimura, Kamitani, Nakamura, Onozuka, Hagihara. Administrative/technical/material support: K Nishimura, Kamitani. Study supervision: Iihara.

Supplemental Information

Online-Only Content

Supplemental material is available with the online version of the article.

Online Supplement. <https://thejns.org/doi/suppl/10.3171/2016.12.JNS161039>.

Correspondence

Koji Iihara, Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. email: kiihara@ns.med.kyushu-u.ac.jp.

Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin

Ryota Kurogi, MD, Kunihiro Nishimura, MD, PhD, Michikazu Nakai, PhD, Akiko Kada, MPH, Satoru Kamitani, MD, PhD, Jyoji Nakagawara, MD, PhD, Kazunori Toyoda, MD, PhD, Kuniaki Ogasawara, MD, PhD, Junichi Ono, MD, PhD, Yoshiaki Shiokawa, MD, PhD, Toru Aruga, MD, PhD, Shigeru Miyachi, MD, PhD, Izumi Nagata, MD, PhD, Shinya Matsuda, MD, PhD, Shinichi Yoshimura, MD, PhD, Kazuo Okuchi, MD, PhD, Akifumi Suzuki, MD, PhD, Fumiaki Nakamura, MD, PhD, Daisuke Onozuka, PhD, Keisuke Ido, MD, Ai Kurogi, MD, Nobutaka Mukae, MD, PhD, Ataru Nishimura, MD, PhD, Koichi Arimura, MD, PhD, Takanari Kitazono, MD, PhD, Akihito Hagihara, DMSc, MPH, and Koji Iihara, MD, PhD, J-ASPECT Study Collaborators

Correspondence

Dr. Iihara
kiihara@ns.med.kyushu-u.
ac.jp

Neurology® 2018;90:e1143-e1149. doi:10.1212/WNL.0000000000005207

Abstract

Objectives

This cross-sectional survey explored the characteristics and outcomes of direct oral anticoagulant (DOAC)-associated nontraumatic intracerebral hemorrhages (ICHs) by analyzing a large nationwide Japanese discharge database.

Methods

We analyzed data from 2,245 patients who experienced ICHs while taking anticoagulants (DOAC: 227; warfarin: 2,018) and were urgently hospitalized at 621 institutions in Japan between April 2010 and March 2015. We compared the DOAC- and warfarin-treated patients based on their backgrounds, ICH severities, antiplatelet therapies at admission, hematoma removal surgeries, reversal agents, mortality rates, and modified Rankin Scale scores at discharge.

Results

DOAC-associated ICHs were less likely to cause moderately or severely impaired consciousness (DOAC-associated ICHs: 31.3%; warfarin-associated ICHs: 39.4%; $p = 0.002$) or require surgical removal (DOAC-associated ICHs: 5.3%; warfarin-associated ICHs: 9.9%; $p = 0.024$) in the univariate analysis. Propensity score analysis revealed that patients with DOAC-associated ICHs also exhibited lower mortality rates within 1 day (odds ratio [OR] 4.96, $p = 0.005$), within 7 days (OR 2.29, $p = 0.037$), and during hospitalization (OR 1.96, $p = 0.039$).

Conclusions

This nationwide study revealed that DOAC-treated patients had less severe ICHs and lower mortality rates than did warfarin-treated patients, probably due to milder hemorrhages at admission and lower hematoma expansion frequencies.

From the Departments of Neurosurgery (R.K., K. Ido, A. Kurogi, N.M., A.N., K.A., K. Iihara), Health Communication (D.O., A.H.), and Medicine and Clinical Science (T.K.), Graduate School of Medical Sciences, Kyushu University; Department of Neuroendovascular Surgery (R.K.), National Hospital Organization, Clinical Research Institute, Kyushu Medical Center, Fukuoka; Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (K.N., M.N.), Integrative Stroke Imaging Centre (J.N.), and Department of Cerebrovascular Medicine (K.T.), National Cerebral and Cardiovascular Center, Suita; Department of Clinical Trials and Research (A. Kada), National Hospital Organization, Nagoya Medical Center; Division of Health Services Research (S.K.), Center for Cancer Control and Information Services, National Cancer Center, Tokyo; Department of Neurosurgery (K. Ogasawara), Iwate Medical University, Morioka; Department of Neurosurgery (J.O.), Sanmu Medical Center; Department of Neurosurgery (Y.S.), Kyorin University, Mitaka; Department of Emergency and Critical Care Medicine (T.A.), Showa University Hospital, Shinagawa; Department of Neurosurgery (S. Miyachi), Osaka Medical College, Takatsuki; Department of Neurosurgery (I.N.), Kokura Memorial Hospital; Department of Preventive Medicine and Community Health (S. Matsuda), School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Department of Neurosurgery (S.Y.), Hyogo College of Medicine, Nishinomiya; Department of Emergency and Critical Care Medicine (K. Okuchi), Nara Medical University, Kashihara; Department of Surgical Neurology (A.S.), Research Institute for Brain and Blood Vessels, Akita; and Division of Data Management Center for Cardiovascular Disease Information (F.N.), National Cerebral Cardiovascular Disease Information, Suita, Japan.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Coinvestigators are listed at links.lww.com/WNL/A285.

The Article Processing Charge was funded by AMED (JP17ek0210088 and JP17ek021006).

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

AF = atrial fibrillation; **DOAC** = direct oral anticoagulant; **DPC** = Diagnosis Procedure Combination; **FFP** = fresh frozen plasma; **ICD-10** = *International Classification of Diseases–10*; **ICH** = intracerebral hemorrhage; **JCS** = Japan Coma Scale; **mRS** = modified Rankin Scale; **OR** = odds ratio; **PCC** = prothrombin complex; **PT-INR** = prothrombin time–international normalized ratio.

Clinical trials have shown that 4 direct oral anticoagulants (DOACs)—dabigatran, rivaroxaban, apixaban, and edoxaban—are as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation (AF).¹ In randomized clinical trials with strict indication criteria, DOAC-treated patients are reportedly at lower risk for hemorrhagic strokes than are warfarin-treated patients.¹ Mortality rates were similar among patients randomly prescribed either DOAC or warfarin according to a secondary analysis of intracerebral hemorrhages (ICHs) occurring in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial² and the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.³ However, because those trials featured very strict inclusion criteria, these results cannot be generalized to all patients with DOAC- or warfarin-associated ICHs. Notably, in clinical practice of stroke prevention in AF, stroke outcomes can depend on various patient baseline characteristics, suboptimal dosage, and oral anticoagulant therapy adherence.⁴ However, few studies have compared the characteristics and outcomes of DOAC- and warfarin-associated ICHs in clinical practice. Because DOACs are used liberally in clinical practice, we expect that the incidence of DOAC-associated ICHs will increase in coming years.⁵ We therefore aimed to compare the characteristics and outcomes of patients with DOAC- and warfarin-associated ICHs in clinical practice in Japan using a nationwide Diagnosis Procedure Combination (DPC) database.

Methods

Standard protocol approvals, registrations, and patient consents

This study was approved by the Kyushu University Institutional Review Board, which waived the requirement for individual informed consent.

The DPC database

The DPC is a mixed-case patient classification system that was launched in 2002 by the Japanese Ministry of Health, Labour and Welfare and is linked with a hospital financing system.⁶ By 2015, the DPC system had been adopted by an estimated 1,580 acute care hospitals, representing approximately half of all Japanese hospital beds and encompassing a wide variety of centers, including rural and urban, academic and non-academic, and small and large hospitals.⁷ The DPC database includes data about all patients admitted to participating

hospitals, including each patient's profile (e.g., age, sex); principal diagnoses and comorbidities at admission (both coded by the International Classification of Diseases and Injuries, 10th revision); complications after admission (coded similarly); procedures including surgeries, medications, and devices used during hospitalization; length of stay; discharge status; and medical expense.⁸ The J-ASPECT study group has analyzed the DPC database to gain new clinical insights,^{7,9–11} an approach we applied again for this cross-sectional survey.

Sampling strategy

Of the 1,369 training institutions certified by the Japan Neurosurgical Society, the Japanese Society of Neurology, and the Japan Stroke Society, 621 agreed to participate in the J-ASPECT study. We identified patients hospitalized for nontraumatic ICH in the deidentified discharge database using the ICD-10 diagnosis codes related to nontraumatic ICH (I61.0-9, I62.0-1, and I62.9). We further selected those patients who had been urgently hospitalized between April 1, 2010, and March 31, 2015, and were receiving a DOAC or warfarin before admission. We then extracted data about age and sex; comorbidities on admission, including those based on Charlson scores¹²; level of consciousness on admission according to the Japan Coma Scale (JCS), the most widely used grading scale for impaired consciousness in Japan (table e-1, links.lww.com/WNL/A284)^{7,9,13}; concurrent pre-admission use of antiplatelet drugs including aspirin, clopidogrel, ticlopidine, cilostazol, sarpogrelate, and prasugrel; hematoma removal with craniotomy, endoscopic surgery, or stereotactic aspiration; CSF drainage coded with Japanese original K-codes; use of reversal agents including vitamin K, prothrombin complex (PCC) concentrate, and fresh frozen plasma (FFP); length of hospital stay; mortality; and modified Rankin Scale (mRS) score at discharge. Patients with missing data were excluded from this survey.

Statistical analysis

We compared the characteristics of DOAC- and warfarin-associated ICHs using Wilcoxon rank sum tests for continuous variables and χ^2 tests for categorical variables. Multivariable analysis was undertaken to estimate the 2 groups' odds ratios (ORs) for mortality rates within 1 day, within 7 days, and during hospitalization and for discharge mRS scores in the 0–3 (good functional outcome) or 4–6 (poor functional outcome) ranges. The ORs were adjusted for sex, age, comorbidities, admission JCS scores, concurrent antiplatelet therapies, and treatment with surgery or reversal agents. We also estimated ORs for outcomes after 1:1 propensity score matching to account for between-group

differences in baseline characteristics. To match patients, we used an automated matching procedure in STATA (STATA Corp., College Station, TX) that randomly selected a DOAC-treated patient and a warfarin-treated patient within a propensity score caliper of ± 0.01 . Successfully matched pairs were removed, and the procedure was repeated until all patients were matched or until no further matches were available within the caliper. Propensity scores for warfarin-associated outcomes were estimated using a probit model in which the independent variables were sex, age, comorbidities, admission JCS scores, concurrent antiplatelet therapy, and treatment with surgery or reversal agents. The interaction between usage of DOAC and usage of reversal agents for ICH removal surgeries was examined. The analyses were performed using JMP 11.0 (SAS Institute, Cary, NC), SAS 9.3 (SAS Institute), STATA 12, and SPSS 12 (IBM, Armonk, NY). We defined statistical significance as $p < 0.05$.

Results

Patient demographics

We identified 2,245 patients with DOAC- or warfarin-associated ICHs (DOAC: 227; warfarin: 2,018). The percentages of DOAC-treated patients in each year from 2010 to 2014 were 0%, 0.4%, 3.8%, 9.6%, and 21.4%, respectively. The proportions of dabigatran, rivaroxaban, apixaban, and edoxaban among DOAC-associated cases were 23.8%, 57.8%, 18.5%, and 0%, respectively.

Table 1 shows the characteristics of patients with DOAC- and warfarin-associated ICHs. No significant between-group differences were noted for age (mean age in years: DOAC, 74.4; warfarin, 74.2); comorbidities such as Charlson scores (mean: 4.9, 5.0), hypertension (56.4%, 53.0%), diabetes mellitus (22.5%, 22.0%), or hyperlipidemia (12.3%, 12.0%); or median lengths of hospital stays (median days: 18.0, 18.0). The DOAC-treated group had a greater proportion of men (75.3%, 65.1%; $p = 0.002$) and smaller proportion of JCS 2- and 3-digit codes (moderately or severely impaired consciousness, respectively) (31.3%, 39.4%; $p = 0.002$). Concurrent use of antiplatelet drugs was more frequent among warfarin-treated patients (25.1%, 40.1%; $p < 0.001$). Overall usage rates for reversal agents, especially PCC, were quite low for both warfarin- and DOAC-treated patients. The DOAC-treated patients were less likely to be given vitamin K (2.6%, 63.1%; $p < 0.001$) or FFP (4.9%, 11.7%; $p < 0.001$); tended to be given PCC (3.1%, 5.8%; $p = 0.094$), the most effective early reversal agent for warfarin; and were less likely to require ICH removal surgeries (5.3%, 9.9%; $p = 0.024$).

Considering the lack of specific antidotes for DOACs during the study period, we further analyzed the relationships between the frequency of ICH removal surgeries and the use of vitamin K, FFP, or PCC in warfarin- and DOAC-treated patients. We found that surgical ICH removal was associated with the use of vitamin K (presence, 13.6%; absence, 3.6%;

Table 1 Characteristics of direct oral anticoagulant (DOAC) and warfarin-associated intracerebral hemorrhage (ICH) patients

	DOAC, n = 227	Warfarin, n = 2,018	p Value
Patients			
Male, n (%)	171 (75.3)	1,314 (65.1)	0.002
Age, y, mean \pm SD	74.4 \pm 8.5	74.2 \pm 10.5	0.737
Comorbidities			
Charlson score, mean, n \pm SD	4.9 \pm 1.4	5.0 \pm 1.6	0.172
Hypertension, n (%)	128 (56.4)	1,070 (53.0)	0.335
Diabetes mellitus, n (%)	51 (22.5)	443 (22.0)	0.859
Hyperlipidemia, n (%)	28 (12.3)	242 (12.0)	0.880
JCS score on admission			0.002
0- or 1-digit code, n (%)	156 (68.7)	1,224 (60.7)	
2- or 3-digit code, n (%)	71 (31.3)	794 (39.4)	
Concurrent antiplatelet therapy, n (%)	57 (25.1)	810 (40.1)	<0.001
Treatment/surgery			
ICH removal, n (%)	12 (5.3)	200 (9.9)	0.024
External CSF drainage, n (%)	7 (3.1)	77 (3.8)	0.582
Treatment/reversal agent			
Vitamin K, n (%)	6 (2.6)	1,273 (63.1)	<0.001
PCC, n (%)	7 (3.1)	116 (5.8)	0.094
FFP, n (%)	11 (4.9)	236 (11.7)	0.002
Length of hospital stay, d, median \pm SD	18 \pm 26.1	18 \pm 27.6	0.684

Abbreviations: FFP = fresh frozen plasma; PCC = prothrombin complex concentrate.

$p < 0.001$), FFP (presence, 47.9%; absence, 4.9%; $p < 0.001$), or PCC (presence, 31.0%; absence, 8.6%; $p < 0.001$) in patients with warfarin-associated ICHs, whereas no significant associations were observed for the use of vitamin K (presence, 0%; absence, 5.3%; $p = 0.558$), FFP (presence, 9.1%; absence, 5.1%; $p = 0.563$), or PCC (presence, 14.3%; absence, 5.0%; $p = 0.280$) in patients with DOAC-associated ICHs. After adjusting for the use of vitamin K, PCC, or FFP, the DOAC- and warfarin-treated groups exhibited no significant difference in ORs for ICH removal surgeries (OR 1.21, $p = 0.608$), but the interaction between usage of DOAC and usage of reversal agents for ICH removal surgeries was marginally significant ($p = 0.062$) (table e-2, links.lww.com/WNL/A284). This suggested that warfarin vs DOAC tends to show different effect on ICH removal surgeries within the group based on usage of reversal agents. Table e-3 shows the hemorrhage locations of DOAC- and warfarin-associated ICHs obtained from DPC data representing 68.9% of the study cases. These

Table 2 Outcomes of direct oral anticoagulant (DOAC) and warfarin-associated intracerebral hemorrhage patients

	DOAC, n = 227	Warfarin, n = 2,018	p Value
Mortality within 1 day, n (%)	6 (2.6)	131 (6.5)	0.022
Mortality within 7 days, n (%)	27 (11.9)	368 (18.2)	0.017
In-hospital mortality, n (%)	40 (17.6)	510 (25.3)	0.011
Discharge mRS, mean ± SD	3.30 ± 1.95	3.50 ± 2.04	0.158
Discharge mRS 4–6, n (%)	119 (52.4)	1111 (55.1)	0.45

Abbreviation: mRS = modified Rankin Scale.

data suggest no significant between-group differences in hematoma locations.

Table 2 shows mortality rates and discharge mRS scores for the DOAC- and warfarin-treated patients. The warfarin-treated patients exhibited higher mortality rates within 1 day (2.6%, 6.5%; $p = 0.022$), within 7 days (11.9%, 18.2%; $p = 0.017$), and during hospitalization (17.6%, 25.3%; $p = 0.011$). There were no significant differences in mean discharge mRS scores (3.30, 3.50) or the proportion of discharge mRS scores of 4–6 (52.4%, 55.1%).

Table 3 shows the 2 groups' ORs for mortality within 1 day, within 7 days, and during hospitalization and for discharge mRS scores of 4–6 after adjusting for sex, age, comorbidities, admission JCS scores, concurrent antiplatelet therapy, and treatment with surgery or reversal agents. The warfarin-treated patients exhibited higher ORs for mortality within 1 day (OR 4.06, $p < 0.001$), within 7 days (OR 1.96, $p = 0.012$), and during hospitalization (OR 1.60, $p = 0.041$). The 2

Table 3 Odds ratios (ORs) of mortality within 1 day, 7 days, and during hospitalization, and modified Rankin Scale (mRS) 4–6 at discharge in warfarin-associated intracerebral hemorrhage patients compared with direct oral anticoagulant-associated patients after adjusting for sex, age, comorbidities, Japan Coma Scale on admission, concurrent antiplatelet therapy, and treatment (surgery and reversal agent)

	OR	95% CI	p Value
Mortality within 1 day	4.06	1.78–10.99	<0.001
Mortality within 7 days	1.96	1.15–3.39	0.012
In-hospital mortality	1.6	1.02–2.56	0.041
Discharge mRS 4–6	0.79	0.56–1.12	0.181

Abbreviation: CI = confidence interval.

Table 4 Odds ratios (ORs) of mortality within 1 day, 7 days, and during hospitalization, and modified Rankin Scale (mRS) 4–6 at discharge in warfarin-associated intracerebral hemorrhage patients compared with direct oral anticoagulant-associated patients after matching by propensity score

	OR	95% CI	p Value
Mortality within 1 day	4.96	1.61–15.25	0.005
Mortality within 7 days	2.29	1.05–5.00	0.037
In-hospital mortality	1.96	1.03–3.72	0.039
Discharge mRS 4–6	0.76	0.48–1.20	0.246

Abbreviation: CI = confidence interval.

groups' ORs for discharge mRS scores of 4–6 were not significantly different.

Propensity score analysis

Table 4 shows the 2 groups' ORs for mortality within 1 day, within 7 days, and during hospitalization and for discharge mRS score of 4–6 after matching patients by propensity scores ($n = 221$ vs $n = 221$). Table e-4 (links.lww.com/WNL/A284) shows the propensity score–adjusted data for sex, age, comorbidities, admission JCS scores, concurrent antiplatelet therapies, and treatment with surgery or reversal agents. The warfarin-treated patients exhibited higher ORs for mortality within 1 day (OR 4.96, $p = 0.005$), within 7 days (OR 2.29, $p = 0.037$), and during hospitalization (OR 1.96, $p = 0.039$). The 2 groups did not significantly differ in ORs for discharge mRS scores of 4–6.

We also applied propensity score analysis to the outcomes for DOAC- and warfarin-treated patients. The propensity score–matched patients tended to have similar characteristics. Compared to the warfarin-treated patients, the dabigatran ($n = 51$ vs $n = 51$) and apixaban-treated patients ($n = 42$ vs $n = 42$) did not exhibit significantly different mortality rates or likelihoods of discharge mRS scores of 4–6 (table e-5 and e-6). The rivaroxaban-treated patients ($n = 127$ vs $n = 127$), however, exhibited lower mortality rates within 1 day (OR = 11.22, $p = 0.023$), though this was not the case for mortality rates within 7 days or during hospitalization or for the likelihood of discharge mRS scores of 4–6 (table e-7).

Discussion

Our objective in this study was to compare the characteristics and outcomes of DOAC- and warfarin-associated ICHs in clinical practice. Administrative databases of hospital admissions are increasingly used for clinical outcome studies. Despite several limitations, using nationwide databases provides large sample sizes and produces more generalizable results than randomized trials because it eliminates potential

selection and referral biases.¹⁰ The J-ASPECT study is the first nationwide survey on the clinical practice of stroke care in Japan that uses data obtained from hospitals subject to the DPC-based payment system.¹⁰ This study had a larger sample of clinical patients than did previous reports comparing DOAC- and warfarin-associated ICHs.^{5,14–16} Furthermore, we added a propensity score analysis and a multivariable analysis to compare the clinical outcomes from warfarin-associated ICHs to DOAC-associated ICHs collectively and the ICHs associated with each individual DOAC separately, with adjustments for key variables such as concurrent antiplatelet therapies^{17–19} and reversal agents.^{17,20,21} Compared to the warfarin-associated ICHs, the DOAC-associated ICHs were of lesser severity in the univariate analysis and were associated with lower in-hospital mortality after matching with propensity scores derived from clinical data. Our results are therefore robust and provide important clinical insights into optimizing oral anticoagulation therapy for stroke prevention in patients with AF.

Few studies have compared the clinical and radiologic characteristics and outcomes of DOAC- and warfarin-associated ICHs,^{5,15,16} and they have featured small sample sizes of DOAC-associated ICHs.^{5,15,16} These studies found that patients with DOAC-associated ICHs had lower mortality rates,¹⁵ smaller hematomas,^{5,15,16} and less hematoma expansion.^{5,15} In a case series study of DOAC-associated ICHs,^{22,23} none showed small hematoma expansion. In animal model studies, dabigatran treatment results in lower ICH volumes and less hematoma expansion than does warfarin treatment.^{24,25} These reports support our observation that DOAC-associated ICHs were less severe and were associated with lower mortality rates.

Several reports have explored the mechanisms behind DOAC-associated ICHs having smaller volumes and less hematoma expansion than warfarin-associated ICHs.^{5,22,23,26} Complexes of tissue factor VII are essential for the first reaction in the extrinsic coagulation cascade.²⁷ Warfarin inhibits vitamin K–dependent coagulation proteins II, VII, IX, and X, while DOAC never inhibits factor VII function.²⁸ Furthermore, DOAC half-lives are shorter than warfarin's half-life.²⁸

Our univariate analysis showed that warfarin-treated patients were more likely to undergo ICH removal surgeries, but this difference did not survive adjustments for the use of reversal agents. However, it is difficult to interpret these contradictory results, because the interaction between ICH removal surgeries and reversal agent usage was marginally significant. The appropriateness of surgery for most patients with spontaneous ICHs remains controversial, but it is recommended for patients with cerebellar hemorrhages who are deteriorating neurologically or who have brainstem compression or hydrocephalus from ventricular obstruction.²⁹ Initial hematoma volume is the most powerful predictor of neurologic deterioration, functional outcome, and mortality in both spontaneous and oral anticoagulant-associated ICHs, whereas the

level of consciousness is highly predictive in infratentorial ICHs.^{30,31} The proportion of cerebellar hemorrhages in this study is notably similar to that of a previous Japanese study that showed that prior treatment with antiplatelets, warfarin, or both is predictive of cerebellar hemorrhages, hematoma enlargement, and early death in Japanese patients with ICHs.³² In line with previous studies comparing patients with DOAC- and warfarin-associated ICHs,^{5,16,33} we found no significant between-group difference in ICH locations. However, the DPC data excluded information about the eloquence of the ICH lesions and the size and expansion of hematomas. In terms of lesion eloquence, our study revealed that DOAC-associated ICHs were associated with similar functional outcomes. Given the strong effect of initial hemorrhage locations on functional outcomes following DOAC- and warfarin-associated ICHs regardless of hematoma size or expansion,³⁴ we doubt there were any between-group differences in the proportions of eloquent area ICHs in our sample. Therefore, the localization and eloquence of the lesions does not seem to explain the different rates of ICH removal surgeries for our warfarin- and DOAC-treated groups. Regarding the size and expansion of hematomas, past studies^{5,15–20} have shown that DOAC-associated ICHs have smaller hemorrhage volumes and lower chances of hematoma expansion, which may explain our observation. A previous study comparing the effects of different reversal agents on hematoma growth and outcomes in patients with warfarin-related ICHs found that PCC was associated with a reduced incidence and extent of hematoma growth relative to FFP and vitamin K.³⁵ The present study, however, revealed that reversal strategies are not as widely applied in clinical practice in Japan as they are in Western countries,^{16,33} with PCC being used less frequently for warfarin-treated patients and specific reversal agents for DOACs such as idarucizumab being unavailable during the study period.^{17,20,21} Despite such overall low usage, more frequent usage in specific scenarios, especially PCC for patients who underwent removal surgeries for warfarin-associated ICHs, suggests that such strategies are mainly indicated for patients with large initial hematoma volumes and a high risk of neurologic deterioration. Furthermore, our study revealed that patients with warfarin-associated ICHs who were treated with reversal agents were more likely to require removal surgeries. This suggests that among patients with warfarin-associated ICHs, those who require surgical removal of large ICHs are more likely to use reversal agents.

Despite the release of DOACs, issues with warfarin such as overuse for low-risk patients and underuse for high-risk patients persist, as does discordance between guidelines and clinical practice. Our results are inconsistent with those of comparative studies of DOAC- or warfarin-associated ICHs in clinical settings in Western countries.^{5,14,33} Alonso et al.¹⁴ found no significant medication-related differences in mortality for any type of intracranial hemorrhage (intracerebral, subdural, or subarachnoid). However, the results of subtype analyses should be interpreted cautiously because of imprecise

estimates and small numbers.¹⁴ Considering the prognosis differences between ICH subtypes, we focused on 227 DOAC-associated ICHs while excluding other hemorrhage subtypes. In contrast, the Registry of Acute Stroke Under New Oral Anticoagulants³³ showed that DOAC-associated ICHs were associated with higher mortality rates, more unfavorable outcomes, and greater hematoma expansion frequencies. However, these conclusions were derived from comparisons with both warfarin-associated ICHs in that study and those in previously published retrospective observational studies. Another comparative study showed slightly higher mortality rates in patients with DOAC-associated ICHs but did not adjust for confounding factors with multivariate analyses or propensity score matching.⁵ Another explanation for the disparity between our study and that of those 3 studies^{5,14,33} may be the differences in patient ethnicity. The median case-fatality at 1 month for patients with ICHs is lower in Japan than in other countries,³⁶ and there are slight differences in the efficacy and safety of DOACs and warfarin between Asian and non-Asian populations.^{37,38} Resolving these discrepancies will require multinational observational collaborative studies and randomized controlled trials comparing DOACs and warfarin.

Each DOAC exhibits a unique dose-dependent efficacy and safety profile.¹ We therefore used propensity score analysis to separately compare the outcomes for each DOAC to those of warfarin. Compared to warfarin-treated patients, rivaroxaban-treated patients exhibited significantly lower 1-day mortality rates, while dabigatran- and apixaban-treated patients did not. These differences may be explained by the sample sizes for each DOAC. In Japan, dabigatran, rivaroxaban, and apixaban were launched in March 2011, April 2012, and February 2013, respectively, and edoxaban was approved for additional indications in September 2014. The timing of these launches may account for the proportions of each DOAC in this study. Larger sample sizes are needed to compare the characteristics and outcomes of each DOAC with those of warfarin.

The DPC database lacks several types of data. First, the database does not include laboratory data. The prothrombin time–international normalized ratio (PT-INR) is a particularly important factor in assessing the influence of hemorrhagic stroke.¹⁷ In this respect, it is interesting to note that the Japanese Fushimi AF Registry reported that over 90% of patients had PT-INR values within the optimal range.³⁹ Given this observation, it is unlikely that high PT-INR values alone could account for our observation of warfarin-associated ICHs being more severe, requiring removal more often, and being associated with higher mortality rates. Second, it does not contain vital signs data. Notably, a meta-analysis of 5 randomized controlled trials also showed that early intensive blood pressure reduction did not significantly reduce the mortality rate.⁴⁰ Admittedly, these missing data are unmeasured confounders for this study, so there is a need for further research that combines DPC database information with laboratory and radiologic data.

Although end-of-life decisions are an important factor in mortality, we had no information about such decisions. Previous studies comparing patients with DOAC- and warfarin-associated ICHs revealed no between-group differences in end-of-life decisions and found that mortality due to end-of-life decisions was low (i.e., 6%).⁵ In Japan, the proportion of end-of-life decisions is reportedly much lower than in other countries.⁴¹ Collectively, these facts lead us to suspect a minor effect of end-of-life decision on mortality in our patients.

This is the largest Japan-wide study of DOAC-associated ICHs in clinical practice, and it revealed that DOAC-associated ICHs were less lethal than warfarin-associated ICHs, probably due to lower hemorrhage severity at admission and lower hematoma expansion frequencies.

Author contributions

Ryota Kurogi drafted the manuscript. Koji Iihara was involved in conceptualizing and designing the study and in obtaining funding. Jyoji Nakagawara, Kazunori Toyoda, Kuniaki Ogasawara, Junichi Ono, Yoshiaki Shiokawa, Toru Aruga, Shigeru Miyachi, Izumi Nagata, Shinya Matsuda, Shinichi Yoshimura, Kazuo Okuchi, and Akifumi Suzuki were involved in data acquisition. Ryota Kurogi, Kunihiro Nishimura, Michikazu Nakai, Akiko Kada, Satoru Kamitani, Daisuke Onozuka, Keisuke Ido, Ai Kurogi, Nobutaka Mukae, Ataru Nishimura, Koichi Arimura, Akihito Hagihara, and Koji Iihara were involved in analyzing and interpreting the data. Jyoji Nakagawara, Kazunori Toyoda, Kuniaki Ogasawara, Junichi Ono, Yoshiaki Shiokawa, Toru Aruga, Shigeru Miyachi, Izumi Nagata, Shinya Matsuda, Shinichi Yoshimura, Kazuo Okuchi, Akifumi Suzuki, Takanari Kitazono, and Koji Iihara were involved in study supervision.

Acknowledgment

The authors thank the J-ASPECT study collaborators for their contributions. The names of the 621 participating hospitals and their representatives are listed in the online-only data supplement. All contributors were involved in data collection. The authors also thank Drs. Manabu Hasegawa, Tomoatsu Tsuji, and Yasuhiro Nishijima for discussion, Profs. Takamasa Kayama and Nobuo Hashimoto for supervision of the collaboration with the Japan Neurosurgical Society, and Arisa Ishitoko for secretarial assistance.

Study funding

This work was supported by Grants-in-Aid from the Japanese Ministry of Health, Labour and Welfare and a KAKENHI grant (25293314; principal investigator: Koji Iihara) from the Japan Society for the Promotion of Science. This research is partially supported by the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus managed by the Japan Agency for Medical Research and Development. The funding sources had no role in the study design, data collection and analysis, manuscript preparation, or decision to publish.

Disclosure

R. Kurogi reports no disclosures relevant to the manuscript. K. Nishimura reports receiving lecture fees from Bristol-Myers Squibb. M. Nakai, A. Kada, S. Kamitani, and J. Nakagawara report no disclosures relevant to the manuscript. K. Toyoda reports receiving honoraria for lectures from Bayer, Daiichi-Sankyo, Boehringer-Ingelheim, and Bristol-Myers Squibb. K. Ogasawara reports receiving grants from Nihon Medi-Physics and Bristol-Myers Squibb. J. Ono, Y. Shiokawa, T. Aruga, and S. Miyachi report no disclosures relevant to the manuscript. I. Nagata reports receiving honoraria for lectures from Bristol-Myers Squibb. S. Matsuda reports receiving honoraria for lectures from Chugai Pharmaceutical. S. Yoshimura reports receiving grants from Shionogi & Co., Terumo, Takeda, and Bristol-Meyers Squibb and honoraria for lectures from Mitsubishi Tanabe Pharma, Sanofi, Bristol-Myers Squibb, Boehringer-Ingelheim, Otsuka Pharmaceutical, Bayer, Daiichi Sankyo, and Pfizer. K. Okuchi reports no disclosures relevant to the manuscript. A. Suzuki is a member of the medical advisory committee to the Akita Pilot Study undertaken by Bayer. F. Nakamura reports receiving grants from Asahi Kasei. D. Onozuka, K. Ido, A. Kurogi, N. Mukae, A. Nishimura, and K. Arimura report no disclosures relevant to the manuscript. T. Kitazono reports receiving speaker fees from Bayer Yakuhin and Daiichi Sankyo, consulting fees from Chugai Pharmaceutical, and grants from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Eisai, Merck Sharp & Dohme, Astellas Pharma, Daiichi Sankyo, and Chugai Pharmaceutical. A. Hagihara reports no disclosures relevant to the manuscript. K. Iihara reports receiving grants from Otsuka Pharmaceutical, Nihon Medi-Physics, and AstraZeneca. Go to Neurology.org/N for full disclosures.

Received June 24, 2017. Accepted in final form December 27, 2017.

References

- Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. *Thromb Haemost* 2014;111:798–807.
- Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. *Stroke* 2012;43:1511–1517.
- Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. *Stroke* 2014;45:1304–1312.
- Nguyen E, White CM, Patel MR, et al. Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. *Curr Med Res Opin* 2016;32:1277–1279.
- von der Bröle C, Doukas A, Naumann R, et al. Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulants. *Acta Neurochir* 2017;159:101–109.
- Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese Diagnosis Procedure Combination-based payment system on cardiovascular medicine-related costs. *Int Heart J* 2005;46:855–866.
- Iihara K, Nishimura K, Kada A, et al. The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: a nationwide study in Japan: J-ASPECT study. *J Stroke Cerebrovasc Dis* 2014;23:1001–1018.
- Nakamura K. Diagnosis Procedure Combination database would develop nationwide clinical research in Japan. *Circ J* 2016;80:2289–2290.
- Iihara K, Nishimura K, Kada A, et al. Effects of comprehensive stroke care capabilities on in-hospital mortality of patients with ischemic and hemorrhagic stroke: J-ASPECT study. *PLoS One* 2014;9:e96819.
- Nishimura A, Nishimura K, Kada A, Iihara K; J-ASPECT study group. Status and future perspectives of utilizing big data in neurosurgical and stroke research. *Neurol Med Chir* 2016;56:655–663.
- Onozuka D, Hagihara A, Nishimura K, et al. Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). *BMJ Open* 2016;6:e009942.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–383.
- Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome: reintroduction of Japan Coma Scale: a cohort study. *BMJ Open* 2013;3:e002736.
- Alonso A, Bengtson LG, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. *Stroke* 2014;45:2286–2291.
- Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. *Stroke* 2014;45:2805–2807.
- Wilson D, Charidimou A, Shakeshaft C, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. *Neurology* 2016;86:360–366.
- Mittal MK, LacKamp A. Intracerebral hemorrhage: perihemorrhagic edema and secondary hematoma expansion: from bench work to ongoing controversies. *Front Neurol* 2016;7:210.
- Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. *Eur Heart J* 2013;34:1670–1680.
- Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. *Stroke* 2008;39:1740–1745.
- Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. *Am J Hematol* 2012;87(suppl 1):S141–S145.
- Pollack CV Jr. Managing bleeding in anticoagulated patients in the emergency care setting. *J Emerg Med* 2013;45:467–477.
- Akiyama H, Uchino K, Hasegawa Y. Characteristics of symptomatic intracranial hemorrhage in patients receiving non-vitamin K antagonist oral anticoagulant therapy. *PLoS One* 2015;10:e0132900.
- Komori M, Yasaka M, Kokuba K, et al. Intracranial hemorrhage during dabigatran treatment. *Circ J* 2014;78:1335–1341.
- Lauer A, Cianchetti FA, Van Cott EM, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. *Circulation* 2011;124:1654–1662.
- Won SY, Schlunk F, Dinkel J, et al. Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography. *Stroke* 2013;44:2883–2890.
- Tempaku A. Intracranial hemorrhage during administration of a novel oral anticoagulant. *J Rural Med* 2016;11:69–72.
- Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. *Blood* 1984;63:1338–1347.
- Ieko M, Naitoh S, Yoshida M, Takahashi N. Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. *J Intensive Care* 2016;4:19.
- Hemphill JC III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2015;46:2032–2060.
- Berwaerts J, Dijkhuizen RS, Robb OJ, Webster J. Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. *Stroke* 2000;31:2558–2562.
- Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. *Stroke* 1993;24:987–993.
- Toyoda K, Yasaka M, Nagata K, et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage: The Bleeding with Antithrombotic Therapy (BAT) Retrospective Study. *Cerebrovasc Dis* 2009;27:151–159.
- Purrucker JC, Haas K, Rizos T, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. *JAMA Neurol* 2016;73:169–177.
- Rost NS, Smith EE, Chang Y, et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. *Stroke* 2008;39:2304–2309.
- Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. *Stroke* 2006;37:1465–1470.
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol* 2010;9:167–176.
- Senoo K, Lau YC, Dzeshka M, Lane D, Okumura K, Lip GY. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation: meta-analysis. *Circ J* 2015;79:339–345.
- Yasaka M, Lip GY. Stroke prevention in Asian patients with atrial fibrillation. *Stroke* 2014;45:1608–1609.
- Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. *Circ J* 2014;78:2166–2172.
- Ma J, Li H, Liu Y, You C, Huang S, Ma L. Effects of intensive blood pressure lowering on intracerebral hemorrhage outcomes: a meta-analysis of randomized controlled trials. *Turk Neurosurg* 2015;25:544–551.
- Makino J, Fujitani S, Twohig B, Krasnica S, Oropello J. End-of-life considerations in the ICU in Japan: ethical and legal perspectives. *J Intensive Care* 2014;2:9.

Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin

Ryota Kurogi, MD, Kunihiro Nishimura, MD, PhD, Michikazu Nakai, PhD, Akiko Kada, MPH, Satoru Kamitani, MD, PhD, Jyoji Nakagawara, MD, PhD, Kazunori Toyoda, MD, PhD, Kuniaki Ogasawara, MD, PhD, Junichi Ono, MD, PhD, Yoshiaki Shiokawa, MD, PhD, Toru Aruga, MD, PhD, Shigeru Miyachi, MD, PhD, Izumi Nagata, MD, PhD, Shinya Matsuda, MD, PhD, Shinichi Yoshimura, MD, PhD, Kazuo Okuchi, MD, PhD, Akifumi Suzuki, MD, PhD, Fumiaki Nakamura, MD, PhD, Daisuke Onozuka, PhD, Keisuke Ido, MD, Ai Kurogi, MD, Nobutaka Mukae, MD, PhD, Ataru Nishimura, MD, PhD, Koichi Arimura, MD, PhD, Takanari Kitazono, MD, PhD, Akihito Hagihara, DMSc, MPH, and Koji Iihara, MD, PhD, J-ASPECT Study Collaborators

Correspondence

Dr. Iihara
kiihara@ns.med.kyushu-u.ac.jp

Cite as: *Neurology*® 2018;90:e1143-e1149. doi:10.1212/WNL.0000000000005207

Study question

How do outcomes for direct oral anticoagulant (DOAC)-associated intracerebral hemorrhages (ICHs) compare to those for warfarin-associated ICHs?

Summary answer

DOAC-associated ICHs are less severe and are associated with lower mortality rates.

What is known and what this paper adds

Past studies reported that patients with DOAC-associated ICHs have lower mortality rates than patients with warfarin-associated ICHs do, but strict inclusion criteria limited the generalizability of their results. This study provides corroborating evidence obtained by analyzing the nationwide Japanese Diagnosis Procedure Combination (DPC) clinical practice database.

Participants and setting

This study examined 2,245 patients who experienced non-traumatic ICHs while taking anticoagulants (DOAC, 227; warfarin, 2,018) and were urgently hospitalized at 621 Japanese institutions between 1 April 2010 and 31 March 2015.

Design, size, and duration

This study accessed the DPC database to obtain clinical data including consciousness impairment levels upon admission (as measured with the Japan Coma Scale), surgical removal rates, at-discharge modified Rankin Scale (mRS) scores, and mortality rates.

Primary outcomes

The primary outcomes were ICH severities, which were assessed based on consciousness impairments or the need for surgical removal, and mortality rates within 1 day, within 7 days, or during hospitalization.

Timeframe	Odds ratio for mortality	p Value	95% confidence intervals
1 d	4.06	<0.001	1.78–10.99
7 d	1.96	0.012	1.15–3.39
During hospitalization	1.60	0.041	1.02–2.56

Main results and the role of chance

Compared to warfarin-associated ICHs, DOAC-associated ICHs were less likely to cause moderate or severe consciousness impairments at admission (39.4% vs 31.3%; $p = 0.002$) or to necessitate surgical removal (9.9% vs 5.3%; $p = 0.024$) but were not associated with a lower mean at-discharge mRS score (3.50 vs 3.30; $p = 0.158$). Furthermore, the patients with DOAC-associated ICHs had lower mortality rates within 1 day (6.5% vs 2.6%; $p = 0.022$), within 7 days (18.2% vs 11.9%; $p = 0.017$), and during hospitalization (25.3% vs 17.6%; $p = 0.011$).

Bias, confounding, and other reasons for caution

The DPC database lacks some potentially relevant data, including laboratory data, vital signs data, and end-of-life decisions data.

Generalizability to other populations

The use of a nationwide database makes this study's results more generalizable than those of previous reports.

Study funding/potential competing interests

This study was funded by the Japanese government and the Japan Society for the Promotion of Science. Some authors report receiving honoraria, funding, and advisory committee appointments from various pharmaceutical companies. Go to Neurology.org/N for full disclosures.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
塩川芳昭	合併症をきたさないための組織の体制づくりとガバナンスの構築	森田明夫	脳神経外科M&Mカンファレンス	メジカルビュー	東京	2016	486-591
塩川芳昭	脳卒中(脳出血・脳梗塞・クモ膜下出血・もやもや病)	岡庭 豊	year noteTOPICS 2016-2017 内科・外科疾患5th edition 研修医・非専門医でも知っておくべき近年と今後の主な動向	メディックメディア	東京	2016	377-383
塩川芳昭	くも膜下出血	田村 晃他	EBMに基づく脳神経疾患の基本治療指針 第4版	メジカルビュー	東京		2-8
塩川芳昭	序文	塩川芳昭	脳神経外科学用語集改訂第3版	日本脳神経外科学会用語委員会	東京	2016	5-6
塩川芳昭	脳卒中(脳出血・脳梗塞・クモ膜下出血・もやもや病)	岡庭 豊	year noteTOPICS 2018内科・外科編	メディックメディア	東京	2017	-
豊田一則	脳卒中治療ガイドライン2015[追補2017対応]	日本脳卒中学会脳卒中治療ガイドライン委員会	脳卒中治療ガイドライン2015[追補2017対応]	日本脳卒中学会	東京	2017	-
黒木 愛、飯原弘二	ビッグデータから見た脳卒中救急医療	鈴木則宏	Annual Review of Neurology 2018	中外医学社	東京	2018	174-9

豊田一則		豊田一則	脳梗塞診療読本第3版	中外医学社	東京	2019	全443
長谷川泰弘	一過性脳虚血発作	田川皓一 他	マスター脳卒中 中学	西村書店	東京	2018	229-232
長谷川泰弘	潜因性脳梗塞と塞栓源不明脳塞栓症	田川皓一 他	マスター脳卒中 中学	西村書店	東京	2018	233-237
石原秀行、鈴木倫保	脳卒中の遠隔医療(Telestroke)	鈴木則宏	Annual Review w神経2018	中外医学社	東京	2018	155-158

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kada A, Nishimura K, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Iihara K; J-ASPECT Study Collaborators.	Development and validation of a score for evaluating comprehensive stroke care capabilities: J-ASPECT Study.	BMC Neurol.	17(1)	46	2017
Nishimura A, Nishimura K, Kada A, Iihara K; J-ASPECT Study GROUP.	Status and Future Perspectives of Utilizing Big Data in Neurosurgical and Stroke Research.	Neurol Med Chir (Tokyo).	56(11)	655-663	2016
Yoshimoto K, Kada A, Kuga D, Hatae R, Murata H, Akagi Y, Nishimura K, Kurogi R, Nishimura A, Hata N, Mizoguchi M, Sayama T, Iihara K.	Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor).	Neurol Med Chir (Tokyo).	56(11)	664-673	2016

Lavine SD, Cockroft K, Hoh B, Bambakidis N, Khalessi AA, Woo H, Riina H, Siddiqui A, Hirsch JA, Chong W, Rice H, Wenderoth J, Mitchell P, Coulthard A, Signh TJ, Phatorous C, Khangure M, Klurfan P, Ter Brugge K, Iancu D, Gunnarsson T,	Training guidelines for endovascular stroke intervention: an international multi-society consensus document.	Nihon Rinsho.	74(4)	621-6	2016
Arimura K, Iihara K.	Surgical Management of Intracranial Artery Dissection.	Neuroradiolog	58(6)	537-41	2016
Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Nishimura A, Kurogi R, Sayama T, Iihara K; J-ASPECT Study Collaborators.	Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study).	Neurol Med Chir (Tokyo).	56(9)	517-23	2016

Lavine SD, Cockcroft K, Hoh B, Bambakidis N, Khalessi AA, Woo H, Riina H, Siddiqui A, Hirsch JA, Chong W, Rice H, Wenderoth J, Mitchell P, Coulthard A, Singh TJ, Phatorous C, Khangure M, Klurfan P, terBrugge K, Iancu D, Gunnarsson T, Jansen O, et al.	Training Guidelines for Endovascular Ischemic Stroke Intervention: An International Multi-Society Consensus Document.	BMJ Open.	6(3)	e009942	2016
飯原弘二	【DPCの新展開】脳卒中医療の質向上に資するDPCデータ活用	病院	76(2)	114-8	2017
黒木愛、飯原弘二	知って得するワンポイントアドバイス 一次脳卒中センターと総合脳卒中センターの違い	脳と循環	22(1)	70-3	2017
黒木亮太、飯原弘二	【ビッグデータ解析に基づく臨床研究】DPC情報を活用した日本の脳卒中急性期医療の可視化 J-ASPECT study	神経内科	84(6)	572-7	2016
有村公一、飯原弘二	【脳卒中-新時代の治療を求めて-】臨床上の課題 脳血管内治療 新たなエビデンス	日本臨床	74(4)	621-6	2016

Yoshimura S, Sakai N, Okada Y, Kitagawa K, Kimura K, Tanahashi N, Hiyogo T, Yamagami H, Egashira Y.	Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry Investigators: Efficacy of endovascular treatment for acute cerebral large-vessel occlusion: analysis of nationwide prospective registry.	J Stroke Cerebrovasc Dis.	23	1183-1190	2014
Takagi T, Yoshimura S, Uchida K, Enomoto Y, Egashira Y, Yamagami H, Sakai N.	Intravenous tissue plasminogen activator before endovascular treatment increases symptomatic intracranial hemorrhage in patients with occlusion of the middle cerebral artery second division: subanalysis of the RESCUE-Japan Registry.	Neuroradiology	58	147-153	2016
Y Enomoto, S Yoshimura, Y Egashira, H Yamagami, N Sakai.	The risk of intracranial hemorrhage in Japanese patients with acute large vessel occlusion; subanalysis of the RESCUE-Japan Registry.	J Stroke Cerebrovasc Dis	25	1076-1080	2016
塩川芳昭	序 脳梗塞急性期治療のブレイクスルー	分子脳血管病	15(1)	37	2016
塩川芳昭	クモ膜下出血のまとめ	Geriatric Neurosurgery	28	51-53	2016
Kawada M, Yokoi H, Maruyama K, Matsumoto Y, Yamanaka H, Ikeda T, Shiokawa Y, Saito K.	Rhinogenic intracranial complication with postoperative frontal sinus pyocele and inverted papilloma in the nasal cavity: A case report and literature review	SAGE Open Med Case Rep	4	2050313X16629828	2016
塩川芳昭	画像検査と脳卒中3	日本脳ドック学会報	3	44-45	2016
豊田一則	急性期脳梗塞の最新治療	神経治療学.	33	155-157	2016

Suzuki Y, Hasegawa Y, Tsumura K, Ueda T, Suzuki K, Sugiyama M, Nozaki H, Kawaguchi S, Nakane M, Nag	Prehospital triage for endovascular clot removal in acute stroke patients	Acute Medicine & Surgery	4	68-74	2016
Koga M, Yoshimura S, Hasegawa Y, Shibuya S, Ito Y, Matsuoka H, Takamatsu K, Nishiyama K, Todo K, Kumura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Kamada T, Nagakane Y, Yagita Y, Kario K, Shiozawa M, Sato S, Yamagami H, Arihiro S, Toyoda K; SAMURAI Study Investigators.	Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation.	Stroke	47(10)	2582-2588	2016
Akiyama H, Hoshino M, Shimizu T, Hasegawa Y.	Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran	Medicine	95(14)	1-5	2016
Taguchi H, Hasegawa Y, Bando K, Koyasu H, Watanabe Y, Yamashita K, Shimazaki K, Shimizu H, Miyakawa M, Niwa Y.	Implementation of a Community-Based Triage for Patients with Suspected Transient Ischemic Attack or Minor Stroke Study : A Prospective Multicenter Observational Study	Journal of Stroke and Cerebrovascular Diseases	25(4)	745-751	2016
Akiyama H, Nukui S, Araga T, Hoshino M, Tanaka K, Kogashima S, Sasaki R, Uchino K, Hasegawa Y.	Utility of Durata, a wireless patch-type electrocardiographic monitoring system developed in Japan, in detecting covert atrial fibrillation in patients with cry	Medicine	96(6)	e5995	2016
Hagiwara Y, Yoshie T, Shimizu T, Oogura H, Akamatsu M, Fukano T, Takada T, Nogoshi S, Ueda T, Hasegawa Y.	Contrast-enhanced transoral carotid ultrasonography for the evaluation of a long stenotic lesion in the internal carotid artery	Clinical Case Reports	4(12)	1215-1216	2016

Hagiwara Y, Yoshie T, Shimizu T, Oogura H, Fukano T, Takada T, Ueda T, Hasegawa Y.	A case in which contrast-enhanced transoral carotid ultrasonography was useful for pre-and post-procedural evaluation in carotid artery stenting.	Journal of Medical Ultrasonics		1-4	2016
徳永誠、三宮克彦、渡邊進、寺崎修司、平田好文、山鹿眞紀夫、橋本洋一郎	日常生活機能評価の急性期病院時点数と回復期入院時点数の違い —熊本脳卒中地域連携パスの回復期リハ10病院における調査—	Journal of Clinical Rehabilitation	25(3)	297-303	2016
石原秀行, 奥高行, 山根亜希子, 杉山修一, 末廣栄一, 貞廣浩和, 鈴木 倫保	Drip-ship treatment の安全性について	The Mt. Fuji Workshop on CVD	34	153-155	2016
鈴木倫保、石原秀行、篠山瑞也、岡史朗	画像検査の進歩	日本脳ドック学会報	3	43-44	2016
内山真一郎、阿部康二、松本昌康、鈴木倫保、北川一夫、塩川芳昭	脳卒中研究・臨床におけるトピックス 2016	分子脳血管病	15(1)	1-7	2016
Takagi T, Yoshimura S, Uchida K, Shirakawa M, Yamada K,	The current status of endovascular thrombectomy for acute ischemic stroke in Japan: results of a	JNET	11	504-11	2017
Sakamoto Y, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, Shiokawa	Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in	Stroke	44(7)	1846-51	2017
Sasaki R, Maki F, Hara D, Tanaka S, Hasegawa Y.	Stratification of disease progression in a broad spectrum of degenerative cerebellar ataxias with a	Cerebellum Ataxias	4	9	2017

Hagiwara Y, Yoshie T, Shimizu T, Ogura H, Fukano T, Takada T, Ueda T, Hasegawa	A case in which contrast-enhanced transoral carotid ultrasonography was useful for pre- and post-procedural	J Med Ultrasonics.	44	207-210	2017
Isahaya K, Kawakami T, Shiraishi M, Akiyama H,	Nerve conduction study of lower extremities in cutaneous arteritis patients with neurological	The Journal of dermatology	56(12)	1569-73	2017
Wakisaka Y, Matsuo R, Hata J, Kuroda J, Kitazono T, Kamouchi M, Ago T,	Adverse Influence of Pre-Stroke Dementia on Short-Term Functional Outcomes in Patients with Acute	Cerebrovasc Dis.	43	82-9	2017
Ogata T, Matsuo R, Kiyuna F, Hata J, Ago T, Tsuboi Y, Kitazono T,	Left Atrial Size and Long-Term Risk of Recurrent Stroke After Acute Ischemic Stroke in Patients with	J Am Heart Assoc.	6	e006402	2017
Matsuo R, Yamaguchi Y, Matsushita T, Hata J, Kiyuna F, Fukuda K,	Association Between Onset-to-Door Time and Clinical Outcomes After Ischemic Stroke.	Stroke.	48	3049-56	2017
Uchino K, Shiraishi M, Tanaka K, Akamatsu M, Hasegawa Y.	Impact of inability to turn in bed assessed by a wearable three-axis accelerometer on patients with Parkinson's	PLoS One	12(11)	e0187616	2017
黒木 愛、飯原弘二	包括的脳卒中センターと ASPECT Study.	J-カレントセラピー	35(12)	92	2017
中島昌典、岡野晴子、傳法倫久、平野照之、千葉厚郎、遠藤英仁、窪田 博、	大動脈原性脳塞栓症を発症し、上行大動脈置換術を施行した 80 歳男性例	脳卒中	39(2)	129-133	2017

塩川芳昭	無症候性脳血管病変 脳血管障害診療のエッセンス	日本医師会雑誌生涯教育委シリーズ92	146 (特別号)	S247-9(1)	2017
塩川芳昭	画像検査と未破裂脳動脈瘤 03. 脳ドックに関わる最近の文献情報	日本脳ドック学会報	第5号	63-64	2017
塩川芳昭	脳神経外科ホットラインの運用について 自施設での経年的比較から	脳神経外科ジャーナル	vol.27、 No.2	130	2017
Kurogi R, Kada A, Nishimura K, Kamitani S, Nishimura A,	Effect of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage: a nationwide	J Neurosurg.	128(5)	1318-26	2018 (Epub 2017)
Kurogi R, Nishimura K, Nakai M, Kada A, Kamitani S, Nakagawara J,	Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin.	Neurology	90(13)	e1143-9	2018
Hacke W, Lyden P, Emberson J, Baigent C, Blackwell L, Albers G, Bluhmki	Effects of alteplase for acute stroke according to criteria defining the EU and US marketing authorizations:	Int J Stroke	13(2)	175-189	2018
Hagiwara Y, Takada T, Shimizu T, Yoshie T, Ogura H, Ueda T, Hasegawa Y.	Ultrasonography in Preoperative Assessment for Carotid Artery Stenting.	Journal of Neuroendovascular Therapy	12	14-9	2018
Sato T, Ariella L.G.Coler-Reilly ALG, Yagishita N, Araya N, Inoue	Mogamulizumab(Anti-CCR4)in HTLV-1 Associated Myelopathy.	N Engl J Med	378(6)	529-38	2018

Akiyama H, Hasegawa Y.	Awareness of atrial fibrillation in Japan: A large-scale, nationwide Internet survey of 50,000 Japanese	Geriatr Gerontol Int.	18(7)	1100-1107	2018
黒木愛、飯原弘二	DPC・レセプトデータを活用した大規模データベースの現状と今後の展望.	医学の歩み	264(10)	889-93	2018
豊田一則(部会長) (日本脳卒中学会脳卒中治療ガイドライン委員会「抗凝固	抗凝固療法中患者への脳梗塞急性期再開通治療に関する推奨 2017年11月	脳卒中	40(2)	123-135	2018
Miura M, Yoshimura S, Sakai N, Yamagami H, Uchida K, Nagao Y.	Endovascular therapy for middle cerebral artery M2 segment occlusion: subanalyses of RESCUE-	J Neurointerv Surg	In press		
Toyoda K, Yamagami H, Koga M	Consensus guides on stroke thrombolysis for anticoagulated patients from Japan: Application to other	J Stroke	20	321-331	2018
Bang OY, Toyoda K, et al	Intracranial large artery disease of non-atherosclerotic origin: recent progress and clinical	J Stroke	20	208-217	2018
Toyoda K, Koga M, Yamagami H, et al.	Seasonal variations in neurological severity and outcomes of ischemic stroke: five-year single-center	Stroke	82(5)	1443-1450	2018
Toyoda K, Koga M, Yamamoto H, et al.	Clinical outcomes depending on acute blood pressure after cerebral hemorrhage.	Ann Neurol.	85(1)	105-113	2019

Ogawa A, Toyoda K, Kitagawa K, et al.	Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: the	Lancet Neurol	18	238-247	2019
Akiyama H, Hasegawa Y.	Awareness of atrial fibrillation in Japan: A large-scale, nationwide Internet survey of 50,000 Japanese	Geriatr Gerontol I	18(75):	1100-1107	2018
Yoshie T, Ueda T, Takada T, Nogoshi S, Miyashita F, Takaishi S, Fukano T, Tokuura	Effects of Pretreatment Cerebral Blood Volume and Time to Recanalization on Clinical Outcomes in	J Stroke Cerebrovasc Dis	27(7)	1802-1809	2018
Hoshino M, Shimizu T, Ogura H, Hagiwara Y, Takao N, Soga K, Usuki N,	Intraplaque Microvascular Flow Signal in Superb Microvascular Imaging and Magnetic Resonance	J Stroke Cerebrovasc Dis	27(12)	3529-3534	2018
Kashima S, Shimizu T, Akiyama H, Hasegawa Y.	Magnetic Resonance Imaging White Matter Hyperintensity as a Predictor of Stroke Recurrence in	J Stroke Cerebrovasc Dis	27(12):	3613-3620	2018
萩原悠太, 星野俊, 栗田千尋, 宮内元樹, 清水高弘, 佐々木直, 長谷川泰弘.	Superb Micro-vascular Imaging を用いた下肢静脈超音波検査.	Neurosonology	31(2)	42-46	2018
萩原悠太, 小倉英, 清水高弘, 今井悠, 長谷川潤一, 長谷川泰弘	Superb microvascular imaging を用いた経口腔頸動脈超音波検査	Neurosonology	31(1)	13-17	2018
長谷川泰弘	脳卒中緊急医療における遠隔医療の活用.	Progress in Medicine	38(11)	1193-1196.	2018

伊佐早健司, 櫻井謙三, 秋山久尚, 長谷川泰弘.	脳卒中の遠隔医療 (Telestroke) のための教育ツール開発.	日本遠隔医療学会雑誌	14(2)	124-127	2018
秋山久尚, 鹿島悟, 長谷川泰弘.	一般市民を対象とした非侵襲的長時間連続転送テレメトリー式心電送信機 Duranta®を用いた心房細	日本遠隔医療学会雑誌	14(2)	143-146.	2018
石原秀行・鈴木倫保	telemedicine と telestroke	分子脳血管病	17(1)	52-56	2018
石原秀行・鈴木倫保	救急システム整備と遠隔医療	医学と薬学	74(12)	1543-1548	2018
Suehiro E, Suzuki M.	Pitfalls in the Treatment of Geriatric Traumatic Brain Injury].	No Shinkei Geka.	46(12)	1127-1135.	2018
Kiyuna F, Sato N, Matsuo R, Kamouchi M, Hata J, Wakisaka Y, Kuroda J, Ago T.	Association of Embolic Sources with Cause-Specific Functional Outcomes Among Adults with	JAMA Network Open	1(5)	e182953	2018
Shono Y, Sugimori H, Matsuo R, Fukushima Y, Wakisaka Y, Kuroda	Safety of antithrombotic therapy for patients with acute ischemic stroke harboring unruptured	Int J Stroke	13	734-742	2018
Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, Kamouchi M;	Insulin resistance and clinical outcomes after acute ischemic stroke.	Neurology	90	e1470-e1477	2018